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Abstract 
Introduction 
Unfractionated heparin (UFH) belongs to a class of linear, highly sulfated, acidic 
polysaccharides known as glycosaminoglycans. Low-molecular-weight heparins 
(LMWHs) are modified heparin fragments with a molecular weight range of 2000 to 
8000 Da. LMWHs are prepared by either chemical or enzymatic depolymerisation of 
UFH. In clinical practice, UFH is largely replaced by LMWHs because of their 
improved pharmacokinetic profiles as decreased risk of side effects. Heparins (UFH 
and LMWHs) are comprised of heterogeneous mixture of anticoagulant and non-
anticoagulant fractions. Much recently, these polysaccharides have shown to possess 
anti-inflammatory effects and such effects are strongly influenced by degree of 
sulfation, distribution of sulfate groups and chain length. Interestingly, the potential 
anti-inflammatory activities of heparins, such seen in asthma, are reported to be 
because of the interactions between their non-anticoagulant molecules and various 
biological molecules. Numerous studies highlight the role of heparins in the 
management of inflammatory disorders including asthma. Asthma is a common 
chronic inflammatory condition of the conducting airways. It is estimated that 
approximately 300 million people worldwide suffer from asthma and it is associated 
with severe morbidity, and sometimes even mortality. Asthma is known to be driven 
by various inflammatory cytokines including interleukin-(IL)-4, IL-5, IL-6, IL-8, IL-
13 and tumor necrosis factor-alpha (TNF-α). The current drug modalities used for the 
management of asthma are reported to have a number of drawbacks and it is also 
estimated that up to 10% asthmatic patients have difficult-to-treat asthma that is often 
resistant to first line treatment with inhaled corticosteroids. Some recent in vivo 
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studies have confirmed that heparins possess significant anti-asthmatic activity. 
However, the use of heparins for the management of asthma is hindered by the risk of 
bleeding associated with their anticoagulant fractions. For example, in one study, 
administration of LMWH resulted in massive haemorrhage in a patient with 
inflammation. Apart from this, the investigation of anti-inflammatory effects of 
LMWH is challenging because these activities are expressed with high LMWH 
concentrations where the anticoagulant effects predominate. Therefore, the overall 
aim of the study was to confirm that a LMWH (e.g. enoxaparin and dalteparin) can 
inhibit various inflammatory mediators involved in the pathogenesis of asthma with a 
view of identifying non-anticoagulant fraction(s) of the parent LMWH responsible for 
its anti-asthmatic effect.  
Methodology 
Stimulation of Cells: Peripheral blood mononuclear cells (PBMCs) were isolated 
from whole blood of asthmatic subjects and were cultured for 72 hours in the presence 
of phytohaemagglutinin for the release of IL-4, IL-5, IL-13 and TNF-α. Similarly, 
human respiratory pulmonary epithelial cells were cultured for 24 hours in the 
presence of trypsin for the release of IL-6 and IL-8.  
Identification of a LMWH exhibiting high anti-inflammatory activity: PBMCs were 
pre-treated in the presence of intact enoxaparin or dalteparin to investigate the effect 
of parent LMWHs to inhibit the release of tested cytokines.  
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Separation, isolation and desalting of parent LMWH exhibiting high anti-
inflammatory effects:  
Chromatographic separation of enoxaparin was carried out using ion-exchange 
chromatography (IC). Separations were performed on a semi-preparative CarboPac 
PA100 column (250 × 9 mm ID). The optimised sodium chloride (NaCl) eluent 
gradient was: 0-70 min: gradient from 32-74% 2 M NaCl in Milli-Q water (0.64-1.48 
M NaCl). Total flow rate of 2.0 mL/min was maintained and UV detection at 232 nm 
was performed. The collected fractions were concentrated on a centrifugal 
concentrator and desalted using PD MidiTrap G-10 columns. 
Determination of average molecular weight and anticoagulant activity of separated 
fractions:  
The average molecular weight of separated fractions was determined using a 
Superdex
TM
 peptide 10/300 GL (300×10 mm) size-exclusion column. Isocratic elution
of intact LMWH parent LMWH and the separated fractions along with the known 
LMWH standards were performed with a 0.3 M sodium sulfate eluent at a flow rate of 
0.2 mL/min and UV detection at 232 nm was performed.  The anticoagulant effect of 
the separated fractions was determined using low-volume microtitre plate anti-factor 
Xa assay using anti-thrombin III and factor Xa. 
Identification of fraction(s) exhibiting high anti-inflammatory effects: 
Each separated fraction of the parent LMWH was analysed for its ability to inhibit the 
release of tested cytokines to identify the fraction(s) responsible for the observed anti-
inflammatory effect exhibited by the parent molecule.  
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Structural identification of fraction(s) exhibiting high anti-inflammatory effects: 
The particular structure of fractions exhibiting high anti-inflammatory effect was 
determined using nuclear magnetic resonance. Structural characterisation of 
fraction(s) was performed using 1D and 2D 
1
H spectroscopy (TOCSY 120 ms, 
COSY, ROESY 500 ms) and 2D 
13
C-
1
H spectroscopy (HSQC, HSQCTOCSY 120ms) 
with standard Bruker pulseprograms. 
The role of sulfate groups on the observed inhibitory effect:  
The parent LMWH as well as its separated fractions was selectively desulfated using 
well established and validated methods to investigate the character of sulfate groups 
which could play a role in inhibiting the release of tested cytokines. Selective 
desulfation at was 2-O, 6-O and N-sulfated positions were performed using sodium 
hydroxide, tetrahydrofuran and N-methyl-N-(trimethylsilyl) trifluroacetamide 
respectively.  
Results and Discussion   
When compared, enoxaparin inhibited the release of IL-4, IL-5, IL-13 and TNF-α 
whereas dalteparin stimulated their release. However, the clinical use of enoxaparin as 
an anti-inflammatory agent is largely limited because of the presence of anticoagulant 
fractions, being associated with the risk of bleeding. The high negative charge, 
structural complexity and polydispersity of enoxaparin present a special set of 
difficulties for its separation. Nevertheless, a novel ion-exchange chromatographic 
(IC) technique was developed to separate enoxaparin into several different fractions. 
The technique successfully resolved enoxaparin into 30 different peaks and had 
superior resolution than previously reported methods for the separation and 
xv 
identification of various fractions of enoxaparin. The separated fractions were found 
to have molecular weights ranging from 600 to 8000 Da having no, low, moderate or 
high anticoagulant activities. Two fractions of enoxaparin were structurally identified 
using nuclear magnetic resonance consisting of two and four sugar units (a di- and a 
tetrasaccharide; approximate molecular weight 600 and 1200 Da respectively) 
exhibiting 85% of the inhibitory effect on the release of IL-4, IL-5, IL-13 and TNF-α 
displayed by the parent enoxaparin. The finding from the current study also suggests 
an interaction of 6-O-sulfated tetrasaccharide with specific or allosteric binding to 
cellular receptor(s) for the observed inhibition.  
Parent enoxaparin was also found to inhibit the release of IL-6 and IL-8 released from 
human respiratory pulmonary epithelial cells. IC-derived disaccharide fraction of 
enoxaparin displayed the maximum inhibitory effect (>90%) exhibited by the parent 
molecule. Our findings indicate that the observed inhibition of IL-6 and IL-8 was 
most likely due to an interaction between the N-terminal domain of protease activated 
receptors and 6-O-sulfated disaccharide.  
It is known that a minimum of five saccharide chain length with specific sulfation 
pattern is required for the anticoagulant activity of any type of LMWH. The identified 
fractions a di- and a tetrasaccharide (two and four sugar units respectively) exhibited 
high anti-inflammatory activity.  This finding is important because these fractions 
have no effect on blood coagulation and hence, support the hypothesis that non-
anticoagulant fractions of heparins are associated with anti-inflammatory.  
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Conclusion and Future Directions 
In conclusion, a widely used LMWH (enoxaparin) was identified having high anti-
inflammatory potential in inhibiting the release of critical inflammatory cytokines 
involved in the pathogenesis of asthma. A novel IC method was developed to separate 
various fragments of the parent anti-inflammatory LMWH. The method was 
successfully applied to investigate and identify the fractions responsible for the anti-
inflammatory effects observed by the parent molecule in inhibiting the release of 
tested cytokines. Separated fractions of enoxaparin were structurally identified which 
displaying high anti-inflammatory effect. The fractions were found to have no effect 
on blood coagulation and therefore eliminate the potential risk of bleeding. These 
studies provide a solid platform for future experimental and clinical studies for the 
interpretation of fine/specific non-anticoagulant sequences and their precise structural 
information to enable better understanding of structure-activity relationships. This 
would allow us to answer various biological questions and to provide new targets for 
therapeutic interventions in different inflammatory disease states. Lastly, to identify 
the precise underlying cellular mechanism(s) by which the non-anticoagulant fractions 
of enoxaparin inhibit the release of various inflammatory cytokines associated with 
the pathogenesis of asthma.  
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Non-Anticoagulant Derivatives of Heparin for the Management of Asthma: 
Distant Dream or Close Reality? 
1.1 ABSTRACT 
Background: Approximately 300 million people worldwide are currently affected by 
asthma. An improved understanding of the mechanisms involved in such 
inflammatory airway disorders has led to the recognition of new therapeutic 
approaches. Heparin, a widely used anticoagulant, has been shown to be beneficial in 
the management of asthma. It belongs to the family of highly sulfated polysaccharides 
referred to as glycosaminoglycans, containing a heterogeneous mixture of both 
anticoagulant and non-anticoagulant polysaccharides. Experimental finding suggest 
that heparin has potential anti-asthmatic properties due to the ability of its non-
anticoagulant oligosaccharides to bind and modulate the activity of a wide range of 
biological molecules involved in the inflammatory process. 
Areas Covered: This review focuses on the potential mechanisms of action and 
clinical application of heparin as an anti-inflammatory agent for the management of 
asthma. 
Expert Opinion: Heparin may play a significant role in the management of asthma. 
However, these properties are often hindered by the presence of anticoagulant 
oligosaccharides, which possess a significant risk of bleeding. Therefore, its 
therapeutic potential must be explored using well-designed clinical studies that focus 
on identifying and isolating the anti-inflammatory oligosaccharides of heparin, and 
further elucidating the structure and mechanisms of actions of these non-anticoagulant 
oligosaccharides. 
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1.2 Heparin and its low molecular weight derivatives 
Heparin was discovered in 1916 by Jay McLean, a medical student at Johns Hopkins 
Medical School, who was initially examining procoagulant phosphatides extracted 
from canine liver and serendipitously discovered that a compound exhibited 
anticoagulant effects in vitro; this was later named heparin [1]. Heparin belongs to the 
family of glycosaminoglycans (GAGs), which contains a complex heterogeneous 
mixture of linear, polysulfated polysaccharides composed of alternating disaccharide 
units of D-glucosamine and uronic acid residues linked by 1→4 glycosidic bonds 
(Figure 1.1) [2]. It is a naturally occurring endogenous substance, which is 
sequestered within the mast cells of several mammalian tissues, including the 
intestine, lung, liver and skin [3]. The length of heparin polysaccharide unit not only 
depends on its source of isolation (bovine lung or porcine intestinal mucosa) but also 
varies in the mast cell granules and therefore, the molecular weight composition of 
heparin differs [4].  
Figure 1.1 Building blocks of heparin-repeating disaccharide unit made up of alternating 
iduronic and glucosamine residues. 
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The precise mechanism by which heparin exerts its characteristic anticoagulant effect 
was elucidated 50 years after its discovery. It binds to serine protease inhibitor 
antithrombin III using its anticoagulant oligosaccharides, composed of a unique 
pentasaccharide sequence (Figure 1.2), thereby accelerating the inhibition of the final 
two proteases of the coagulation cascade (thrombin and factor Xa) [5].  
Figure 1.2 Unique pentasaccharide sequence of heparin having three glucosamine and two 
iduronic acid. The binding between this specific sequence and antithrombin III results in the 
anticoagulant effect of heparin. 
Over the past 50 years, heparin has gained a widespread popularity and has been 
extensively used in clinical practice for its well-known anticoagulant effect.  
Nevertheless, heparin has been largely replaced in recent times by its clinically useful 
analogues known as low-molecular-weight heparins (LMWHs). The LMWHs have 
been proven to be more efficacious than heparin in some clinical situations, with 
superior pharmacokinetic profiles and reduced adverse outcomes, including heparin-
induced thrombocytopaenia, bleeding, osteoporosis and the propensity to interact with 
a wide range of plasma proteins [6].  Currently, there are a number of commercially 
available LMWHs preparations which are synthesised from unfractionated heparin by 
either chemical or enzymatic depolymerisation processes (Table 1.1). These 
structurally similar analogues of heparin are also composed of anticoagulant and non-
anticoagulant polysaccharides [7]. The LMWH preparations have been primarily used 
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for the treatment and prophylaxis of deep-vein thrombosis; they are also effective in 
artery bypass grafting, treatment of pulmonary embolism and maintaining vessel 
patency during haemodialysis [8, 9]. 
Table 1.1 Currently available LMWHs and their properties 
LMWH Manufacturing Process Average 
Molecular Weight 
(Da) 
Nadroparin Deaminative cleavage with nitrous acid 4300 
Reviparin Deaminative cleavage with nitrous acid 4400 
Enoxaparin Alkaline β-eliminative cleavage of the benzyl ester of 
heparin 
4500 
Parnaparin Oxidative depolymerisation with cupric acid and 
hydrogen peroxide 
5000 
Certoparin Deaminative cleavage with isoamyl nitrite 5400 
Ardeparin Oxidative depolymerisation with hydrogen peroxide 5,500-6,500 
Dalteparin Deaminative cleavage with nitrous acid 6000 
Tinzaparin β-eliminative cleavage by the heparinase enzyme 6500 
1.3 Heparin and inflammation 
Currently, heparin and LMWHs are at the forefront in the field of glycobiology 
because of the recognition of various biological applications of these macromolecules 
beyond their well-established anticoagulant activity. Only a sub-population of heparin 
chains constitute a pentasaccharide sequence (anticoagulant oligosaccharide) for anti-
thrombin III binding site and the majority of the chains are composed of relatively 
non-specific sequences (non-anticoagulant oligosaccharides) [10]. The diverse nature 
of heparin with respect to its molecular weight composition and sulphation pattern 
results in wide-ranging biological effects (specific and non-specific) [11]. The 
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heterogeneity of heparin enables it to interact with basic amino acids presents in 
numerous proteins and biological molecules, and thereby play a pivotal role in 
modulating inflammatory responses. The interaction of heparin with proteins is 
mostly non-specific and dependent on the charged groups especially the sulfate 
groups, charge density and the degree of polymerisation (molecular weight of an 
oligosaccharide chain) [12]. These interactions induce functionally important 
conformational changes, resulting in either aggregation of proteins to accelerate their 
interactions with specific cell receptors or the displacement and subsequent binding of 
proteins to specific cell receptors.  
 Heparin is thought to be an inhibitor of inflammation because of its interaction 
with important proteins involved in the complement system and process of 
inflammation, hence limiting cellular activation and subsequent tissue damage and 
remodelling [13]. These proteins include cytokines, growth factors, adhesion 
molecules, tissue-destructive enzymes and cytotoxic mediators. Specifically, heparin 
binds to numerous adhesion proteins present on the extracellular matrix, such as 
fibronectin, laminin, thrombospodin and vitronectin, and consequently alters the 
reactions involved in cell signalling and cell adhesion [3]. Because of the myriad of 
interactions with numerous proteins, heparin has been subject to intensive clinical and 
non-clinical investigations for potential therapeutic roles other than the control of 
coagulation.  
Heparin has greater biological activity compared to the structurally similar 
members of the GAG family, like heparan sulphate. This is due to the fact that heparin 
is more sulphated and contains a far higher percentage of iduronate residues (Figure 
1.3). The conformational flexibility of the polysaccharide chain in heparin increases 
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because of the presence of these iduronate residues; this flexibility, together with 
other electrostatic interactions, enables heparin to possess greater biological activity 
compared to glucuronate-containing GAGs [14].  Also, the difference in the 
composition and extent of sulphation of the polysaccharide chain of heparin is a key 
characteristic of its higher biological response. The sulphation pattern along the 
heparin chain is different, having sites of sulphation at the 2-O position of iduronate 
residues, glucosamine residues and glucuronic acid; 6-O position of glucosamine 
residues; and 3-O position of disulphated glucosamine residues. However, sulphation 
at the 2-O position of glucuronic acid and 3-O position of disulphated glucosamine 
residues is infrequent [15]. Heparin interacts with a diverse range of biological 
molecules; many of these molecules have preferential binding in accordance with the 
specific sulphation pattern within heparin. For instance, it has been elucidated that 
presence of sulphate groups at the 2-O position are required for the interaction 
between heparin and fibroblast growth factor (FGF)-2, while sulphation at 2-O and 6-
O positions is key for its interaction with FGF-1 [16]. Similarly, for specific 
interaction of heparin with vascular endothelial growth factor, N- and 6-O-sulphate 
groups are essential [17]. Therefore, it can be postulated that since heparin is enriched 
in sulphate groups at different positions this facilitates its interaction with a wide 
array of biological molecules and thus enables significant biological activity 
compared to the other members of the GAG family. 
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Figure 1.3 Alterations in the sulfation patterns of the repeating major and variable 
disaccharide units of heparin and heparan sulfate. 1, heparin (HP); 2, heparan sulfate (HS); 3, 
fully O-sulfonated and re-N-acetylated HP; 4, fully O-sulfonated and re-N-acetylated HS; 5, 
de-N-sulfonated and re-N-acetylated HP; 6, de-N-sulfonated and re-N-acetylated HS; 7, 6-O-
desulfonated HP; 8, 6-O-desulfonated HS. 
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1.4 Asthma: an overview  
Asthma is a complex multifactorial disorder of conducting airways, characterised by 
airway hyper-responsiveness and recurrent reversible airway obstruction [18]. The 
defining features of asthma that lead to decreased lung function include contraction or 
hypertrophy of airway smooth muscle, resulting in bronchoconstriction, and airway 
inflammation to airway remodelling [19, 20]. The symptoms of asthma often include 
chest tightness, dyspnoea, cough and wheezing. These symptoms, together with 
limitation of airflow, lead to the exacerbation of underlying airway inflammation, 
which may cause severe morbidity, and even mortality [21].  
 Recent advancements in the methods for investigating airway inflammation in 
asthma, such as brochoalveolar lavage, endobronchial biopsy, fibro-optic 
bronchoscopy, exhaled breath condensate and sputum induction, has led to the 
recognition of the cells and mediators contributing to airway inflammation in asthma 
[22]. Exposure to acute respiratory infection or allergens like pollution, smoke, or 
stress and the subsequent allergic cascade initiate an acute immune response which 
leads to airway inflammation. For decades, the role of the allergic cascade in the 
development of airway inflammation has remained the focal point of research interest. 
Mast cells have been recognised as the principal effector cells of allergic reaction in 
asthma [23]. However, other cells that contribute to ongoing inflammation include 
lymphocytes, eosinophils, neutrophils, macrophages, dendritic cells and structural 
cells (such as fibroblasts, epithelial cells and smooth muscle cells) [24].  
  The allergic reaction and underlying inflammation in asthma can be sub-
divided into three distinct phases: the induction phase, the early-asthmatic phase and 
the late-phase asthmatic reaction (Figure 1.4) [23]. Antigen presenting cells (APCs) 
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are distributed throughout the respiratory tract (from nasal mucosa to the lung pleura). 
Induction of an allergic reaction is caused by the inhaled allergens that are taken up 
and processed by APCs and presented to the allergen-specific T and B cells present in 
the lymph node [25]. APCs then activate the naïve T-helper (Th) cells, which further 
differentiate into either Th1 or Th2 cells; Th2 cells are in preponderance over Th1 
cells,  resulting in the production of important cytokines (such as interleukin (IL)-4, 
IL-5, IL-9 and IL-13) involved in the development of the features of asthma [23]. 
Furthermore, IL-4 and IL-13 lead to the activation of B cells and concomitant 
production of immunoglobulin E (IgE) [26]. The synthesised IgE antibodies bind to 
high-affinity IgE receptor Fc𝜀RI, which is present on the mast cell surface or on the 
surface of the peripheral blood basophils. On the other hand, IL-5 plays a pivotal role 
in the pathogenesis of respiratory inflammation by rapidly attracting circulating 
eosinophils to the locally affected area [27]. IL-5 also primes eosinophils and mast 
cells which, when activated, release significantly higher quantities of IL-5 and tumor 
necrosis factor-alpha (TNF-α). The early-asthmatic phase is caused by the release of 
preformed mediators (histamine), newly synthesised lipid mediators (prostaglandins 
and leukotrienes), cytokines and growth factors (TNF-α, IL-4, IL-13, vascular 
endothelial growth factor) upon degranulation of mast cells or basophils or upon re-
exposure to allergens [28]. This phase is characterised by vascular leakage, 
constriction of airway smooth muscle cells, enhanced airway hyper-responsiveness, 
mucus production and recruitment of inflammatory cells [29].  
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Figure 1.4 Schematic representation of the inflammatory cascade associated during distinct phases of allergic asthma. The activation and recruitment of 
several inflammatory cells and subsequent release of numerous inflammatory mediators that are involved in allergic airway inflammation, together with the 
primary structural changes that contributes to airway remodelling. H (-), denote the inhibitory effects of heparin on various inflammatory mediators shown.  
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 Ongoing inflammation results in the late-phase asthmatic reaction, which is 
characterised by excessive inflammation of the airways producing permanent 
structural changes in the airway. The primary structural changes include the 
deposition of extracellular matrix (ECM) proteins, such as collagen, laminin, elastin 
and proteoglycans, around the airway smooth muscle (ASM), ASM hypertrophy and 
hyperplasia contributing to airway wall thickening, and myofibroblast proliferation 
associated with thickening of basement membrane (sub-basement membrane fibrosis), 
epithelial damage and mucus metaplasia [20, 30]. These changes are collectively 
referred to as airway remodelling. Several contributing factors lead to airway 
remodelling, these include growth factors and cytokines, such as FGF-1, FGF-2, 
transforming growth factor (TGF)-β1, epidermal growth factor (EGF), IL-4, IL-5 and 
IL-13, which are actively involved in the enhanced deposition of ECM and ASM 
proliferation [31]. 
1.5 Biological effectiveness of heparin in asthma  
It has been shown that heparin has potential in the management of inflammatory 
airway disorders. Heparin appears in the late foetal life and only small amounts have 
been detected during the early foetal development, probably because the protection 
against foreign bodies is not required during the early foetal life [32].  Therefore, it 
was suggested that, in addition to the intervention of the immune system, the 
manifestation of heparin also acts as one of the defense mechanisms against foreign 
bodies. The presence of heparin granules in the cytoplasm of mast cells and its release 
by inflammatory effectors, like allergens which bind to antigen-binding sites situated 
on mast cell surface, lead to the hypothesis that heparin is actively involved in 
counterbalancing the inflammatory response [33]. Heparin administration leads to 
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pain and swelling at the injection site; however, amelioration of pain and swelling 
shortly after heparin administration indicates an in vivo anti-inflammatory effect of 
heparin which has been observed in patients with deep-vein thrombosis [12]. Also, 
data from clinical studies indicate that elevated plasma levels of heparin and altered 
platelet function have been detected in atopic patients with asthma, supporting the 
potential role of heparin in respiratory diseases [34]. 
The anti-inflammatory potential of heparin has been reinforced by preclinical 
and clinical studies that have shown its effectiveness in the treatment of a wide array 
of inflammatory airway disorders, including asthma [35] and chronic obstructive 
pulmonary disease (COPD) [36]. It has been demonstrated that heparin binds to a 
large number of biologically active proteins and, thereby, leads to the inhibition of a 
variety of factors implicated in airway inflammation and remodelling (Figure 1.4). 
The consequences of these effects include the inhibition of the (i) function of T-
lymphocytes [37], (ii) infiltration of eosinophils and neutrophils into lungs [38], (iii) 
proliferation of airway smooth muscle [39], (iv) induction of asthma by exercise [40, 
41] and (v) allergen-induced early and late-asthmatic response [42]. There are many 
hypothesised explanations of the potential anti-inflammatory mechanisms of heparin 
during respiratory inflammation. The key proposed mechanisms that may account for 
the anti-inflammatory effects of heparin in asthma are outlined below. 
1.5.1 Anionic and cationic interactions 
Heparin contains a high net negative charge because of the presence of sulphate 
groups and therefore has a high affinity for positively charged biological proteins. 
Among such cationic proteins, heparin binds and inhibits eosinophil cation protein 
(ECP) and eosinophil peroxidase (EP) which are cytotoxic mediators released after 
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the activation of eosinophils [43]. ECP and EP are involved in late-asthmatic 
reactions causing airway remodelling. Inhibition of ECP moderates its cytotoxic 
effects on the respiratory epithelial cells; mucus production in the airways and ECP-
mediated release of histamine and mast cells in vitro are repressed [44]. Other cationic 
proteins that are inhibited by heparin are derived from platelets such as platelet factor-
4 (PF4). The inhibition of PF4 results in the reduction of further release of 
inflammatory mediators by eosinophils due to the decline in the chemotactic 
properties of PF4 for eosinophils [45].  
1.5.2 Anti-adhesive nature of heparin 
Adherence of  inflammatory cells to the vascular endothelium and their subsequent 
diapedesis into tissues is considered as an important element of the inflammatory 
response [46]. The recruitment of inflammatory cells into tissues is a multi-step 
process and it has been reported that heparin is active in each step to inhibit the 
recruitment of inflammatory cells into tissues, including the adhesion and 
transmigration of leucocytes to endothelial cells, and to consequently limit 
inflammation (Figure 1.5) [12]. The adhesion of leucocytes to the vascular 
endothelium is directly inhibited by non-anticoagulant derivatives of heparin [47, 48]. 
It was reported by Lever et. al. that the adhesion of polymorphonuclear leucocytes to 
endothelial cells was inhibited after pre-incubation of leucocytes with heparin [47].  
Apart from this direct inhibitory action, the anti-adhesive activity of heparin is 
also partly due to its binding to several adhesion molecules expressed during 
inflammation; these include selectins (L-, P- and E-selectin) and macrophage-1 (Mac-
1; CD11b/CD18) [33, 49-51]. L-selectin is constitutively expressed on the leukocytes, 
P-selectin on activated endothelium or platelets and E-selectin on activated 
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endothelium [52]. Interaction with selectin proteins and their counter glycoconjugate 
ligand(s) enables the leukocyte to “tether and roll” on the endothelium, which is the 
first step of leukocyte recruitment. Heparin acts as a counter-ligand for the selectins 
and binds in a calcium-dependent manner via lectin domains, resulting in the 
inhibition of the binding of L-, and P- selectin to their natural ligands (sialyl-Lewis
x
 
receptors) [49]. Thus, heparin constrains the early adhesive interactions between the 
inflammatory cells and the vessel wall mediated by L-selectin and sequestration of 
neutrophils to the site of inflammation interceded by P- and E-selectin [53, 54].  
 The firm adhesion of leukocytes to the endothelium, another major adhesion 
step, is mediated by the interaction between the integrin family of adhesion molecules 
(Mac-1; CD11b/CD18) and intercellular adhesion molecule-1 (ICAM-1) [55]. 
Heparin binds to Mac-1, thus blocking the interaction between Mac-1 and ICAM-1 
and, subsequently, inhibiting the adhesion of leukocytes to the endothelium [51].  
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Figure 1.5 Multi-step process involving the tethering, rolling, arrest and adhesion of leukocyte along the endothelium followed by extravasation (para- or 
trans-cellular migration) of leukocytes into tissues and the effectiveness of heparin in limiting inflammation by inhibiting the recruitment of inflammatory cell 
into tissues. 
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1.5.3 Anti-chemokine mechanism of heparin for its anti-migratory activity 
Heparin is known to neutralise or modify the properties of bound proteins, which are 
involved in the inflammatory process, and thereby help in limiting inflammation. 
Among such proteins, the migration of the leukocyte to the site of inflammation and 
the immune response following its activation is mediated by small, basic, chemotactic 
cytokines, such as chemokines [56]. It has been proposed that chemokines selectively 
bind to the GAGs expressed on the surface of endothelial cells and/or leukocytes, or 
in tissues. The interaction between chemokines and GAGs, especially heparan 
sulphate, results in enhanced migration of leukocytes to the site of inflammation by 
migration through the tissues and also by directing extravasation from the blood 
vessels via chemokine gradients (either chemotaxis or haptotaxis) and hence is 
implicated in the induction of inflammation [57].  
There is strong evidence that heparin inhibits the chemotactic potential of 
chemokines via competitive binding to displace other GAGs such as heparan sulphate, 
which are bound to chemokines, forming a biologically inert or anti-inflammatory 
heparin-chemokine complex (Figure 1.5) [58]. The displacement of heparan sulphate 
also prevents the binding of chemokines to their receptors, as it is known that heparan 
sulphate is also involved in presenting chemokines to their receptors [59]. 
1.5.4 Inhibition of the endoglycosidase heparanase 
Heparin acts as competitive inhibitors of heparanase, which is an endoglycosidase 
enzyme released from inflamed epithelial cells and a number of inflammatory cells 
including platelets, neutrophils, monocytes and activated T-lymphocytes [60]. The 
enzyme is believed to play a significant role during inflammation, causing 
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degradation and remodelling of extracellular macromolecules which enhance 
endothelial retraction and migration of leukocytes through the vascular endothelium 
[37, 61]. Heparanase is also involved in the direct activation of macrophages, 
resulting in the release of various cytokines and growth factors that promote 
inflammation. Heparin has the potential to modulate cell trafficking via its anti-
adhesive and anti-chemokine mechanisms. In addition to these mechanisms, the 
inhibition of heparanase by heparin reduces cell diapedesis and trafficking into tissues 
(Figure 1.5). 
1.5.5 Inhibition of 1,4,5-inositol triphosphate  
The therapeutic utility of non-anticoagulant oligosaccharides of heparin is often 
hindered by the presence of anticoagulant oligosaccharides causing the risk of 
bleeding. Nevertheless, the use of high doses (up to 80,000 U) of heparin in 
aerosolised form by Ahmed et al. [40] circumvented the risk induced by anticoagulant 
oligosaccharides. It was observed that after the patients inhaled aerosolised heparin, 
the specific post-exercise airway conductance value did not decrease when compared 
with positive control (cromolyn sodium; a mast cell stabiliser) and heparin was shown 
to be effective in the prevention of exercise-induced asthma. In contrast, no change in 
the level of coagulation was detected by monitoring the partial-thromboplastin time. 
However, the mechanism via which heparin was effective in preventing a decrease in 
the post-exercise airway conductance value is still uncertain. Ahmed et al. postulated 
that the protective action of heparin on exercise-induced asthma could be due to its 
inhibition of second-messenger (1,4,5-inositol triphosphate) mediated calcium release, 
through the blockade of receptors present on lung mast cells, leading to the inhibition 
of signal transduction, mast cell degranulation and mediator release. However, 
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alongside 1,4,5-inositol triphosphate, there are multiple other factors responsible for 
causing exercise-induced asthma, which were not considered in the study conducted 
by Ahmed et al.  
1.5.6 Inhibition of nuclear factor-κB (NF-κB) 
NF-κB is a pivotal transcription factor which, upon activation by nuclear translocation 
of cytoplasmic complexes, increases the pro-inflammtory gene expression leading to 
the synthesis of cytokines, chemokines, adhesion molecules, growth factors and 
enzymes [62]. Several lines of evidence indicate that NF-κB plays a central role in 
inflammatory airway diseases and persistent activation of the NF-κB pathway has 
been observed in  asthmatic tissues [63]. The persistent activation of NF-κB via a 
variety of stimuli (physical and chemical stress, T and B cell mitogens, 
lipopolysaccharides) is involved in the expression of pro-inflammatory cytokines, 
such as TNF-α, IL-6, IL-8, IL-12, IL-18 and IL-1β, which may influence the severity 
of chronic inflammatory diseases [62].  
It has been recently reported that heparin exerts an anti-inflammatory response 
by inhibiting p38 mitogen-activated protein kinase (MAPK) and NF-κB, subsequently 
quenching the activation of endothelial cells induced by lipopolysaccharides [64]. A 
study has documented a significant decrease in the release of interferon- γ and TNF- α 
by activated T-lymphocytes when pretreated with sulphated disaccharides of heparin. 
It was recognised that this effect of heparin was due to the inhibition of NF-κB 
activation of anti-CD3 activated T-lymphocytes [65]. As described previously, the 
extent of sulphation of the polysaccharides chain of heparin is a key characteristic for 
its higher biological activity. Similar response was observed in this study, suggesting 
that the degree of sulphation is essential for the inhibition of NF-κB; tri-suphated 
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disaccharide exhibited an inhibitory effect on NF-κB, but not the mono- or un-
sulphated disaccharides.  
1.5.7 Inhibition of inflammatory mediator release 
Proteoglycans, including heparin, are released after degranulation of mast cells during 
the early-asthmatic phase. It has been hypothesised that the physiological role of 
heparin in asthma could be due to its binding to, and consequent inhibition of, the 
preformed mediators such as histamine, leukotrienes and cytokines (IL-4, IL-5 and 
IL-13) released during the early-asthmatic phase. On the other hand, heparin can also 
inhibit the release of preformed mediators by preventing mast cell degranulation via 
its competitive binding to IP3 receptors, hence controlling stimulus-secretion coupling 
in mast cells [66]. An alternative hypothesis by Page [67] specified that the natural 
anti-inflammatory mechanism of the released endogenous heparin is inhibited by the 
prolonged use of β2-agonists in asthma, which reduce mast cell degranulation. 
Consequently, the prolonged use of adrenoceptor agonist deprives the release of 
heparin and other protective factors, which play a defensive role in the management 
of respiratory disorders.  
A wide array of inflammatory mediators, including cytokines, chemokines and 
complement factors, are released from the inflammatory cells during asthma. Among 
all the inflammatory cell types, mast cells play a major role in promoting ongoing 
airway inflammation and occurrence of late-phase asthmatic reactions through the 
release of multifunctional cytokines (TNF-α, IL-3, IL-4, IL-5, IL-6, IL-8, IL-16 and 
GM-CSF), chemokines (macrophage inflammatory protein- MIP-1, monocyte 
chemotactic protein- MCP-1, regulated on activation, normal T cell expressed and 
secreted- RANTES) and growth factors (transforming growth factor- TGF-β, 
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fibroblast growth factor- FGF) [68].  Heparin has the ability to bind and neutralise the 
release of inflammatory mediators and thereby attenuate the ongoing inflammatory 
process by condensing the influx of inflammatory cells, including eosinophils, T-
lymphocytes and neutrophils into the site of inflammation. Numerous clinical studies 
have documented that GAGs like heparin or heparin-derived oligosaccharides are able 
to bind and modulate the activity of several cytokines, chemokines and growth factors 
that are involved in the early or late asthmatic reaction and contribute to inflammatory 
disease severity. These include IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-
12, TNF-α, PF4, MIP-1α, MIP-1β, MCP-1, RANTES, platelet-derived growth factor, 
acidic and basic FGF, TGF-β, hepatocyte growth factor and vascular endothelial 
growth factor [69-80]. Additionally, heparin has been shown to bind and inhibit the 
activity or release of inflammatory mediators like cathepsin G [81] and elastase [82], 
which are toxic to bronchial epithelium and promote the ongoing inflammatory 
response causing tissue damage and remodelling. Furthermore, heparin interacts with 
secretory leukocyte protease inhibitor, through which it enhances the inhibition of 
cathepsin G and human neutrophil elastase [83].  The highly anionic nature of heparin 
enables it to bind and inhibit cytotoxic eosinophil-specific inflammatory mediators 
including major basic protein (MBP) and eosinophil peroxidase [84, 85]. Therefore, it 
can be seen  that heparin exhibits a broad spectrum of anti-inflammatory activities by 
exerting a variety of protective mechanisms [86]. Nevertheless, the fundamentals for 
the management of asthma seem to be heparin-mediated modulation of an array of 
inflammatory mediators released from the inflammatory cells.  
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1.5.8 Airway remodelling 
As mentioned, persistent inflammation is associated with airway remodelling which is 
due to the permanent structural alteration of the airways. Among several structural 
changes, the key alterations associated with airway remodelling are ASM cell 
hypertrophy and hyperplasia leading to the thickening of ASM [30]. It is noteworthy 
that these structural changes are generally insensitive or not fully responsive to the 
currently available treatments like corticosteroids [31, 87]. Heparin, however, has 
anti-proliferative effects and is able to inhibit the proliferation of ASM [88]. 
Nonetheless, the anti-proliferative activity of heparin largely depends on its molecular 
weight, charge density, position and degree of sulphation, as desulphated and 
disaccharides moiety of heparin failed to inhibit ASM proliferation [88]. The anti-
proliferative activity of heparin increases with an increase in the negative charge of 
the polymer [89]. Alongside the negative charge, the anti-proliferative activity of 
heparin also requires oligosaccharide chain greater than six saccharides; for instance, 
the non-anticoagulant heparin decasaccharide exhibited anti-proliferative effects [90]. 
On the other hand, selectively O-sulphated heparin retained anti-proliferative activity 
and oversulphation at O-positions enhances this activity [89, 91]. Remarkably, only 
the non-anticoagulant oligosaccharides of heparin retained these effects, since the 
pentasaccharide sequence (anticoagulant oligosaccharide) specific for anti-thrombin 
III binding, having a 3-O-sulphate group, displayed negligible anti-proliferative 
activity [89].  
Furthermore, heparin is also capable of modulating the effects of many basic 
growth factors that are crucially involved in airway remodelling, such as FGF-1, FGF-
2 and TGF-β1 [39, 79]. There are a few studies suggesting that heparin may inhibit the 
Chapter One 
 
22 
 
binding of EGF to its receptor and could serve in EGF-mediated inflammation in 
different disease models [92, 93]. It is evident that EGF is one of the major drivers of 
inflammation and airway remodelling in asthma [31]. However, to date there is no 
clear evidence of the effectiveness of heparin in inhibiting EGF-mediated asthmatic 
reactions. 
1.6 Clinical Studies 
The anti-inflammatory potential of heparin for the treatment of acute asthma was first 
assessed in 1960 using intravenously administered heparin [94]. In this small, 
subjective trial, heparin was found to be effective by immediately ameliorating the 
symptoms of asthma (wheezing, cough and difficulty in breathing). Since then, a large 
number of randomised trials have focused on the potential efficacy of heparin and its 
low-molecular weight derivatives in the management of asthma (summarised in Table 
1.2). In most cases, heparin was found to be effective in improving the signs of 
asthma - for example, the inhibition of exercise and methacholine-induced 
bronchoconstriction [40, 41, 95], inhibition of bronchospastic response induced by 
house dust mite [35, 42], and inhibition of eosinophil recruitment after nasal allergen 
challenge [96]. Remarkably, none of these trials reported heparin induced 
haemorrhagic side effects. Later a trial conducted by Bendstrup et al. [97] on lung 
deposition and clearance of inhaled heparin reported that after 24 h, 40% of the 
single-inhaled dose of heparin was detected in the lung, with no effect on blood 
coagulation.  
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Table 1.2 Clinical Studies 
Trial Design Type of Asthma No. of 
Subjects 
Heparin/LMWH 
Type/Dose 
Tested 
Experimental Design Delivery 
System 
Effects Reference 
Double-blind, placebo-
controlled, crossover 
design 
Early asthmatic 
response 
15 20,000 U 
heparin 
Administration of heparin 10 min 
before antigen challenge 
Nebulization Bronchospastic response 
induced by house dust mite 
was inhibited 
[35] 
Randomised, single-
blind, crossover design 
Exercise-induced 
asthma 
12 4 mL of 20,000 
U/mL heparin 
Administration of heparin sodium 
from 0.25 to 6 h before exercise 
challenge 
Nebulization Bronchoconstrictive response 
was inhibited from 0.25 to 3 h; 
ineffective at 6 h 
[40] 
Randomised, double-
blind, crossover design 
Exercise-induced 
asthma 
13 4 mL, 7.5 
mg/Kg Heparin 
or 0.5, 1 and 2 
mg/Kg 
enoxaparin 
Administration of heparin or 
enoxaparin 45 min before 
exercise challenge 
Aerosolized Bronchoconstrictive response 
was attenuated by 28%, 38% 
and 48% at 0.5, 1 and 2 mg/Kg 
enoxaparin, respectively and 
by 31% using heparin 
[41] 
Randomised, two-
period,  double-blind, 
crossover design 
Early and late 
asthmatic 
response 
8 1,000 U/Kg 
heparin 
Administration of heparin sodium 
at 0.5 and 1.5 h before and 2, 4 
and 6 h after antigen challenge 
Nebulization Immediate asthmatic response 
was attenuated and the late 
asthmatic response was 
significantly reduced 
[42] 
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Randomised, single-
blind, crossover design 
Bronchoconstrictiv
e response to 
bronchostimulants 
13 1,000 U/Kg 
heparin 
Administration of heparin sodium 
45 min before provocation with 
methacholine 
Nebulization Methacholine-induced 
bronchoconstriction was 
inhibited 
[95] 
Randomised, placebo-
controlled crossover 
design 
Early and late 
asthmatic 
response 
10 20,000 U 
heparin 
Administration of heparin calcium 
followed by antigen challenge 
Nebulization No effect [98] 
Randomised, double-
blind design 
Bronchoconstrictiv
e response to 
bronchostimulants 
11 4 mL, 1,000 
U/Kg 
Administration of heparin sodium 
10 min before provocation with 
methacholine or metabisulphite 
Nebulization No effect [99] 
Randomised, single-
blind, crossover design 
Exercise-induced 
asthma 
9 4 mL of 20,000 
U/mL heparin 
Administration of heparin sodium 
from 15 min to 6 h before 
exercise challenge 
Nebulization Bronchoconstrictive response 
was inhibited from 15 min to 3 
h; ineffective when 
administered before 6 h 
[100] 
Double-blind, placebo-
controlled, crossover 
design 
Early and late 
asthmatic 
response 
13 5,000 U Heparin Administration of heparin sodium 
10 min before provocation with 
allergen 
Nebulization Allergen (grass pollen) induced 
airway obstruction and 
bronchial hyper-
responsiveness was inhibited 
[101] 
 
Chapter One 
 
25 
 
Since inhaled heparin has shown favourable effects with no adverse changes to 
coagulation parameters, combined therapy with currently used standard medication 
could serve as a useful approach in the clinical management of asthma. For instance, 
one such combined therapy has already been tested in a trial with patients suffering 
from COPD, showing the effectiveness of enoxaparin with a combination of 
salmeterol/fluticasone [36]. Similar approaches could be tested in clinical trials with 
asthmatic subjects. 
1.7 Degree of uncertainty associated with anti-inflammatory effects of heparin 
Although inhaled heparin has shown encouraging results for the management of 
asthma, the preliminary clinical data are limited. There are several questions yet to be 
answered in regards to the use of inhaled heparin, including its long-term efficacy and 
adverse effects, dose and duration of action, before it can be recommended as an 
alternative or adjunct therapy for the management of asthma. Administration of 
heparin via oral route would be preferable over inhalation. However, very little or no 
gastrointestinal absorption of heparin is reported after its oral administration [102]. 
Nevertheless, attempts have been made to improve the absorption of oral heparin. For 
example, the oral absorption of heparin was found to be promoted when administered 
with a delivery agent such as sodium N-[8(-2-hydroxybenzoyl)amino]caprylate 
(SNAC) [103]. Lately, Ahmed et. al. [104] compared the effectiveness of oral and 
intravenous heparin tetrasaccharide on allergic airway responses. It was found that 
orally delivered heparin had comparable anti-allergic activity to that of intravenous 
heparin. This also suggests that orally administered tetrasaccharide had good oral 
bioavailability. However, the potential mechanism behind the absorption of orally 
administered tetrasaccharides needs to be elucidated. Other studies have indicated that 
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the larger oligosaccharides such as hexa- and deca-saccharides are also responsible for 
the anti-inflammatory activity of the parent heparin [70, 90, 105] and the oral 
bioavailability of such oligosaccharides is currently unknown. Nevertheless, delivery 
agents like SNAC could be further evaluated for oral administration of such larger 
oligosaccharides. 
Importantly, the use of heparins as anti-inflammatory agents is handicapped 
not only because of the risk of bleeding associated with anticoagulant 
oligosaccharides but also due to inconsistent results observed in various pre-clinical 
and clinical studies. Despite some preliminary clinical studies showing promising 
outcomes with the use of inhaled heparin, other randomised clinical trials have 
reported conflicting results [98, 99]. For example, one of the randomised trials 
reported an inhibitory effect of inhaled heparin on methacholine-induced 
bronchoconstrictive response [95]. In contrast, no such inhibitory effect of heparin on 
bronchoconstriction was observed in another randomised trial [99]. Likewise, recent 
clinical studies investigating the anti-inflammatory potential of different LMWHs 
have shown varying results. For instance, tinzaparin was the most potent inhibitor of 
selectins among all the tested LMWHs, and enoxaparin had a greater interference with 
P- and L-selectin compared to nadroparin [106, 107]. The contradictory results 
observed with heparin preparations are not only restricted to inflammatory airway 
disorders, but such findings have also been reported in many other types of 
inflammatory conditions. For instance, several studies have reported that heparin 
preparations can be beneficial for the management of ulcerative colitis and lichen 
planus. However, there are also reports indicating heparins have no or little 
therapeutic effect when used for the management of the same conditions [108, 109]. 
One likely explanation for these inconsistent findings could be the compositional 
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differences between different heparin preparations. All unfractionated heparin and 
LMWH preparations display many similar physical, chemical and biological 
properties.  However, a close examination has suggested significant structural 
differences between different LMWHs. Quantitative comparisons of the 
polysaccharide mixture by polyacrylamide gel electrophoresis showed substantial 
difference between oligosaccharide components of various LMWH preparations. 
Detailed study of different LMWHs by nuclear magnetic resonance showed enormous 
differences in their structures [110]. Two LMWHs, dalteparin sodium and nadroparin 
sodium, both are produced by nitrous acid treatment. Disaccharide and 
oligosaccharide analysis showed that they are more similar than two other LMWHs 
produced by different processes, but less similar than two batches of a LMWH from a 
single manufacturer [111, 112]. Anti-inflammatory effects of heparins are mainly 
attributed to their non-anticoagulant oligosaccharides and the commercially available 
heparins are standardised only according to the anticoagulant activity, which results in 
batch-to-batch variations of non-anticoagulant oligosaccharides. For example, using 
capillary electrophoresis, Patel et. al. [113] have demonstrated the differences in 
composition of non-anticoagulant oligosaccharides between batches of a LWMH 
obtained from the same manufacturer. They suggested that these compositional 
differences between non-anticoagulant oligosaccharides could be due to the inherent 
structural variability of the precursor heparin from which the LMWH is derived or 
due to differences in the fractionation process.  Also, enoxaparin was reported to be 
effective for the management of lichen planus, only when it was derived from a 
selected batch, indicating not all the batches of enoxaparin preparations possess 
equivalent anti-inflammatory activity [109]. Therefore, a key aspect in the use of 
heparins as effective anti- inflammatory agents is the necessity to maintain 
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consistency of non-anticoagulant oligosaccharides between different batches. An 
appropriate way seems to be to obtain the standard electrophoretic or chromatographic 
separation profiles of non-anticoagulant oligosaccharides of the particular batch of 
heparin having an anti-inflammatory activity. Other batches of enoxaparin could be 
then verified for the batch-to-batch uniformity by comparing the separation patterns of 
their non-anticoagulant oligosaccharides against a standard separation profile. This 
could minimise both batch-to-batch variations of non-anticoagulant oligosaccharides 
and inconsistency in clinical outcomes. 
1.8 Development of novel non-anticoagulant analogues of heparin 
Given that the anti-inflammatory potential of heparin is independent of its 
anticoagulant effect, the development of novel non-anticoagulant oligosaccharides of 
heparin which retain the anti-inflammatory properties of the parent compound could 
be useful in the future for the treatment of inflammatory diseases, including asthma. 
An example of such preparation is 2,3-O-desulphated heparin (ODSH), which is 
developed by selective desulphation of unmodified heparin under extreme alkaline 
conditions. The ODSH preparation had no anticoagulant activity, on the other hand 
exhibited anti-inflammatory potential similar to that possessed by the parent heparin 
[91]. In pre-clinical studies, ODSH showed promising anti-inflammatory effects by 
inhibiting airway hyperactivity and airway smooth muscle proliferation in mammals 
and, therefore, it is being subjected to clinical trial in patients with exacerbations of 
COPD [114].  
Another approach to minimise heparin-induced bleeding complications when 
used for the management of inflammatory disorders is to separate, isolate and 
characterise the non-anticoagulant and anticoagulant oligosaccharides. The current 
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approach to identify the non-anticoagulant oligosaccharides of heparin is to perform 
its depolymerisation by chemical or enzymatic methods [33]. These depolymerised 
oligosaccharides are then tested for their anticoagulant and anti-inflammatory effects. 
However, a chemical or enzymatic depolymerisation results in the structural 
modification of oligosaccharides
 
and it has been demonstrated that certain biological 
functions of the parent heparin could indeed be removed by the depolymerisation 
process [115]. Some oligosaccharides in heparin are heat sensitive and can undergo 
chemical modification, especially desulphation during the elevated temperatures of 
the depolymerisation process [116]. The sulfation pattern of an oligosaccharide is a 
key characteristic for its anti-inflammatory properties. Depolymerisation can also be 
performed through a freeze-drying process; however, freeze-drying results in physical 
changes of some oligosaccharides present within the parent heparin molecule [117]. 
Therefore, the non-anticoagulant oligosaccharides obtained by chemical or enzymatic 
depolymerisation could have different biological effects than the parent molecule. 
Another approach to identify the non-anticoagulant oligosaccharides without their 
structural modification could be to separate and isolate the non-anticoagulant and 
anticoagulant oligosaccharides and examine their anti-inflammatory effects. However, 
separation of such a complicated molecule is a long-standing problem. Nevertheless, 
in recent years various separation techniques, such as capillary electrophoresis [113], 
reversed-phase ion-pair chromatography [118, 119] and ion-exchange 
chromatography (IC) [105], have been developed not only for the separation but also 
for the finger printing of LMWHs. For example, we have recently developed a novel 
IC technique capable of separating a LMWH into several different oligosaccharides 
with high, low and no anticoagulant activities [105]. Inhibitory effects of such IC-
derived oligosaccharides on the release of macrophage-derived nitric oxide (NO) were 
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investigated. It is known that the production of NO in inflammatory disorders, 
including asthma, is increased in response to the secretion of cytokines and 
endogenous lipopolysaccharides [120]. It has been found that oligosaccharides with 
no or low anticoagulant activity significantly inhibited NO production. On the other 
hand, oligosaccharides having high anticoagulant effect had minimal or no effect on 
NO production [105]. Investigations with such approaches may lead to new 
formulations of purified heparin oligosaccharide (or combination of purified 
oligosaccharides) that exhibit effective anti-inflammatory properties but are devoid of 
anticoagulant activity.  
1.9 CONCLUSION 
In summary, the authors believe that heparin may play a significant role in the 
management of asthma. However, further trials on the efficacy of heparin or its 
derivatives are warranted before they can be indicated in the management of asthma. 
Its potential must be explored using well-designed clinical trials and experimental 
studies that also focus on identifying the anti-inflammatory oligosaccharides of 
heparin and further elucidating the mechanisms of action of these non-anticoagulant 
oligosaccharides. 
1.10 EXPERT OPINION 
The current drug modalities used for the management of asthma are reported to have a 
number of drawbacks. In general, conventional agents like salbutamol have a 
relatively short duration of action and associated with reduced lung function when 
over-used [121]. On the other hand, the safety of long-acting agents such as 
salmeterol has come into question, as these agents when used alone, may increase 
mortality or potentially result in lessened asthma control with time [122]. At present, 
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corticosteroids are the only effective agents available which diminish bronchial 
inflammation and chronic hyper-reactivity. However, inhaled corticosteroids as a 
first-line therapy often do not adequately control inflammatory airway disorders [123, 
124]; a sufficient number of patients suffer from adverse effects and the symptoms of 
asthma recur within few weeks or one year after the cessation of the treatment [125, 
126]. Apart from the risk of osteoporosis with long-term use, the inhaled 
corticosteroids are considered relatively safe in adults, while these agents are 
associated with significant toxicity in children, including reduced bone density and 
growth if used in high doses [127]. Thus, the search for safer and more effective 
agents for the management of asthma continues. Among these agents, heparin has 
attracted much research interest for its paradoxical response(s). Heparin, a commonly 
used anticoagulant, is a heterogeneous mixture of complicated and highly negatively 
charged polysaccharides. It is now well recognised that heparin possesses a wide 
range of biological activities, including anti-inflammatory effects. A number of 
studies have indicated that the anti-inflammatory effect of heparin could be due to the 
presence of non-anticoagulant oligosaccharides. However, these anti-inflammatory 
properties are largely hindered by the risk of bleeding caused by the presence of 
anticoagulant oligosaccharides. Therefore, there has been interest in developing 
pharmaceutical formulations containing non-anticoagulant oligosaccharides which are 
devoid of anticoagulant activity. Hence, in the future, molecular biologists and 
structural chemists will be focused on two existing challenges: (i) what are the 
underlying cellular and molecular mechanisms for the anti-inflammatory effects of 
these oligosaccharides? (ii) what are the differential structural requirements of 
oligosaccharides that possess anti-inflammatory properties? To develop a better 
understanding of the anti-inflammatory mechanisms of heparin-derived 
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oligosaccharides, a more detailed knowledge of their structures is required. There is 
evidence that the anti-inflammatory effects of heparin are mediated through multiple 
mechanisms including inhibition of macrophage-induced nitric oxide synthesis as 
well as inhibition of T lymphocytes-mediated release of inflammatory cytokines. We 
and others have demonstrated that the hexasaccharide nature of heparin is largely 
responsible for the inhibition of nitric oxide synthesis and the suppression of 
inflammatory cytokine release [70, 105]. Therefore, the key question for the 
molecular biologists would be whether the binding of heparin oligosaccharides to 
various inflammatory proteins requires unique structural sequences in the 
oligosaccharide chains for each protein, as with the pentasaccharide sequence found 
for anti-thrombin III binding, or the particular sequence allows the binding of 
oligosaccharides to a wide range of proteins and adhesion molecules involved in 
inflammation. However, given that heparin’s polysaccharides have a high degree of 
structural diversity, their structural characterisation appears to be the biggest 
challenge. Most often heparin polysaccharides are structurally characterised using a 
bottom-up approach. In this approach, intact polysaccharides are depolymerised into 
smaller disaccharide fragments and then subjected to structural characterisation using 
various analytical techniques such as mass spectrometry (MS) and nuclear magnetic 
resonance (NMR). However, there are two potential problems associated with this 
approach: (a) we and others have demonstrated that the oligosaccharides larger than 
disaccharides are mainly responsible for the anti-inflammatory effects and (b) 
depolymerisation may impart other process specific structural changes in the digested 
oligosaccharides [116, 117]. Hence, the research goal should be to isolate and 
characterise the structurally unmodified polysaccharides, in part to explore their anti-
inflammatory activity. In considering these two problems it must be recalled that 
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currently available advanced analytical techniques such MS and NMR are not capable 
of characterising the mixtures of heterogeneous polysaccharides present in intact 
heparin. However, an ion-exchange chromatography has been recently developed to 
separate and isolate polysaccharides of heparin without their structural modification, 
and the continued efforts of structural chemists to improve the resolution power of 
new hyphenated techniques (e.g. liquid-chromatography-MS/MS and liquid-
chromatography-NMR) will increase the efficiency of structural characterisation of 
ion-exchange derived oligosaccharides. However, structural characterisation and 
development of non-anticoagulant formulations of heparin will require extensive 
validation and formulation steps, and is likely to take a long time to eventuate. In the 
meantime, using murine experimental models we aim to focus on investigating the 
long-term anti-inflammatory effectiveness and safety of different doses of various 
sized oligosaccharides.  
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Opposing Effects of Low Molecular Weight Heparins on the Release of 
Inflammatory Cytokines from Peripheral Blood Mononuclear Cells of 
Asthmatics
 
2.1 ABSTRACT 
Background:  T-cell-mediated inflammatory cytokines, such as interleukin (IL)-4, IL-
5, IL-13 and tumor necrosis factor-alpha (TNF-α), play an important role in the 
initiation and progression of inflammatory airways diseases. Low-molecular-weight 
heparins (LMWHs), widely used anticoagulants, possess anti-inflammatory properties 
making them potential treatment options for inflammatory diseases, including asthma. 
In the current study, we investigated the modulating effects of two LMWHs 
(enoxaparin and dalteparin) on the release of cytokines from stimulated peripheral 
blood mononuclear cells (PBMCs) of asthmatic subjects to identify the specific 
components responsible for the effects.    
Methods: PBMCs from asthmatic subjects (consist of ~75% of T-cells) were isolated 
from blood taken from ten asthmatic subjects. The PBMCs were pre-treated in the 
presence or absence of different concentrations of LMWHs, and were then stimulated 
by phytohaemagglutinin for the release of IL-4, IL-5, IL-13 and TNF-α. LMWHs 
were completely or selectively desulfated and their anticoagulant effect, as well as the 
ability to modulate cytokine release, was determined. LMWHs were 
chromatographically fractionated and each fraction was tested for molecular weight 
determination along with an assessment of anticoagulant potency and effect on 
cytokine release.  
Results: Enoxaparin inhibited cytokine release by more than 48%, whereas dalteparin 
increased their release by more than 25%. The observed anti-inflammatory effects of 
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enoxaparin were independent of their anticoagulant activities. Smaller fractions, in 
particular dp4 (four saccharide units), were responsible for the inhibitory effect of 
enoxaparin. Whereas, the larger fractions, in particular dp22 (twenty two saccharide 
units), were associated with the stimulatory effect of dalteparin. 
Conclusion: Enoxaparin and dalteparin demonstrated opposing effects on 
inflammatory markers. These observed effects could be due to the presence of 
structurally different components in the two LMWHs arising from different methods 
of depolymerisation. This study provides a platform for further studies investigating 
the usefulness of enoxaparin in various inflammatory diseases.  
2.2 INTRODUCTION 
Unfractionated heparin (UFH), a member of the glycosaminoglycan family, is a 
complex heterogeneous mixture of polysulfated chains comprised of alternating 
disaccharide residues of D-glucosamine and uronic acid residues linked by 1→4 
glycosidic bonds [128]. The well-known biological role of UFH is its ability to 
influence blood coagulation and it has been extensively used in clinical practice as an 
anticoagulant [129]. In recent years, UFH has largely been replaced by low-
molecular-weight heparins (LMWHs) for the treatment and prophylaxis of deep vein 
thrombosis because of more favourable pharmacokinetic properties and with a 
reduced rate of side effects [6, 130].  LMWHs are modified derivatives of UFH 
obtained by either chemical or enzymatic depolymerisation of UFH [131]. The key 
structural unit of heparins (UFH and LMWHs) responsible for their anticoagulant 
activity consists of three D-glucosamine and two uronic acid residues (known as a 
pentasaccharide sequence). This pentasaccharide sequence binds to the serine protease 
inhibitor anti-thrombin III and induces conformational changes within the structure of 
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anti-thrombin, thereby accelerating its interaction and subsequent inhibition of 
thrombin and/or factor Xa of the coagulation cascade  [5]. However, not all 
fragments, also known as oligosaccharides, within heparins contain an anti-thrombin 
specific pentasaccharide sequence. For example, merely 20-50% of  the 
oligosaccharides of UFH contain the specific anti-thrombin binding domain and the 
bulk of the oligosaccharides  are composed of relatively non-specific sequences, also 
known as non-anticoagulant oligosaccharides [10, 132].  
It is now recognised that besides the well-recognised anticoagulant effect, 
heparins also exhibit a broad spectrum of anti-inflammatory and immune-modulating 
properties [36, 41, 133-135]. The anti-inflammatory effect of heparins is thought to be 
due to their ability to alter the activity of a wide range of proteins, such as adhesion 
molecules, growth factors, cytotoxic mediators and tissue-destructive enzymes [13]. 
Clinical studies have reported the successful use of heparins for the treatment of 
chronic obstructive pulmonary disease [36], cancer [133], ulcerative colitis (UC) 
[134] and lichen planus [135]. The anti-angiogenesis effect in cancer has been shown 
to be mediated through suppression of  tumor vascular endothelial growth factor 
expression [136]. Anti-UC properties are thought to be exhibited by inhibiting the 
recruitment of neutrophils, as well as healing of ulcerated mucosa by restoring the 
high-affinity receptor binding of fibroblast growth factor [137]. Similarly, the 
therapeutic effectiveness of heparins in lichen planus is thought to be mediated by 
competitive inhibition of an important component of the extracellular matrix, known 
as heparinase [109].  
A number of clinical studies have also reported the beneficial effects of 
heparins in asthma [35, 40-42, 95]. However, the mechanisms behind these effects are 
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not well understood and there are plausible inflammatory pathways that remain to be 
explored. Despite being a complex disorder, the aetiology and pathophysiology of 
asthma is relatively well understood. Cytokines play a pivotal role in orchestrating the 
inflammation and structural changes of the airways in asthma. Among several types of 
important inflammatory mediators, T-cell mediated cytokines are known to be the key 
drivers of respiratory inflammation [138]. During early respiratory inflammation, the 
activated naïve T-helper cells release several inflammatory mediators, including IL-4, 
IL-5 and IL-13 [23]. IL-4 and IL-5 rapidly attract and prime eosinophils and mast 
cells. These cells, when activated, release high quantities of IL-5 and tumor necrosis 
factor (TNF)-α [139]. TNF-α sustains lung inflammatory responses by increasing the 
accumulation and activation of neutrophils and eosinophils in the airways. Their 
activation triggers the release of cytotoxic products, further damaging the airways 
[140].  IL-13 is associated with airway hyper-responsiveness, mucus production and 
structural changes in the airways called airway remodelling [141]. Also, IL-13 is 
known to play a key role in corticosteroid-resistant asthma by diminishing binding 
affinity between corticosteroids and their receptor ligands present on the surface of 
immune cells [142]. This is clinically significant as it is estimated that up to 10% of 
asthmatic patients have difficult-to-treat asthma that is often resistant to first line 
treatment with inhaled corticosteroids [143]. Given the high prevalence of asthma 
[144], 10% of asthmatic patients represent a significant number. Therefore, the 
development of potential therapeutic agents targeting difficult-to-treat asthma is 
highly desirable. 
Because of the ability of highly negatively charged heparins to interact with a 
wide range of biological molecules, we and others have postulated that the possible 
anti-asthmatic activity of heparins is caused by their inhibitory effects on the release 
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of important inflammatory mediators involved in the pathogenesis of asthma [145-
147]. Therefore, in the current ex-vivo study we investigated the ability of two widely 
used LMWHs (enoxaparin and dalteparin) to modulate the T-cell mediated release of 
IL-4, IL-5, IL-13 and TNF-α in asthmatic subjects, with the aim of identifying the 
specific oligosaccharide(s) responsible for the anti-inflammatory activity of the parent 
LMWH.  
2.3 MATERIALS AND METHODS 
2.3.1 Materials 
Enoxaparin (Clexane, 20 mg/0.2 mL; 2,000 IU/0.2 mL) was obtained from Aventis 
Pharma Ltd. (NSW, Australia). Dalteparin (Fragmin, 16 mg/0.2 mL; 2500 IU/0.2 mL) 
was purchased from Pfizer Inc. (NSW, Australia). Fondaparinux (Arixtra, 2.5 
mg/0.5mL) was purchased from GlaxoSmithKline (Victoria, Australia). RPMI-1640 
cell culture medium, Histopaque, antibiotics (penicillin G and streptomycin), 
phytohaemagglutinin (PHA), ethanol, hydrogen peroxide, sodium hydroxide, acetic 
acid, potassium hydroxide, sodium sulfate and lactate dehydrogenase (LDH) activity 
assay kits were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Fetal 
bovine serum was obtained from Invitrogen (Grand Island, NY, USA). ELISA kits for 
IL-4, IL-5, IL-13 and TNF-α were purchased from Mabtech Australia Pty. Ltd. 
(Victoria, Australia). Fluroaldehyde assay reagent was purchased from Pierce 
(Rockford, IL, USA). The anti-factor Xa (AFXa) assay kit was purchased from 
American Diagnostica (Stamford, CT, USA). Ultrafiltration disk membranes were 
purchased from Millipore (NSW, Australia). Heparin-derived unsaturated 
oligosaccharide standards were purchased from V-LABS (Covington, LA, USA). 
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2.3.2 Study sample 
A total of 10 healthy (mean age: 34.4 years; range: 28-48 years, 8 males, 2 females) 
and 10 asthmatic (mean age: 45.6 years; range: 39-51 years, 4 males, 6 females) 
subjects were recruited from the Medical Science Precinct, University of Tasmania, 
Australia. The healthy volunteers were not suffering from any acute or chronic 
diseases and the asthmatic subjects were suffering from no other diseases apart from 
mild asthma. The asthmatic subjects had not consumed systemic or inhaled 
corticosteroids or any other immunomodulatory medications to control their asthma in 
the 2 months before the blood samples were drawn. No information of either the use 
of other medications or forced expiratory volume (FEV1) was obtained from the 
recruited participants. 
2.3.3 Ethics statement 
All volunteers were recruited by invitation and the research protocol was approved by 
the Health and Medical Human Research Ethics Committee (Tasmania, Australia) 
Network (Approval number: H0013117). Written informed consent for the collection 
of blood samples was obtained from the recruited volunteers. 
2.3.4 Isolation of peripheral blood mononuclear cells (PBMCs) 
Whole blood (80 mL) from each volunteer was collected and mixed with an equal 
volume of incomplete RPMI-1640 culture medium to reduce the density of blood, 
allowing efficient separation of PBMCs from other cells. Aliquots of blood (30 mL) 
were layered over 20 mL of Histopaque (a density gradient cell separation medium). 
Following centrifugation at 200g for 30 minutes at 20°C (Eppendorf; Model: 5810R), 
PBMCs were aspirated from the Histopaque/aqueous interface and centrifuged at 
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700g for 10 minutes. Cells were washed twice with serum-free medium and 
resuspended in complete medium [RPMI-1640 supplemented with 2.0 mM L-
glutamine, 10% fetal bovine serum and antibiotics (penicillin G and streptomycin)].  
2.3.5 Preparation of stock solutions 
Stock solutions of enoxaparin, dalteparin and fondaparinux at 1 mg/mL were prepared 
in RPMI-1640 medium and filtered sterile through 0.2 µm pore size syringe filters 
(Pall Life Sciences, Victoria, Australia). Similarly, stock solution of PHA (2.5 mg/mL 
in RPMI-1640 medium; stored at -20°C) was prepared. The stock solutions of 
LMWHs were serially diluted with RPMI-1640 medium to obtain concentrations over 
the range of 5 to 1000 µg/mL. Likewise, PHA was diluted with RPMI-140 medium to 
obtain a concentration of 10 µg/mL.  
2.3.6 Stimulation and LMWHs treatment of PBMCs  
PBMCs were cultured in 24-well cell culture plates at a concentration of 1 × 10
6 
cells/mL/well and stimulated with 10 µg/mL of PHA (T-cell specific stimulant) in the 
presence of either RPMI-1640 medium (negative control), different concentrations (5, 
10, 20, 50, 80 and 100 µg/mL) of enoxaparin or dalteparin, or 5 to 1000 µg/mL of 
fondaparinux. After 72 hours of incubation (37°C, humidified 5% CO2 atmosphere), 
PBMC cultures were centrifuged, and supernatants were removed and analysed for 
the levels of released cytokines (IL-4, IL-5, IL-13 and TNF-α) using enzyme-linked 
immunosorbent assay (ELISA). 
2.3.7 ELISA 
Each high protein binding 96-well ELISA plate was prepared as per manufacturer’s 
recommendations. Briefly, plates were coated with 100 µL/well of capture antibody 
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(diluted in ELISA diluent) and incubated overnight at 4-8°C. The plates were washed 
twice with wash buffer (200 µL/well); blocked by addition of blocking buffer (PBS 
with 0.05% Tween 20 containing 0.1% bovine serum albumin) and incubated for 1 
hour at room temperature before washing again for 5 times. Stock solutions of 
cytokine standards were prepared in ELISA diluent. PBMC supernatants and cytokine 
standards (100 µL/well) were added to plates, incubated for 2 hours and washed 5 
times. Next, 100 µL/well of biotinylated detection antibody, at a concentration of 1 
µg/mL, was added to each plate and washed 5 times after incubating for 1 hour. 
Further, 100 µL/well of standard horseradish peroxidase conjugated streptavidin (a 
commonly used enzyme to modify substrate resulting in colour development) was 
added to each plate and incubated for 1 hour. Plates were again washed for five times 
and 3,3',5,5'-tetramethylbenzidine as a chromogenic substrate solution (100 µL/well) 
was added. Plates were then allowed to stand in dark for 20-30 minutes and the 
reaction was quenched using 50 µL/well of stop solution (1N hydrochloric acid). 
Measurement of the optical density was performed using a plate reader (Spectra Max 
M2 microplate reader, Sunnyvale, CA) at 450 nm. Each PBMC treatments were 
performed in triplicates and supernatants of each treatment was analysed in duplicate.  
2.3.8 PBMC viability and cytotoxicity assay  
The effect of LMWHs on viability of cells after 72 hours of incubation was assessed 
using two methods. Firstly, a trypan blue exclusion test was performed on cells and 
their viability was determined by counting the unstained cells (cells which did not 
take up trypan blue) using a haemocytometer, as described previously [148]. 
Secondly, the activity of LDH in culture supernatant was tested to investigate the 
cytotoxic effect of LMWHs using a LDH in-vitro toxicology assay, as described 
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before [149]. The LDH assay kit was prepared as per the manufacturer’s instructions. 
Briefly, PBMC culture supernatants were centrifuged at 250g for 4 minutes. An 
aliquot containing 50 μL of either blank (complete medium), control (PBMCs only), 
cells treated with PHA alone or with PHA in the presence of 100 μg/mL  enoxaparin 
or dalteparin was mixed with 100 μL of solution containing LDH assay mixture (LDH 
substrate, LDH dye and LDH cofactor). The mixture was then covered with 
aluminium foil and incubated at room temperature for 20-30 minutes for colour 
development and the reaction was terminated by the addition of 1 N hydrochloric acid 
(15 μL). The absorbance was measured spectrophotometrically using a plate reader 
(Spectra Max M2 microplate reader, Sunnyvale, CA) at a wavelength of 490 nm. 
Each sample was prepared and analysed in triplicate. Lastly, cell proliferation was 
carried out by counting the total number of cells 72 hours after PBMC treatments. 
2.3.9 Desulfation of LMWHs 
2.3.9.1 Complete desulfation of LMWHs  
A solution containing 5 mg/100 μL of enoxaparin and dalteparin was subjected to acid 
hydrolysis for complete removal of sulfate groups, as described previously [150]. 
Briefly, 1.5 mL of nitric acid was added to each sample in a capped glass vial and the 
solution was heated at 80°C overnight before adding 0.3 mL of hydrogen peroxide. 
The temperature was further raised to 110°C for the following 6 hours. An 
experimentally determined volume of 1 M sodium hydroxide was used to neutralise 
the mixture containing nitric acid, hydrogen peroxide and enoxaparin or dalteparin. 
The neutralised solution was diluted with 8 mL of Milli-Q water and 400 μL of this 
solution was further diluted to 8 mL.  
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2.3.9.2 N-desulfation of LMWHs  
A solution containing 5 mg/100 μL of enoxaparin or dalteparin was incubated at 50°C 
for 30 minutes in the presence of tetrahydrofuran (650 µL) and Milli-Q water (50 µL) 
for partial N-desulfation, as described previously [151] with minor modifications. The 
mixture was neutralised using 0.1 M sodium hydroxide. The resulting product was 
evaporated to dryness and precipitated by the addition of anhydrous methanol (80% 
v/v) followed by centrifugation at 3000 rpm for 10 minutes. The supernatant was 
carefully discarded and samples were kept at 4°C overnight. Any remaining traces of 
methanol were removed using a miVac DNA centrifugal concentrator (Genevac Ltd, 
Suffolk, UK) and the precipitants were dissolved in 5 mL Milli-Q water.  
2.3.9.3 Selective 2-O and 3-O-desulfation of LMWHs 
Selective 2-O and 3-O-desulfation was performed using a previously described 
method [151].  Briefly, a solution containing 5 mg/100 μL of enoxaparin or dalteparin 
was dissolved in 0.1 M sodium hydroxide (200 μL). The solution was then frozen and 
lyophilised to dryness. The residues were dissolved in Milli-Q water (0.5 mL) and the 
pH was adjusted to 8 by the addition of acetic acid solution. The solution was dialysed 
against water for 2 days and lyophilised to obtain 2-O, 3-O-desulfated enoxaparin and 
dalteparin fragments.  
 Free sulfate content, free amino groups and anticoagulant activity of 
completely and selectively desulfated enoxaparin samples was investigated, along 
with their effects on the PHA-induced release of cytokines from activated PBMCs of 
the asthmatic subjects.  
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2.3.10 Ion chromatography analysis of free sulfate content 
Free sulfate content of completely and selectively desulfated LMWHs was determined 
using a previously developed ion chromatography (IC) method [116].  Samples were 
injected into a Dionex DX-120 instrument (Sunnyvale, CA, USA) consisting of a 
GP50 gradient pump and AS50 auto sampler. Mobile phases were composed of 
potassium hydroxide (KOH) and Milli-Q water. Hydroxide eluent gradients were 
prepared through mixing of KOH solution and Milli-Q water online using a Dionex 
EluGen II KOH cartridge. A Dionex IonPac AS11 column was used to detect the 
sulfate content with the optimised KOH eluent gradient from 1 mM to 15 mM over a 
period of 15 minutes. A total flow rate of 1.0 mL/minute and an injection volume of 
25 μL was maintained. Conductivity detection in suppression mode was carried out 
using a CD25 conductivity detector. Instrument control and data acquisition were 
performed using Chromeleon
®
 software. Sodium sulfate containing 0-20 µg/mL of 
sulfate was used to prepare the standard curves. For comparison, the presence of free 
sulfate content in intact LMWHs (before desulfation) was also investigated after ultra-
filtration of enoxaparin/dalteparin at 15000 rpm for 10 minutes. Each sample was 
prepared in triplicate and analysed in duplicate. 
2.3.11 Analysis of free amino groups 
The determination of free amino groups in selectively desulfated LMWHs was 
determined using a sensitive fluoraldehyde-based assay, as described previously 
[117]. Briefly, selectively desulfated samples (20 µL) were mixed with deionised 
water (180 µL) before the addition of fluoraldehyde assay reagent (1 mL). The 
solution was mixed well and fluorescence was measured at 455 nm after excitation at 
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360 nm using a fluorescence spectrophotometer (model 1605-10S, Perkin-Elmer, 
Tokyo, Japan). Standard curves (0 to 600 µg/mL) were prepared using glycine.  
2.3.12 Analysis of anticoagulant activity 
The potentiating effect of intact or desulfated LMWHs on anti-thrombin III inhibition 
of activated factor Xa was determined as previously described [116]. Briefly, a low-
volume microtitre plate anti-FXa assay was performed by incubating (3 minutes, 
37°C) a solution containing anti-thrombin III, FXa and intact or desulfated LMWH 
samples, followed by addition of FXa substrate and further incubation for 10 minutes. 
The reaction was quenched using glacial acetic acid and the intensity of developed 
colour was spectrophotometrically measured at 405 nm (Multiskan Go, SkanIt 
software, Thermo Fisher Scientific).  
2.3.13 Fractionation and collection of LMWH fractions 
Fractionation of enoxaparin and dalteparin was performed using a previously 
developed high-performance size-exclusion chromatography (HP-SEC) method [116] 
with some modifications. A high-performance liquid chromatography (HPLC) system 
consisting of a Prostar 230 solvent delivery module, a Prostar 335 DAD detector and 
a Prostar 410 autosampler (Varian, Melbourne, Australia) was utilised.  Data 
acquisition and instrument control were carried out using Star Chromatography 
Workstation
® 
software.  The analyses were performed by injecting 10 mg/mL of 
enoxaparin or dalteparin using a 200 µL sample loop and a 70 µL sample injection 
volume.  UV detection was monitored at 232 nm.  Isocratic elution of LMWHs was 
performed on a Superdex
TM
 10/300 GL (300×10 mm) size-exclusion column (GE 
Healthcare Bio-Sciences, Uppsala, Sweden) using 0.3 M sodium chloride eluent at a 
flow rate of 0.2 mL/minutes. After each HP-SEC injection (n=20), 8 fractions of 
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enoxaparin and 9 fractions of dalteparin were collected. The collected fractions were 
concentrated on a miVac DNA centrifugal concentrator at 40°C and subsequently 
desalted using PD MidiTrap G-10 columns (GE Healthcare Life Sciences, Uppsala, 
Sweden). Each fraction was filter sterilized using 0.2 µm pore size syringe filters (Pall 
Life Sciences, Victoria, Australia) and stored at 4°C until further use. Fractions were 
analysed in triplicate for their effects on PHA-induced release of cytokines, as well as 
for their anticoagulant activity as described above.  
2.3.14 Statistical analysis 
Data are presented as mean ± standard deviation (SD) or as percentage change in the 
release of cytokines following treatments (enoxaparin, dalteparin, desulfated 
enoxaparin/dalteparin or HPSEC-derived fractions of enoxaparin/dalteparin) 
compared to the control samples. Statistical analysis was performed using GraphPad 
Prism (version 6, GraphPad Software Inc, CA, USA), and significance was evaluated 
using independent sample or paired Student’s t-test, and one way analysis of variance 
(ANOVA), where applicable, followed by Dunnett’s multiple comparison test. A p-
value of <0.05 was considered statistically significant. 
2.4 RESULTS AND DISCUSSION 
2.4.1 Release of cytokines from stimulated PBMCs  
The levels of the four cytokines (pg/mL) measured 72 hours after PHA-induced 
stimulation of PBMCs from healthy and asthmatic volunteers are shown in Figure 2.1. 
The calibration curves used for the measurement of cytokines were generated using 
seven recommended concentrations of respective cytokine standards. The linearity, 
estimated by correlation coefficient (r
2
), was greater than 0.964 for each of the 
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cytokines. As expected, the levels of tested cytokines from PBMCs of asthmatic 
subjects were significantly higher than those released from healthy volunteers. It is 
known that the relative concentrations of the two main types of T-helper cells (Th1 
and Th2) are different in patients with asthma compared to healthy individuals. In the 
healthy population, Th1/Th2 balance is maintained by producing the required Th1 or 
Th2 cells to establish the normal immune tolerance [152]. In patients suffering from 
allergic disorders, including asthma, the Th1/Th2 balance becomes abnormal and it 
shifts abruptly towards Th2 cells [152]. The greater population of Th2 cells upon 
activation release various cytokines, including IL-4, IL-5, IL-13 and TNF-α.   
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Figure 2.1 Ex-vivo cytokine release. PHA-induced release of IL-4, IL-5, IL-13 and TNF-α in 
PBMC culture supernatants of healthy (n=10) and mild asthmatic (n=10) subjects (A to D). 
Error bars are omitted for reasons of clarity. (E) Summary of the results from A to D. Each 
sample was analysed in triplicate. Error bars indicate the standard deviation. ***p<0.001 
versus PHA-stimulated control. 
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2.4.2 Effect of LMWHs on cytokine release 
To investigate the effects of LMWHs on the release of cytokines, enoxaparin or 
dalteparin was added to the cells prior to the addition of PHA. The percentage 
inhibition of cytokine release in the presence or absence of enoxaparin and dalteparin 
is shown in Figure 2.2. The inhibitory effect of enoxaparin was found to be 
concentration-dependent and its maximum effect was observed at 50 µg/mL (Figure 
2.2A to 2.2D).  The release of IL-4, IL-5, IL-13 and TNF-α was inhibited by more 
than 58%, 50%, 55% and 48%, respectively, in the presence of 50 µg/mL of 
enoxaparin. On the other hand, dalteparin failed to supress the release of tested 
cytokines and, on the contrary, the release of IL-4, IL-5, IL-13 and TNF-α was 
increased by more than 25% in the presence of 80 or 100 µg/mL of dalteparin (Figure 
2.2A to 2.2D).  
Enoxaparin and dalteparin are prepared by different depolymerisation 
processes [131]. Enoxaparin (an average molecular weight of 4500Da) is prepared by 
chemical β-eliminative cleavage of benzyl ester of UFH and dalteparin (an average 
molecular weight 6000Da) is prepared by nitrous acid induced deaminative cleavage 
of UFH. Therefore, their oligosaccharides have different sequences as well as terminal 
reducing and non-reducing ends. Compared to dalteparin, enoxaparin is more 
heterogeneous in nature and is mainly composed of oligosaccharides ranging from 
dp2 (two saccharide units) to dp16 (16 saccharide units) [153]. On the other hand, the 
smallest oligosaccharide unit found in dalteparin is dp8 and it mainly contains 
oligosaccharides longer than dp12 [153].  
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Figure 2.2 Concentration-dependent effect of LMWHs on cytokine release. Effect of 
different concentrations of enoxaparin and dalteparin on cytokine levels [IL-4 (A), IL-5 (B), IL-
13 (C) and TNF- α (D)] following PHA-induced ex-vivo stimulation of PBMCs from asthmatic 
subjects (n=10). Data is presented as percentage (mean ± SD) of the maximal observed 
cytokine concentrations. *p<0.05, **p<0.01 and ***p<0.001 versus PHA-stimulated control. 
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In line with our results, other studies have also shown different responses of various 
cells and molecules involved in the process of inflammation to LMWHs. It has been 
proposed that different effects might result from the presence of different proportions 
of small and large oligosaccharide chains within various LMWHs [154, 155]. Based 
on this, it can be postulated that the suppression of cytokine release could be due to 
shorter oligosaccharide chains (≤dp8), prevalent in enoxaparin, whereas an increase in 
cytokine release might be due to longer oligosaccharides (>dp8), which are common 
in dalteparin. It has been shown that Th1-type cytokines such as interferon-γ and IL-
12 play an important role in controlling immune and allergic responses in asthma 
[156]. For example, interferon-γ may counteract Th2 mediated immune responses by 
1) minimising the development of Th2 cells, 2) increasing the production of IL-12, 3) 
inducing apoptosis of eosinophil and 4) preventing immunoglobulin switch in B cells. 
The current study investigated the effects of LMWHs on the release of Th2- but not 
Th1-type cytokines. Therefore, future studies should be focused on determining the 
effects of LMWHs on the level of Th1-type cytokines as well. 
2.4.3 Effect of LMWHs on viability and proliferation of PBMCs  
Different types of heparins have shown to possess pro- or anti-proliferative effects 
[157, 158]. Therefore, it was important to determine whether or not the observed 
effect above on cytokine production was due to either enoxaparin-induced cell 
toxicity or dalteparin-induced cell proliferation. The cell viability was assessed in the 
presence of PHA alone or in combination with PHA and enoxaparin/dalteparin, by 
detecting the release of LDH (Figure 2.3A). Neither enoxaparin nor dalteparin 
increased the release of LDH, whereas PHA, as described before, induced cellular 
toxicity [159, 160]. PHA-induced toxicity was not affected when PHA-stimulated 
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cells were co-incubated with enoxaparin or dalteparin. Cellular viability in the 
presence or absence of enoxaparin and dalteparin is shown in Figure 2.3B. Unlike 
PHA, enoxaparin or dalteparin did not produce signs of cellular cytotoxicity. Cell 
proliferation in the presence or absence of enoxaparin and dalteparin is shown in 
Figure 2.3C. The proliferation of PBMCs was found to be significantly increased in 
the presence of PHA, whereas enoxaparin and dalteparin showed no effect on cell 
proliferation. These results indicate that modulation of cytokine release in the 
presence of tested LMWHs was not related to their cytotoxicity or changes in cellular 
proliferation.  
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Figure 2.3 Effect of LMWHs on cellular 
viability. (A) LDH activity of PBMC 
supernatants from asthmatic subjects 
(n=5) expressed as the percentage of 
maximum LDH release following 72 hours 
of incubation in the presence of either 
PHA, enoxaparin/dalteparin alone or 
enoxaparin/dalteparin co-incubated with 
PHA. Error bars indicate standard 
deviation. ***p<0.001 compared to 
unstimulated cells only control. (B) Effect 
of enoxaparin and dalteparin on the 
viability of PBMCs obtained from 
asthmatic subjects (n=5) after pre-
treatment of cells with either PHA, 
enoxaparin/dalteparin alone or 
enoxaparin/dalteparin co-incubated with 
PHA. Viability was measured using trypan 
blue dye exclusion test 72 hours after 
incubation with drugs and is presented as 
the percentage of viable cells. Error bars 
indicate standard deviation. *p<0.05, 
**p<0.01 and ***p<0.001 compared to 
either unstimulated cells only or PHA-
stimulated control. (C) The effects of 
enoxaparin and dalteparin on PHA-
induced proliferation of PBMCs obtained 
from asthmatic subjects (n=5) measured 
72 hours after incubation with 
enoxaparin/dalteparin alone or 
enoxaparin/dalteparin co-incubated with 
PHA. Error bars indicate standard 
deviation. **p<0.01 and ***p<0.001 
compared to either unstimulated cells only 
or PHA-stimulated control. 
 
 
Chapter Two 
 
54 
 
2.4.4 Effect of desulfated LMWHs on cytokine release   
The anticoagulant activity of LMWHs is strongly influenced by the degree of 
sulfation and the distribution of sulfate groups in their oligosaccharide chains [128]. 
To investigate whether the observed effect of enoxaparin and dalteparin was 
dependent on their anticoagulant activity, they were subjected to complete or selective 
desulfation. Free sulfate in intact enoxaparin and dalteparin was determined by IC and 
was found to be equivalent to 0.42% and 0.36% (w/w), respectively. Total bonded 
sulfate in enoxaparin and dalteparin after complete desulfation, and allowing for the 
free sulfate, was found to be 38.7 and 42.3% (w/w), respectively. This value for 
enoxaparin or dalteparin was similar to the theoretical estimation of sulfate content 
(40% of enoxaparin and 44% w/w of dalteparin) based on 75% trisulfation of the 
heparin disaccharide repeating unit from porcine mucosa and an average of one N-
acetyl group per parent heparin molecule and the type of their reducing ends (2-N, 6-
O-disulfo-D-glucosamine or 1,6-anhydro groups for enoxaparin and 6-O-sulpho-2,5-
anhydro-D-mannitol for dalteparin). 
The effect of completely desulfated enoxaparin and dalteparin on the release 
of TNF-α (levels of which were found to be highest in PBMC supernatants) was 
examined. Unlike intact LMWHs, completely desulfated molecules did not inhibit or 
increase the release of cytokines, indicating the importance of sulfate groups for 
retaining the observed activity of LMWHs. The key structural unit of heparins that 
confers anticoagulant activity is an oligosaccharide sequence consisting of three D-
glucosamine and two uronic acid residues. The anticoagulant activity of heparins has 
been shown to be dependent on N- and O-sulfate groups present in the oligosaccharide 
sequence. Elimination of the N-sulfate groups results in decreased anticoagulant 
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activity, but the elimination of 3-O-sulfate group of the central D-glucosamine results 
in the loss of anticoagulant activity by approximately 20,000 times [128]. 
To determine the role of N- and 2-O/3-O sulfate groups in any pro- or anti-
inflammatory effect, enoxaparin and dalteparin were selectively desulfated. N-
desulfation and 2-O/3-O desulfation was confirmed by commonly used fluoraldehyde 
assay and IC, respectively. It was found that enoxaparin and dalteparin retained their 
activity in the absence of N- and 2-O/3-O sulfate groups (Figure 2.4A and 2.4B) 
indicating these groups are not important for their observed effects. Therefore, the 
anti- or pro-inflammatory effects of LMWHs were independent of their anticoagulant 
activity.  
Clinical studies have indicated that LMWHs can potentially be used in human 
inflammatory disorders [12, 147]. However, they possess both anticoagulant and non-
anticoagulant oligosaccharides. Therefore, their potential use is hampered by the risk 
of bleeding in conditions other than where anticoagulation is required [161]. To 
investigate whether the anti-inflammatory effect of enoxaparin is separable from its 
anticoagulant effect, enoxaparin was separated and the oligosaccharide(s) responsible 
for its anti-inflammatory effect was identified before determining the anticoagulant 
effect of the identified oligosaccharide(s). Dalteparin was also separated to identify 
the oligosaccharide(s) responsible for its pro-inflammatory effect.   
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Figure 2.4 Effect of de-sulfated LMWHs on cytokine release. Suppression of TNF-α 
release by completely desulfated, N-desulfated or 2-O/3-O-desulfated fragments of 
enoxaparin (A) or dalteparin (B) after PHA-induced stimulation of PBMCs from asthmatic 
subjects (n=5). Error bars indicate standard deviation. *p<0.05, **p<0.01 and ***p<0.001 
compared to PHA-stimulated control. 
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2.4.5 Separation and identification of oligosaccharides  
The HP-SEC chromatograms of enoxaparin and dalteparin are presented in Figure 2.5. 
As expected, different chromatographic profiles of enoxaparin and dalteparin were 
observed. The saccharide composition of each HP-SEC separated peak of enoxaparin 
and dalteparin has been reported before [153]. Enoxaparin was separated into 8 
different peaks representing dp2 to dp16, whereas dalteparin was separated into 9 
different peaks representing dp8 to dp24 (Figure 2.5).  
Due to structural complexity and high negative charge, LMWHs cannot be 
effectively separated without prior depolymerisation. Therefore, different techniques, 
such as reversed-phase high-performance liquid chromatography [162] and capillary 
electrophoresis [113], have been used for the separation of depolymerised heparin 
derivatives. However, elevated temperature or freeze drying processes used during 
depolymerisation can result in structural modifications of the oligosaccharides and 
therefore certain biological effects of intact LMWHs are lost or altered after 
depolymerisation process [116, 117]. Hence, enoxaparin and dalteparin in this study 
were separated using the HP-SEC method. This technique can separate 
oligosaccharides without the need for chemical or enzymatic depolymerisation of the 
parent molecule. Although this technique is most widely used for the identification of 
saccharide composition of LMWHs, it has its own specific limitations. For example, 
structurally different oligosaccharides having the same or similar saccharide 
composition cannot be separated using this technique. Therefore, it is possible that the 
HP-SEC separated fractions of LMWHs (e.g. dp4 of enoxaparin) are composed of 
structurally different molecules having the similar saccharide composition.  
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Figure 2.5 HPSEC analysis of enoxaparin and dalteparin. The HP-SEC methodology is 
described in the experimental section. Approximate saccharide composition of the separated 
peaks of enoxaparin and dalteparin is shown; dp2- two saccharide units to dp24- twenty four 
saccharide units.  
2.4.6 Effect of identified oligosaccharides on cytokine release 
Separated fractions of enoxaparin and dalteparin were collected and then re-analysed 
by HP-SEC to confirm their saccharide composition and purified using desalted 
columns. The ability of each desalted fraction to modulate the release of TNF-α is 
shown in Figure 2.6. The tested concentration of each fraction was based on its actual 
concentration, calculated using the peak area, present in 50 µg/mL of enoxaparin or 
80 µg/mL of dalteparin. The release of TNF-α was significantly increased by 15%, 
29% and 21% in the presence of dp20, dp22 and dp24 saccharides of dalteparin, 
respectively. On the other hand, dp8 to dp18 did not significantly modulate cytokine 
release, indicating the oligosaccharides larger than dp18 of dalteparin have pro-
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inflammatory activity (Figure 2.6B). Fondaparinux, a synthetic LMWH, was used to 
determine whether the observed pro-inflammatory effect of dalteparin fractions were 
independent to their anticoagulant effects. Fondaparinux is composed of only 
pentasaccharide sequence responsible for the anticoagulant activity of LMWHs. It, at 
tested concentrations (5 to 1000 μg/mL), failed to inhibit or enhance the levels of IL-
4, IL-5, IL-13 and TNF-α suggesting the observed effect of dalteparin molecules were 
not dependent to their anticoagulant activity. 
 
Figure 2.6 Effect of HPSEC fractions of LMWHs on cytokine release. Suppression of 
TNF-α release by eight HP-SEC derived saccharides (dp2 to dp16) of enoxaparin (A) or nine 
HP-SEC derived saccharides (dp8 to dp24) of dalteparin (B)  after PHA-induced stimulation of 
PBMCs from asthmatic subjects (n=5). Error bars indicate standard deviation. *p<0.05, 
**p<0.01  and ***p<0.001 versus PHA-stimulated control.  
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Several autoimmune diseases are associated with down regulation of T-cell receptor 
signalling pathways, resulting in dysfunction of T-cells [163]. This may have 
important consequences such as insufficient response to various types of infections 
[164]. The therapeutic potential of dalteparin in such medical conditions could 
potentially be explored owing to its stimulatory effect on T-cells. HP-SEC separated 
dp2 and dp4 of enoxaparin inhibited the release of TNF-α by 39 and 52%, 
respectively (Figure 2.6A). Dp6 showed some activity but it was not statistically 
different from the control samples and the fractions larger than dp6 did not show a 
significant inhibitory effect (Figure 2.6A) suggesting the shorter oligosaccharides are 
responsible for the anti-inflammatory effect of enoxaparin. This finding is important 
because a minimum of five saccharide chain length with specific sulfation pattern is 
required for the anticoagulant activity of any type of LMWH. One of the major 
concerns against the development of LMWHs as an anti-asthmatic agent is the 
bleeding risk associated with its use. Disaccharide (dp2) or tetrasaccharide (dp4) 
chains are not sufficiently long enough to bind AT-III and therefore do not exhibit 
anticoagulant activity (which was confirmed by previously described low-volume 
microtitre plate anticoagulant assays). Hence, these fractions of enoxaparin would 
potentially minimise the risk of bleeding associated with intact enoxaparin and could 
be investigated further as potential therapeutic targets for the treatment of 
inflammatory diseases including asthma.  
2.5 CONCLUSION 
In conclusion, the current study provides a solid platform for further experimental and 
clinical studies. Future research should be designed focusing on: i) further separation 
of dalteparin’s dp22 and enoxaparin’s dp4 molecules, with the aim of identification 
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and structural elucidation of the saccharide moieties responsible for the pro- or anti-
inflammatory activity of the parent LMWHs; ii) identification of underlying cellular 
and molecular mechanisms by which dp22 of dalteparin and dp4 of enoxaparin 
modulate the T-cell induced release of pro-inflammatory cytokines; and iii) pre-
clinical and clinical studies confirming the observed non-anticoagulant activities of 
the identified enoxaparin oligosaccharides.  
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Ion-exchange Chromatographic Separation and Isolation of Oligosaccharides of 
Intact Low Molecular Weight Heparin for the Determination of their 
Anticoagulant and Anti-inflammatory Properties 
3.1 ABSTRACT 
Background: It is well-known that enoxaparin, a widely used anticoagulant and low-
molecular-weight heparin containing a large number of oligosaccharides, possesses 
anti-inflammatory activity. While enoxaparin has shown promising results in various 
inflammatory disorders, some of its oligosaccharides have anti-inflammatory 
properties and others increase the risk of bleeding due to their anticoagulant effects. 
The aim of this study was to develop an effective ion-exchange chromatographic (IC) 
technique which allows the separation, isolation and consequently the identification of 
different oligosaccharides of enoxaparin with or without anticoagulant activity.  
Methods: The developed method utilises a semi-preparative CarboPac PA100 (9 × 
250 mm) ion-exchange column with sodium chloride gradient elution and UV 
detection at 232 nm. The anti-inflammatory activity of selected oligosaccharides was 
investigated using the Griess assay. 
Results: The method successfully resolved enoxaparin into more than 30 different 
peaks. IC-derived oligosaccharides with high, moderate, low or no anticoagulant 
activity were identified using an anti-factor Xa assay. Using this technique, the 
oligosaccharides of enoxaparin with low or no anticoagulant activity, whilst 
exhibiting significant anti-inflammatory activity, could be fractionated.  
Conclusion: This technique can provide a platform to identify the oligosaccharides 
which are devoid of significant anticoagulant activity and are responsible for the 
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therapeutic effects of enoxaparin that have been observed in various inflammatory 
conditions. 
3.2 INTRODUCTION 
Heparin is a naturally occurring endogenous substance, sequestered within the mast 
cells and found in granulated cells of organs and tissues, including the intestine and 
lung [165]. In clinical practice, heparin has been used as an anticoagulant for more 
than 50 years [129]. It is a heterogeneous mixture of highly sulfated and structurally 
unknown oligosaccharides belonging to the family of glycosaminoglycans [128]. As a 
therapeutic agent, heparin possesses both pharmacokinetic and pharmacological 
limitations, including variable bioavailability with subcutaneous administration, the 
propensity to interact with a wide range of plasma proteins, and the risk of inducing 
thrombocytopaenia and osteoporosis [6]. Therefore, in recent years heparin has been 
largely replaced by low-molecular-weight heparins (LMWHs), because of their 
improved pharmacokinetic properties, safety and efficacy [6, 130]. 
LMWHs are obtained by depolymerisation of unfractionated heparin and are 
composed of both anticoagulant and non-anticoagulant oligosaccharides [7]. LMWHs 
(e.g. enoxaparin) are primarily approved for the prophylaxis and treatment of deep-
vein thrombosis [8]. However, it is now recognised that LMWHs exhibit a broad 
spectrum of anti-inflammatory and immune-modulating properties beyond their well-
known anticoagulant effect [5, 58, 109, 166]. The anticoagulant activity of a LMWH 
is mainly dependent on the interaction between a specific pentasaccharide sequence 
constituting the antithrombin binding domain (Figure 3.1) and the serine protease 
inhibitor antithrombin-III (AT III) [5]. This sequence consists of three D-glucosamine 
and two uronic acid residues. Sulfate groups on the D-glucosamines are found to be 
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critical for retaining high anticoagulant activity. Elimination of any one of them 
results in a dramatic reduction in the anticoagulant activity. Removal of the unique 3-
O-sulfate group results in complete loss of the anticoagulant activity [167, 168].  
 
Figure 3.1 The unique pentasaccharide sequence of heparin having three D-glucosamine 
and two uronic acid residues. The anticoagulant activity of heparin is because of the binding 
between this sequence and AT III. 
Interestingly, the potential therapeutic activities of LMWHs in a wide array of clinical 
disorders, such as asthma [58], ulcerative colitis [166] and lichen planus [109], 
depend largely on the interactions between its non-anticoagulant oligosaccharides and 
various biological molecules present in the extracellular fluid, extracellular matrix, 
intracellular granules or on the cell surface [13]. For instance, it has been reported that 
the non-anticoagulant oligosaccharides of heparin strongly bind and inhibit the 
functions of L- and P-selectins. These adhesive molecules are involved in the 
recruitment of leukocytes, a necessary first step in the inflammation cascade that 
occurs before the recruitment of various inflammatory mediators, including cytokines 
and integrins [33, 169]. However, the clinical use of a LMWH as an anti-
inflammatory agent is largely limited in the presence of anticoagulant 
oligosaccharides, being associated with a significant risk of bleeding. To minimise 
such complications, low doses of LMWHs have been used, but the risk of bleeding 
still remains a major concern [109, 166, 170]. Also, the anti-inflammatory effects of 
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LMWHs are dose-dependent and at lower doses their anti-inflammatory response is 
reduced [171, 172]. 
Therefore, a clear rationale exists to separate and identify the non-
anticoagulant oligosaccharides within the parent LMWH. This approach would 
provide an opportunity to separate the anticoagulant and anti-inflammatory activities 
of a LMWH. The current approach to identify the non-anticoagulant oligosaccharides 
of a LMWH is to perform enzymatic or chemical depolymerisation of the parent 
compound [33, 173]. By contrast, a chemical or enzymatic depolymerisation results in 
the structural modification of oligosaccharides and it has been demonstrated that 
certain biological aspects of glycosaminoglycans could indeed be removed by the 
depolymerisation process [115, 174]. Some oligosaccharides of LMWH are heat-
sensitive and can undergo chemical modification, especially desulfation during the 
elevated temperatures of the depolymerisation process [116]. An oligosaccharide’s 
sulfation pattern is a key characteristic for anti-inflammatory properties [91]. 
Depolymerisation can also be performed through a freeze-drying process, which can 
result in physical changes of some oligosaccharides within the LMWH molecule 
[117].   
An alternative approach is to separate, isolate and identify the non-
anticoagulant oligosaccharides of LMWH without prior chemical or enzymatic 
digestion. A major limitation in the separation of the structurally complex 
oligosaccharides of LMWHs is the lack of a high-resolution technique. Various 
analytical techniques, such as high-performance size-exclusion chromatography (HP-
SEC) [175, 176], capillary electrophoresis (CE) [110, 113, 177] and reversed-phase 
ion-pair high-performance liquid chromatography (RPIP-HPLC) [118, 162], have 
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been used to separate intact LMWHs. HP-SEC has been used to separate the 
oligosaccharides of LMWHs based on their molecular weights. This technique can 
partially resolve the smaller mass (up to dp8; ~2680 Da), but unable to resolve the 
higher mass oligosaccharides (>dp8) [176]. Apart from this, structurally different 
oligosaccharides having the same or similar molecular masses cannot be separated 
using this technique. Lately, CE has been employed to separate LMWHs [110, 113, 
177]. The major limitation of CE is its limited separation of high molecular weight 
oligosaccharides. A RPIP-HPLC method has been previously developed in our 
laboratory to separate oligosaccharides of LMWHs [118]. This method successfully 
resolved both the higher and lower mass oligosaccharides. However, it requires a non-
volatile tetrabutylammonium hydroxide ion-pairing reagent to effectively separate the 
highly negatively-charged LMWH oligosaccharides. The presence of a non-volatile 
ion-pairing reagent in the isolated oligosaccharides interferes with the biological 
assays while investigating their anti-inflammatory and other pharmacological 
activities [178].  
A widely used analytical technique for the separation of oligosaccharides 
based on their charge is ion-exchange chromatography (IC). Its application has only 
been demonstrated for the separation of enzymatically or chemically digested 
oligosaccharides of LMWHs [179]. For example, IC has been used to separate 
disaccharides (dp2; ~670 Da) or oligosaccharides of uniform size consisting of six 
disaccharide (dp12; ~4020 Da) units. However, an intact LMWH, such as enoxaparin, 
is composed of a complex heterogeneous mixture of oligosaccharides ranging from 
dp2 to dp24 (~670 to 8040 Da). Therefore, in this study, we aimed to develop an 
effective IC technique for the separation of heterogeneous oligosaccharides of 
enoxaparin without its prior enzymatic or chemical depolymerisation. Using this 
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technique, various oligosaccharides or a mixture of oligosaccharides were isolated and 
their approximate molecular weights were determined.  An application of this 
technique was demonstrated by identifying IC-separated oligosaccharides with or 
without anticoagulant activity. Furthermore, for the first time the anti-inflammatory 
activities of non-anticoagulant and anticoagulant oligosaccharides obtained without 
prior modification of the parent LMWH were investigated.  
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
The sodium salt of enoxaparin (100 mg/mL; 10000 IU/mL) was purchased from 
Aventis Pharma (Sydney, Australia). Fondaparinux sodium (5 mg/mL) was purchased 
from GlaxoSmithKline (Melbourne, Australia). Sodium chloride and methanol (AR 
grade) was purchased from Sigma Aldrich (Sydney, Australia). The mobile phase was 
degassed under vacuum and filtered through nylon filter membranes (47 mm 
diameter, 0.2 µm pore size, Grace Davison, Rowville, Australia) before use. The 
heparin derived unsaturated oligosaccharide by enzyme cleavage (dp2 to dp26; ~670 
to 8710 Da) were purchased from V-LABS, (Covington, LA, USA). The anti-factor 
Xa (AFXa) kit was from American Diagnostica (Stamford, CT, USA). The murine 
macrophage cell line (RAW 264.7), L-glutamine, gentamycin, phosphate buffer 
saline, trypsin-EDTA, and lipopolysaccharides (LPS) from Escherichia coli were all 
purchased from Sigma Aldrich (Sydney, Australia). Tissue culture media containing 
RPMI-1640 and fetal bovine serum (FBS) were purchased from Invitrogen (NY, 
USA). N-(1-Naphthyl)ethylenediaminedihydrochloride (NEDD), sulfanilamide 
(SULF) and analytical grade isopropanol were purchased from BDH Chemicals 
(Poole, England).  
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3.3.2 Ion chromatography 
A Dionex ion chromatography (Sunnyvale, CA, USA) consisting of a GP50 gradient 
pump and LC30 thermal compartment was used throughout this work. A GM-3 
gradient mixer was installed before the injection valve. The LC30 thermal 
compartment was set at a column temperature of 40ºC. UV detection at 232 nm was 
performed with a Waters 486 tunable absorbance UV detector (Milford, MA, USA). 
Instrument control and data acquisition were performed using Chromeleon
®
 software. 
A 250 µL sample loop was employed unless otherwise specified.  Separations were 
performed on a semi-preparative Dionex CarboPac PA100 column (250 mm, 9 mm 
ID). Sodium chloride (NaCl) eluent gradients were prepared through mixing of a 2 M 
NaCl solution and Milli-Q water via the GP50 pump. The 2 M NaCl stock solution 
was prepared and filtered offline. The optimised NaCl eluent gradient was: 0-70 min: 
gradient from 32-74% NaCl in Milli-Q water (0.64 to 1.48 M NaCl). Total flow rate 
of 2.0 mL/min was maintained.   
A goal of this work was to collect the relevant oligosaccharides of the 
separated intact LMWH so they could be tested for their pharmacological activity and 
it was advantageous to be able to load a large amount of sample onto the column 
without affecting the separation performance. Therefore, a semi-preparative column 
was chosen for this work with a sample loop of 250 µL. This allowed 10 mg of 
enoxaparin to be loaded onto the column for each injection.   
3.3.3 Assay performance 
Reproducibility of the method was investigated by calculating the intra- (n=6) and 
inter-day precision (five consecutive days, n=30) using peak area from five chosen 
peaks with analysis of 50 mg/mL (n=6) enoxaparin. Mean intra- and inter-day 
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retention times (five consecutive days) were determined based on peak retention time 
with repeat analysis of 50 mg/mL enoxaparin. The method robustness was 
investigated by determining the intra- (n=6) and inter-day (five consecutive days, 
n=30) retention times of five different chosen peaks with repeat analysis of 50 mg/mL 
enoxaparin using one of the three Dionex CarboPac PA100 (250 mm, 9 mm ID) 
column lots (Lot No. 008-20-166 or 004-27-047 or 012-26-041) and one of the three 
Dionex chromatography systems (IC consisting of a GP50 gradient pump, LC30 
thermal compartment and a Waters 486 tunable absorbance UV detector or 
Biocompatible HPLC system consisting of a HPG-3400RS binary separation pump, 
WPD-3000RS auto-sampler, TCC-3000RS column thermal compartment and UV-
3000RS detector or a 3300 UHPLC consisting of  HPG-3400RS binary separation 
pump, WPD-3000RS auto-sampler, TCC-3000RS column thermal compartment and 
VWD-3000RS detector). 
3.3.4 High-performance size-exclusion chromatography 
The HP-SEC was performed on a HPLC system consisting of a Prostar 230 solvent 
delivery module, a Prostar 335 DAD detector and a Prostar 410 autosampler (Varian, 
Melbourne, Australia). Data acquisition and instrument control were carried out using 
Star Chromatography Workstation
®
software. The HP-SEC analyses were performed 
with a 200 µl sample loop and a 20 µl sample injection volume. Detection was 
monitored at 232 nm.  The HP-SEC separations were performed using a Superdex
TM
 
peptide 10/300 GL (300×10 mm) size-exclusion column (GE Healthcare Bio-
Sciences, Uppsala, Sweden) with an average pore size of 13 µm. The pore size of this 
column allows efficient separation of oligosaccharides ranging from 100Da to 
7000Da and it was therefore selected for the analysis of enoxaparin (approximate 
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molecular weight range 600Da to 7000Da). Isocratic elution of enoxaparin, 
oligosaccharide standards or IC-derived enoxaparin oligosaccharides was performed 
with a 0.3 M sodium sulfate eluent at a flow rate of 0.2 mL/min.   
3.3.5 Desalting and recovery of enoxaparin oligosaccharides 
Enoxaparin was fractionated using IC. For each run (n=3), 20 oligosaccharides of 
enoxaparin (approximately 2 to 15 mL each) were collected over the same elution 
period between 29 to 65 minutes. Our initial experiments showed that the presence of 
a high concentration of NaCl (more than 0.9% w/v) interfered with the anticoagulant 
and anti-inflammatory assays. Therefore, the IC-collected oligosaccharides of 
enoxaparin were desalted using methanol precipitation [180, 181]. This involved the 
oligosaccharides being concentrated using a rotary evaporator (Model-Laborota 
4000/4001 efficient, Heidolph Instruments, Schwabach, Germany) operated at 42ºC 
and 120 rpm until salt crystals began to form. Further, the oligosaccharides were 
precipitated by the addition of anhydrous methanol (80% v/v) followed by 
centrifugation at 3000 rpm for 10 min (Sorvall, DJB Labcare, Newport Pagnell, UK). 
Samples were then kept overnight at 4ºC. The supernatant containing NaCl was 
carefully discarded and the remaining traces of methanol were evaporated using 
compressed air. The precipitated oligosaccharides were dissolved in 500 µL of Milli-
Q water. The sodium content and the recovery of desalted oligosaccharides were 
determined using flame photometry and IC respectively.   
For the determination of NaCl content, a stock solution of NaCl (1 mg of 
sodium/mL) was prepared by dissolving 2.54 g of NaCl in one litre of Milli-Q water. 
The stock solution was serially diluted to prepare different standard sodium solutions 
at concentrations of 5 to 50 ppm. The standard solutions (n=3) were introduced into a 
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low temperature, single channel flame photometer (Model-PFP7, VWR International, 
Murarrie, Australia) and emission intensities were measured at 589 nm. The 
concentration of NaCl in the oligosaccharides (n =3) was calculated using the 
standard sodium calibration curve. To determine the loss of oligosaccharides during 
the desalting process, the desalted oligosaccharides were re-analysed using IC under 
the same chromatographic conditions as described previously.   
3.3.6 Determination of molecular weight
 
Enoxaparin (10 mg/mL) or oligosaccharide standards (dp2 to dp18; ~670 to 6030 Da) 
were diluted to 2 mg/mL with Milli-Q water and analysed using HP-SEC. To 
determine the approximate molecular weights of enoxaparin oligosaccharides, the 
retention time of each standard oligosaccharide was compared against the retention 
time of HP-SEC separated enoxaparin peaks. Twenty different IC-separated 
oligosaccharides of enoxaparin were collected, desalted and analysed using HP-SEC 
to determine their approximate molecular weights. Furthermore, the HP-SEC 
separated three oligosaccharides (dp4, dp8 and dp10; ~1340, 2680 and 3350 Da) of 
enoxaparin were collected and individual oligosaccharide was reanalysed by IC.  
3.3.7 Analysis of anticoagulant activity 
The anticoagulant activity of desalted oligosaccharides was determined by a modified 
low-volume microtitre plate AFXa assay as described previously [117]. Briefly, the 
solutions provided in the assay kit were prepared as per the manufacturer’s 
instructions. Ten µL (1 mg/mL) of sample (enoxaparin or IC derived desalted 
oligosaccharide) and 25 µL of anti-thrombin III and factor Xa were incubated for 3 
minutes at 37°C. Substrate FXa was added and the solution was mixed and incubated 
for further 10 minutes. The reaction was quenched using glacial acetic acid and placed 
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in Eppendorf tubes which were centrifuged (Hettich, Tuttlingen, Germany) at 
12,000 rpm for 1 minute and contents carefully transferred to wells of a microplate 
using a micropipette. After shaking for 60 seconds to remove any air bubbles present, 
the intensity of the colour, which was inversely proportional to the anticoagulant 
activity of oligosaccharide, was read at 405 nm using a microplate reader (Model-680, 
Bio-Rad Laboratories, Hercules, CA, USA). Each sample was analysed for AFXa 
activity in triplicate. Oligosaccharides with high, moderate, low or no anticoagulant 
activities were analysed for their anti-inflammatory activity.   
3.3.8 Determination of anti-inflammatory activity 
3.3.8.1 Cultivation of murine monocytic macrophage cell line (RAW 264.7)  
Activated macrophages produce nitric oxide (NO) which is implicated in promoting 
inflammation causing cellular injury and tissue dysfunction [182, 183]. The inhibitory 
effects of enoxaparin-derived oligosaccharides on NO production in RAW 264.7 cells 
were investigated. For initial growth, the cells were seeded into 75 cm
2
 tissue culture 
flasks and grown to confluence in RPMI-1640 culture medium as described 
previously [182]. 
3.3.8.2 Stimulation of cells and measurement of NO 
For subsequent experiments, the cells were seeded into 96-well tissue culture plates at 
a density of 5×10
5 
cells/well and incubated for 24 hours at 37°C and with 5% CO2. 
Immediately after incubation, the cells were stimulated with 20 µL of LPS (100 
mg/mL) in the presence or absence of enoxaparin oligosaccharides (100 µg/mL) or 
fondaparinux (5 mg/mL). Cells were then incubated in serum-free media at 37°C, 5% 
CO2 for another 24 hours and the production of NO was estimated using the Griess 
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assay [184]. Briefly, after 24 hours of incubation, the cell supernatant (100 µL) was 
transferred into a new 96-well microtitre plate followed by the addition of equal 
volumes (100 µL) of Griess reagents (SULF and NEDD). The plate was kept in the 
dark at room temperature for 10 minutes before measuring the production of NO. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Development and validation of IC method  
Enoxaparin is a highly sulfated polysaccharide. Moreover, in basic solution, the 
hydroxide moieties of oligosaccharides deprotonate to provide additional negatively 
charged moieties which are available for interaction with the stationary phase when 
performing ion-exchange separations. Several columns were considered and tested to 
determine their suitability. Initially, the IC separation of enoxaparin was investigated 
using a Dionex AS20 anion exchange column using an instrument generated 
hydroxide gradient (1 to 100 mM) and suppressed conductivity and UV detection at 
232 nm. The ease of on-line eluent generation, potentially highly sensitive suppressed 
conductivity detection and on-line desalting would be advantageous. However, this 
approach resulted in long separation times (200 minutes) exhibiting poor resolution 
and peak shape defects even when mobile phases containing higher concentrations of 
hydroxide were prepared. The resultant poor separation can be attributed to the fact 
that the oligosaccharides of enoxaparin could not be satisfactorily eluted from the 
column using a hydroxide gradient. The use of alternative eluents (which would need 
to be prepared offline) would not be compatible with suppressed conductivity 
detection, negating any advantages in using this column.   
The Dionex CarboPac series of columns are designed for separation of 
carbohydrates, in particular highly negatively charged oligosaccharides. Initial 
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experiments with Dionex CarboPac PA1, PA10 and PA100 analytical columns 
showed promising signs of fractionation using NaCl eluents. An advantage of the 
PA100 over PA1 is that lower salt concentrations are required to elute 
oligosaccharides from the column (most likely due to the slightly lower ion exchange 
capacity and increased cross linking in the stationary phase). This is important if 
desalting of collected fractions is required. Satisfactory results were achieved with the 
CarboPac PA100, and importantly this column is available in a semi-preparative 
scale. This would allow larger sample sizes of highly concentrated samples to be 
injected without loss of resolution. This is an important consideration as fraction 
collection was required for further anticoagulant and anti-inflammatory testing. 
Furthermore, the influence of pH on the separation of enoxaparin was investigated by 
adjusting the mobile phase pH with hydrochloric acid or sodium hydroxide. Improved 
resolution was observed when the separation was performed at pH 6 (no pH 
adjustment required) compared to pH 3 and pH 11. The injection loop volume was 
maximised to 250 µL without significant loss of efficiency or resolution. The 
enoxaparin sample was also diluted in water or normal saline to investigate matrix 
effects. Improved resolution occurred when the sample was diluted in water, possibly 
due to self-elution effects of the saline in the sample. Injection concentrations were 
also maximised in consideration of fraction collection. An upper concentration of 
50% enoxaparin could be injected whilst maintaining optimal chromatographic 
performance. Hence, a CarboPac PA100 semi-preparative column was used for the 
separation of enoxaparin using the same chromatographic conditions as described 
previously. Under these conditions, enoxaparin was separated into more than 30 
different peaks (Figure 3.2). There was no major difference in the chromatographic 
separation of enoxaparin with semi-preparative CarboPac PA100 or analytical PA10 
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column. However, with the semi-preparative column the sample volume injected was 
25 times greater and consequently provided enough mass in each separated fraction to 
facilitate isolation of the various enoxaparin oligosaccharides. 
3.4.2 Assay performance 
The assay performance was investigated using five different chosen peaks of 
enoxaparin (Figure 3.2). The intra- (n=6) and inter-day (five consecutive days, n=30) 
relative standard deviation (RSD) for each peak area was <5% respectively. The intra- 
and inter-day retention time RSDs for each of five peaks were <0.6% (n=6) and 
<0.9% (n=5) respectively. One of the important objectives of this study was to collect 
various oligosaccharides of enoxaparin and test their anticoagulant and anti-
inflammatory activities. Therefore, an excellent reproducibility of retention time 
exhibited by this method is of great importance; allowing the collection of relevant 
oligosaccharides and thereby minimising the possibility of misleading anticoagulant 
and anti-inflammatory assay results.  Method robustness was investigated from five 
chosen peaks of enoxaparin using three chromatography systems and three CarboPac 
PA100 column lots. The intra- (n=6) and inter-day (over five consecutive days, n=30) 
retention time RSDs for each of the five peaks obtained using different 
chromatography systems and different column lots were <0.6% (n=6) and <0.9% 
(n=30) respectively. These results indicated that changes in the chromatography 
systems and column lots did not affect the retention time of selected enoxaparin’s 
oligosaccharides.   
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Figure 3.2 IC separation of enoxaparin (A). Arrows indicate five chosen peaks of enoxaparin 
used for the determination of inter- and intra-day precision. Enoxaparin (50 mg/ml) was 
analysed five times on the same day (B-F).  
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3.4.3 Determination of molecular weight 
The oligosaccharide standards ranging from dp2 to dp18 and enoxaparin were 
analysed using HP-SEC (Figure 3.3A). Enoxaparin was partially resolved into 9 
different peaks. The retention times of enoxaparin peaks were compared with the 
retention times of oligosaccharide standards. Based on this comparison, the 
approximate saccharide composition of enoxaparin oligosaccharides were assigned. 
The HP-SEC separation of analytes is based on the molecular size and therefore, the 
high molecular weight oligosaccharides (e.g. dp18) eluted earlier than the low 
molecular weight oligosaccharides (e.g. dp2).   
Twenty different IC-derived oligosaccharides of enoxaparin were similarly 
analysed using HP-SEC. The approximate molecular weight of each oligosaccharide 
was determined by comparing the elution profiles of oligosaccharides against the HP-
SEC separated enoxaparin peaks. The approximate molecular weights of IC-separated 
enoxaparin oligosaccharides are shown in Figure 3.3B. This technique successfully 
separated the smaller mass oligosaccharides (up to dp12) and partially separated the 
larger oligosaccharides of enoxaparin (up to dp20; ~6700 Da). It can be seen that the 
larger oligosaccharides eluted later during the IC salt gradient separation. As 
enoxaparin is constituted of sulfated oligosaccharides, the mechanism of this 
separation is based on the interaction of the sulfate groups with the oppositely charged 
stationary phase (ion-exchange interaction). As the oligosaccharides increase in size, 
so too does the degree of sulfonation.   
Furthermore, three different oligosaccharides (dp4, dp8 and dp10) of HPSEC-
separated enoxaparin were collected and analysed individually using IC (Figure 
3.3C). Unlike HP-SEC, the IC successfully resolved dp4 and dp8 of enoxaparin into 
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more than five different peaks and dp10 into 4 distinct peaks. This highlights the 
resolving power of IC for the fractionation of structurally complicated 
oligosaccharides of enoxaparin.  A LMWH such as enoxaparin, is highly sulfated 
linear polysaccharide composed of repeating disaccharide units of -D-glucosamine 
and a hexuronic acid (-L-iduronic or β-D-glucuronic acid) linked by 1→4 glycosidic 
bonds [128]. Multiple peaks of enoxaparin oligosaccharide having similar molecular 
weights (e.g. dp4) were observed in the IC chromatogram (Fig. 3c). A possible 
explanation for this could be the uneven distribution of the different pattern of 
sulfation along the enoxaparin’s dp4 (two disaccharide units) chain. For instance, 
some disaccharide units have highly sulfated regions consisting of O-sulfation at 
position 2 of iduronic acid and N-sulfation at position 2 of glucosamine which are 
located at the non-reducing ends.  On the other hand, some disaccharide units have 
under-sulfated regions consisting of non-sulfated iduronic acid residues and N-
acetylation at position 2 of glucosamine. Therefore, the early eluted dp4 peaks 
potentially represent the under-sulfated disaccharide regions and the later eluted peaks 
represent the highly sulfated disaccharide regions of dp4 oligosaccharide of 
enoxaparin. 
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                      Figure 3.3 HP-SEC of enoxaparin (10 mg/mL) and oligosaccharides standards (2 mg/mL) (A). IC of enoxaparin (25 mg/mL) with  
          approximate saccharide compositions of oligosaccharides shown (B). IC of HPSEC-collected dp4, dp8 and dp10 oligosaccharides  
                       of enoxaparin (C). 
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3.4.4 Desalting and recovery of enoxaparin oligosaccharides  
Our initial experiments showed that the presence of a high concentration of salt 
interferes with the anticoagulant and anti-inflammatory assays, and hence the 
desalting of oligosaccharides was crucial. Each collected oligosaccharide was 
precipitated using 80% w/v methanol. The precipitants were diluted with Milli-Q 
water and the concentration of NaCl was determined using flame-photometry. The 
concentration of NaCl in each oligosaccharide was found to be <0.9% w/v and was 
deemed satisfactory, as it is known that “normal” saline (0.9% w/v NaCl) is isotonic 
with body fluids and is used to dilute the oligosaccharides during anti-factor Xa 
analysis and to wash the cultured cells during determination of anti-inflammatory 
activity.   
The recovery of desalted oligosaccharides was estimated using IC. The 
recovery was determined by calculating the differences in the peak areas of desalted 
oligosaccharide and oligosaccharide of enoxaparin eluted at the same time. Three 
oligosaccharides (dp4, dp6 and dp18; ~1340, 2010 and 6030 Da) corresponding to 
low, medium and high molecular weights were selected to determine their losses 
during the desalting process. The recoveries of dp4, dp6 and dp18 oligosaccharides 
were found to be 81%, 84% and 80% respectively suggesting the recovery is 
consistent across the wide molecular weight range. This technique allowed 10 mg of 
enoxaparin to be loaded onto the semi-preparative CarboPac PA100 column with each 
injection. This facilitated the collection of sufficient quantities of oligosaccharides for 
the investigation of their anticoagulant and anti-inflammatory activities. For instance, 
the quantity of IC-derived dp2 after desalting was found to be 0.63 mg/500 µL. 
Briefly, the approximate concentration of desalted dp2 oligosaccharide was 
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determined using a linear regression equation by constructing a calibration curve of 
the peak areas (obtained through IC) of dp2 standard (Sigma Aldrich, NSW, 
Australia) against their six different concentrations (0, 0.1, 0.5, 1, 1.5 and 2 mg/mL). 
This concentration (0.63 mg/500 µL) was sufficient to investigate its anticoagulant 
and anti-inflammatory activities for more than 20 and 5 times respectively.   
3.4.5 Determination of anticoagulant and anti-inflammatory activity 
The calibration curve for AFXa activity was plotted using six different enoxaparin 
concentrations (0-0.5 IU/mL) and the correlation coefficient (r
2
) was greater than 
0.987 (Figure 3.4). Four different oligosaccharides (dp2, dp6, dp12 and dp18) with 
no, low, moderate or high anticoagulant activities were tested for their anti-
inflammatory properties. The anticoagulant activities of the selected oligosaccharides 
are shown in Figure 3.5. Disaccharide (dp2) of enoxaparin did not show any 
anticoagulant activity whereas the anticoagulant activities of dp6, dp12 and dp18 
oligosaccharides were found to be approximately 1000, 5000 and 6000 IU/mL 
respectively. Pentasaccharide is the smallest sequence (dp5; ~1675 Da) required 
within the enoxaparin chain for the anticoagulant activity [5]. Disaccharides of 
enoxaparin are not long enough to bind AT III and hence did not exhibit any 
anticoagulant activity. The observed anticoagulant activities of dp12 and dp18 were 
five and six times higher than the activity of dp6. The possible explanation could be 
that dp12 and dp18 oligosaccharides are higher molecular weight chains than dp6 and 
therefore, they may contain more than a single AT III binding site.   
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Figure 3.4 Calibration curve for the determination of AFXa activity using six different 
concentrations of enoxaparin. Sample (n=6) were analysed in triplicate and results are 
presented as mean ± SD. 
To demonstrate an application of the newly developed IC-technique, the 
ability of IC-derived enoxaparin-derived oligosaccharides (dp2, dp6, dp12 or dp18) to 
inhibit NO production by LPS-activated macrophages was investigated by the Griess 
assay [184]. The concentration of NO present in the cell culture supernatant was 
calculated using the nitrite standard curve (0 to 100 µM). The calculated linearity (r
2
) 
of the standard curve (0-100 µM) was greater than 0.990. Although, during 
inflammatory disorders (rheumatoid arthritis, inflammatory bowel disease, asthma 
etc.) the production of NO is increased in response to the secretion of cytokines and 
endogenous LPS [185, 186], it is not associated with the developmental features of 
these inflammatory disorders including asthma. The percentage of NO production 
inhibited by enoxaparin oligosaccharides is shown in Figure 3.5. Among the tested 
oligosaccharides, dp6 showed the highest inhibition of NO production (80%). 
Oligosaccharides with high anticoagulant activities (dp12 and dp18) were five times 
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less effective than dp6 in inhibiting the production of NO. Enoxaparin disaccharide 
did not exhibit any anticoagulant activity but interestingly it reduced the production of 
NO by 50%. To test whether the anti-inflammatory effects of enoxaparin are 
independent of its anticoagulant activity, the ability of an ultra-LMWH 
(fondaparinux) to inhibit NO production was tested. Unlike enoxaparin, fondaparinux 
is a synthetic pentasaccharide and does not contain non-anticoagulant 
oligosaccharides [187]. Fondaparinux, even at the concentration of 5 mg/mL, failed to 
inhibit NO production. These results are consistent with other published studies 
indicating that the anti-inflammatory effects of LMWHs are not dependent on its 
pentasaccharide sequence, which is essential for its anti-coagulant activity [13, 58, 
109]. 
 
Figure 3.5 AFXa activity of IC-derived enoxaparin oligosaccharides and percentage inhibition 
of NO production by these oligosaccharides in LPS stimulated macrophages (RAW 264.7). 
Sample (n=3) were analysed in triplicate and results are presented as mean ± SD. 
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It is evident from experimental studies that the biological activity of a LMWH (e.g. 
enoxaparin) in a variety of biological disorders is independent of its anticoagulant 
property. These highly sulfated structurally unknown macromolecules are thought to 
play an essential role by interacting with important proteins involved in the 
pathogenesis of many disease states. To better understand these interactions it is 
imperative to identify and then characterize the non-anticoagulant oligosaccharides of 
LMWHs. Although the structure and biological significance of IC-collected 
enoxaparin oligosaccharides need to be elucidated in detail, these results clearly 
demonstrate that the newly developed IC method will provide a powerful tool for 
exploring the non-anticoagulant activities of enoxaparin-derived oligosaccharides.  
3.5 CONCLUSION 
In clinical practice, enoxaparin is widely used as an anticoagulant. However, to be 
employed as an anti-inflammatory agent, the risk of potential bleeding must be 
removed or minimised.  In the present study, structurally complicated enoxaparin was 
successfully fractionated using a newly-developed IC method. An important 
application of this method was demonstrated by investigating the anti-inflammatory 
effects of its oligosaccharides. A number of studies have investigated the anti-
inflammatory effects of intact enoxaparin. However, to our knowledge this is the first 
study demonstrating the anti-inflammatory effect of enoxaparin oligosaccharides 
obtained without prior chemical or enzymatic modification of the parent LMWH. 
Furthermore, this technique could potentially be used for structural characterization 
and identification of sulfation patterns of anti-inflammatory oligosaccharides of 
enoxaparin. 
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Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine 
Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic 
Individuals  
4.1 ABSTRACT 
Background: Enoxaparin, a low-molecular-weight heparin, is known to possess anti-
inflammatory properties. However, its clinical exploitation as an anti-inflammatory 
agent is hampered by its anticoagulant effect and the associated risk of bleeding. The 
aim of the current study was to examine the ability of non-anticoagulant fractions of 
enoxaparin to inhibit the release of key inflammatory cytokines in primed peripheral 
blood mononuclear cells derived from allergic mild asthmatics. 
Methods: Peripheral blood mononuclear cells from allergic asthmatics were activated 
with phytohaemagglutinin (PHA), concanavalin-A (ConA) or phorbol 12-myristate 
13-acetate (PMA) in the presence or absence of enoxaparin fractions before cytokine 
levels were quantified using specific cytokine bead arrays. Together with nuclear 
magnetic resonance analysis, time-dependent and target-specific effects of enoxaparin 
fractions were used to elucidate structural determinants for their anti-inflammatory 
effect and gain mechanistic insights into their anti-inflammatory activity.  
Results: Two non-anticoagulant fractions of enoxaparin were identified that 
significantly inhibited T-cell activation. A disaccharide fraction of enoxaparin 
inhibited the release of IL-4, IL-5, IL-13 and TNF-α by more than 57% while a 
tetrasaccharide fraction was found to inhibit the release of tested cytokines by more 
than 68%. Our data suggest that the observed response is likely to be due to an 
interaction of 6-O-sulfated tetrasaccharide with cellular receptor(s). 
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Conclusion: The two identified anti-inflammatory fractions lacked anticoagulant 
activity and are therefore not associated with risk of bleeding. The findings highlight 
the potential therapeutic use of enoxaparin-derived fractions, in particular 
tetrasaccharide, in patients with chronic inflammatory disorders. 
4.2 INTRODUCTION 
Low-molecular-weight heparins (LMWHs) are a heterogeneous mixture of 
structurally complex oligosaccharides [188]. In clinical practice these molecules are 
widely used as anticoagulants but additionally, they are reported to possess anti-
inflammatory properties [12, 189]. Enoxaparin, the most widely used LMWH, is 
known to inhibit T cell mediated release of multiple cytokines, such as IL-4, IL-5, IL-
13 and TNF-α, involved in various inflammatory disorders including asthma [190]. A 
model for a chronic inflammatory disease and a potential target for an anti-
inflammatory therapy is asthma, a complex multifactorial disorder of conducting 
airways. Its inflammatory pathology is characterised by reversible airway obstruction 
and airway hyper-responsiveness. It is estimated that approximately 300 million 
people worldwide suffer from asthma and it is associated with severe morbidity, and 
sometimes even mortality [18]. Inflammation in asthma is characterised by activation 
of T-helper type 2 (Th2) cells, production of immunoglobulin E (IgE) antibodies and 
eosinophilia [191]. Although T cells residing in the lungs (most of which are memory 
cells) are important for the local defence mechanism, excessive recruitment of T cells 
(mainly Th2 type) in the lungs, as well as their response to various allergens, is 
believed to be largely responsible for coordination of the inflammatory processes 
associated with allergic asthma [192]. In response to allergens, Th2 cells do not 
proliferate in the lungs but rather migrate into the lung from regional lymph nodes and 
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then produce various inflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-9, 
IL-13 and tumor necrosis factor (TNF)-α, and chemokines, such as monocyte derived 
chemokine, in response to the specific allergen [23]. IL-4 and IL-13 are normally 
involved in the process responsible for the production of IgE antibodies. IL-4 and IL-
5 enhance the survival of eosinophils, resulting in eosinophilic inflammation. IL-13 
(and IL-9 to some extent) is reported to be important for bronchial hyper-
responsiveness [193]. On the other hand, TNF-α sustains lung inflammation by 
increasing the recruitment of neutrophils and eosinophils in the airways [194].  
Inhaled corticosteroids are the most effective drugs currently available for the 
treatment of asthma [195]. They effectively control asthma in the majority of patients. 
However, apart from the fact that the prevalence of steroid-resistant asthma is rising 
[143], corticosteroids are associated with a number of problems. For example, the 
symptoms appear soon after the treatment is stopped and with long-term treatment 
they increase the risk of osteoporosis in adults and reduced bone growth in children 
[126, 127]. Also, at recommended doses they have little or no effect on the process of 
asthma-associated lower airway remodelling [31]. An advanced understanding of the 
complex pathophysiology that drives this inflammatory disease has resulted in the 
development of new and emerging biological therapies, such as monoclonal 
antibodies, that are directed against a specific type of cytokine that is involved either 
in cell proliferation or the inflammatory response [196]. Apart from their cost and 
potentially severe side effects (such as hypersensitivity and susceptibility to various 
types of infections), monoclonal antibodies, at least for the treatment of asthma, have 
so far failed to meet initial theoretical expectations. It has been proposed that their 
limited clinical efficacy could be due to their inability to simultaneously inhibit 
multiple cytokines involved in the pathogenesis of asthma [197]. Therefore, the search 
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for safer, cheaper and effective drugs for the treatment of asthma continues. Among 
these drugs, LMWHs have attracted much interest in the field of inflammation.  
Several experimental and clinical studies have shown the beneficial effects of 
LMWHs in various types of inflammatory disorders, including asthma [40, 146, 198]. 
The precise mechanism(s) behind the anti-inflammatory effects of LMWHs are yet to 
be fully explored. However, it has been proposed that because of their high negative 
charge they can interact and modulate the activity of a wide range of biological 
molecules, including various types of immune cells and pro-inflammatory cytokines 
[147]. As the recruitment and activation of T cells in the lung is believed to be one of 
the central events in the initiation, progression and persistence of asthma, drugs (e.g. 
enoxaparin) that can suppress T cell-mediated inflammatory responses can be 
considered a promising therapeutic strategy [199]. However, like any other LMWH, 
enoxaparin is composed of both non-anticoagulant and anticoagulant components, 
referred to as oligosaccharides. Its potential use as an anti-inflammatory agent could 
be problematic due to the inherent risk of bleeding caused by the presence of 
anticoagulant oligosaccharides [147]. This problem can potentially be resolved by 
separating the anticoagulant fractions (oligosaccharides responsible for anticoagulant 
effect) and non-anticoagulant fractions (oligosaccharides potentially responsible for 
anti-inflammatory effect). However, separation of such a complex polysaccharide is a 
long-standing problem [200]. Nevertheless, we recently developed a novel 
chromatographic technique that allows the separation of different oligosaccharides of 
enoxaparin [105]. In the current study we isolated chromatographically separated 
oligosaccharides of enoxaparin and investigated their anticoagulant effect, as well as 
their ability to inhibit the T cell mediated release of important cytokines before 
postulating the potential mode of action alongside the structure activity relationship.   
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4.3 MATERIALS AND METHODS 
4.3.1 Materials 
All chemicals and reagents, if not otherwise stated, were obtained from Sigma-
Aldrich (NSW, Australia). The sodium salt of enoxaparin (100 mg/mL) was 
purchased from Aventis Pharma (NSW, Australia), deuterium oxide (D2O) was 
purchased from Cambridge Isotope Laboratories (Andover, MA, USA), anti-factor Xa 
(AFXa) kit was purchased from American Diagnostica (Stamford, CT, USA) and fetal 
bovine serum was purchased from Invitrogen (NY, USA).  
4.3.2 Recruitment of participants 
Five healthy (mean age: 33.8 years, range: 26-48 years; 4 males, 1 females) and ten 
allergic asthmatic subjects (mean age: 40.9 years, range 19-59 years; 4 males, 6 
females) were recruited by invitation. The healthy volunteers were not suffering from 
any acute or chronic diseases and the asthmatic subjects were suffering from no other 
diseases apart from intermittent asthma exacerbated by allergies. Exclusion criteria 
were use of systemic or inhaled corticosteroids or any other immunomodulatory 
medications within two months prior to blood sampling. No information of either the 
use of other medications or forced expiratory volume (FEV1) was obtained from the 
recruited participants. 
4.3.3 Ethics statement  
The research protocol was approved by the Health and Medical Human Research 
Ethics Committee (Tasmania, Australia) Network (Approval number: H0013117). 
Written informed consent for the collection of blood samples was obtained from the 
recruited subjects. 
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4.3.4 Isolation of peripheral blood mononuclear cells (PBMCs) from whole blood 
Whole blood (80 mL) from each subject was collected before PBMCs were isolated. 
Isolation of PBMCs was conducted by standard methods via density separation using 
30 mL of blood aliquots layered onto 20 mL of Histopaque. Following centrifugation 
at 200g for 30 minutes at 20°C (Eppendorf; Model: 5810R), PBMCs were aspirated 
from the Histopaque/aqueous interface and centrifuged at 700g for 10 minutes. Cells 
were washed twice with serum-free media and resuspended in complete medium 
[RPMI-1640 supplemented with 2.0 mM L-glutamine, 10% fetal bovine serum and 
antibiotics (penicillin G and streptomycin)].  
4.3.5 Separation and isolation of enoxaparin fractions 
Chromatographic separation of enoxaparin was carried out using a previously 
described ion-exchange chromatography (IC) method [105]. Briefly, enoxaparin 
separation was performed on a semi-preparative Dionex CarboPac PA100 (250 mm, 9 
mm ID, 8.5 µm) strong anion-exchange column (Thermo Fisher Scientific, NSW, 
Australia). Mobile phases were composed of Milli-Q water (A) and 2 M NaCl (B). 
The linear NaCl elution gradient (mobile phase B; 32 to 74%) was used over 70 
minutes with a constant flow rate of 2.0 mL/minute. A column temperature of 40°C 
was combined with UV detection at 232 nm.  
4.3.6 Collection and desalting of IC separated enoxaparin fractions 
IC separated enoxaparin fractions were collected and desalted as described previously 
[105] with minor modifications. Briefly, collected fractions were concentrated on a 
miVac DNA centrifugal concentrator (Genevac Ltd, Suffolk, UK) at 40°C and 
subsequently desalted using PD MidiTrap G-10 columns (GE Healthcare Life 
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Sciences, Uppsala, Sweden). The desalted fractions were kept at 4°C until use. The 
concentration of IC separated fraction of enoxaparin was determined by constructing a 
calibration curve from the peak areas of LMWH standards against their known 
concentrations. The recovery of each desalted fraction concentrations was calculated 
using the differences in the peak areas of the desalted fraction and enoxaparin fraction 
eluted at the same time. Each desalted fraction was tested for its anticoagulant activity 
and its inhibitory effect on cytokine release from activated PBMCs. 
4.3.7 Determination of NaCl content 
The NaCl content in the desalted fractions of enoxaparin was determined using flame 
photometry as described previously [105]. Briefly, a stock solution of NaCl (1 mg of 
sodium/mL) was prepared by dissolving 2.54 g of NaCl in one litre of Milli-Q water. 
The stock solution was serially diluted to prepare different standard sodium solutions 
at concentrations of 5 to 50 ppm. The standard solutions (n=3) were introduced into a 
low temperature, single channel flame photometer (Model-PFP7, VWR International, 
Murarrie, Australia) and emission intensities were measured at 589 nm. The 
concentration of NaCl in the desalted enoxaparin fractions (n =3) was calculated using 
the standard sodium calibration curve. 
4.3.8 Analysis of anticoagulant activity 
The potentiating effect of IC-derived enoxaparin fractions on anti-thrombin III 
inhibition of activated factor Xa was determined using a previously described low-
volume microtitre plate anti-factor Xa assay [116]. Briefly, a solution containing anti-
thrombin III, FXa and IC-derived enoxaparin fractions was incubated for 3 minutes at 
37°C. FXa substrate was added immediately and the solution was incubated for 
another 10 minutes. The reaction was quenched using glacial acetic acid and the 
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intensity of developed colour was spectrophotometrically measured at 405 nm 
(Multiskan Go, SkanIt software, Thermo Fisher Scientific).  
4.3.9 Preparation of stock solutions for PBMC culture treatments 
Stock solutions of enoxaparin fractions at 1 mg/mL were prepared in RPMI-1640 
medium and filter sterilized through 0.2 µm pore size syringe filters (Pall Life 
Sciences, Victoria, Australia). Other stock solutions were prepared accordingly: 2.5 
mg/mL of phytohaemagglutinin (PHA) in RPMI-1640 medium, stored at -20°C; 5 
mg/mL of concanvalin-A (Con A) in RPMI-1640 medium, stored at -20 °C; 1 mg/mL 
of phorbol 12-myristate 13-acetate (PMA) in DMSO, stored at -20°C and 5 mg/mL of 
fluticasone propionate in ethanol, stored at 4°C.  
4.3.10 Desulfation of enoxaparin fraction 
4.3.10.1 Complete desulfation 
A solution containing 8 mg/mL of enoxaparin fraction was subjected to acid 
hydrolysis for complete removal of sulfate groups as described previously [150]. 
Briefly, 1 mL of nitric acid was added to the fraction in a capped glass vial and the 
solution was heated at 80°C overnight before adding another 0.2 mL of hydrogen 
peroxide. The temperature was raised to 110°C for an additional 6 hours. The mixture 
was neutralised using 1 M sodium hydroxide and diluted with 4 mL of Milli-Q water. 
Finally 200 μL of this solution was further diluted to 4 mL.  
4.3.10.2 N-desulfation 
A solution containing 8 mg/mL of enoxaparin fraction was incubated at 50°C for 30 
minutes in the presence of tetrahydrofuran (133 µL) and water (7 µL) for partial N-
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desulfation as described previously [151] with minor modifications. The mixture was 
neutralised using 0.1 M sodium hydroxide. The resulting product was evaporated to 
dryness and precipitated by the addition of anhydrous methanol (80% v/v) followed 
by centrifugation at 3000 rpm for 10 minutes. The supernatant was carefully discarded 
and samples were kept at 4°C overnight. Any traces of methanol were removed using 
a miVac DNA centrifugal concentrator and the remaining precipitants were dissolved 
in 1 mL Milli-Q water.  
4.3.10.3 Selective 2-O-/3-O-desulfation 
Selective 2-O-/3-O-desulfation of enoxaparin fraction was performed as described 
previously [151]. Briefly, the fraction (8 mg/mL) was dissolved in 0.1 M sodium 
hydroxide (200 μL) and then lyophilised to dryness. The residues were dissolved in 
Milli-Q water (0.5 mL) and the pH was neutralised by addition of acetic acid. Finally, 
the resulting mixture was precipitated using anhydrous methanol as described above 
and dissolved in 4 mL Milli-Q water.  
4.3.10.4 Selective 6-O-desulfation 
Selective 6-O-desulfation of enoxaparin fraction was performed as previously 
described [151]. Briefly, the fraction (8 mg/mL) was mixed with equal volumes (1 
mL) of tetrahydrofuran (solvent) and N-methyl-N-(trimethylsilyl) trifluroacetamide 
(silylating agent). The mixture was incubated at 50°C for 9 hours, evaporated to 
dryness and precipitated using anhydrous methanol as described above and finally 
dissolved in 4 mL Milli-Q water.  
Each desulfated fraction was tested for its inhibitory effect on PBMC-induced 
release of cytokines. After desulfation, free sulfate groups were removed using a 
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1000Da cut-off filter (Millipore, NSW, Australia) at 15000 rpm for 10 minutes. The 
concentrated supernatant was dissolved in 1 mL of Milli-Q water for further use. 
4.3.11 PBMC culture 
Cells were cultured in 24-well cell culture plates in complete medium at a 
concentration of 1 × 10
6 
cells/mL/well. Cells were incubated with 1, 2.5, 5, 7.5, 10, 20 
or 40 μg/mL of PHA for 72 hours to identify the optimum concentration for the 
release of TNF-α. To measure the effect of fractions on the release of cytokines, the 
cells were stimulated with 10 µg/mL PHA in the presence or absence of IC-derived 
enoxaparin fractions. The effect of fractions was compared to positive control after 
addition of 0.5 ng/mL fluticasone in the presence of 10 µg/mL PHA. The target 
specific effect of enoxaparin fraction on cytokine release was examined after 
stimulation of cells with either 10 µg/mL Con A or 5 ng/mL PMA. The time 
dependency of enoxaparin fraction was determined after addition of the fraction at 
different time points in the presence of 10 µg/mL PHA and vice versa. The effect of 
various desulfated enoxaparin fractions was investigated in the presence of 10 µg/mL 
PHA. After 72 hours of incubation (37°C, humidified 5% CO2 atmosphere), culture 
supernatants from each well were collected and analysed for the determination of 
cytokine concentrations using flow cytometry.  
Each cell supernatant containing cell stimulants and/or various enoxaparin 
fractions, desulfated enoxaparin fractions or fluticasone was prepared and analysed in 
triplicate. 
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4.3.12 Measurement of cytokine release 
The amounts of IL-4, IL-5, IL-13 and TNF-α secreted into the cell culture supernatant 
were analysed using a cytometric bead assay (Cytometric bead array flex sets; BD 
Biosciences, NSW, Australia), which was performed according to the manufacturer’s 
instructions. Briefly, supernatant from different treatments was incubated with the 
beads of interest for 3 hours in the dark, prior to washing, resuspending and 
transferring to 96 well plates. The samples were run on a flow cytometer (FACS 
Canto, Becton Dickinson, CA, USA) and gates were set to include only singlet 
populations of beads. The assay detection limit was stated by the manufacturer to be ≈ 
3 pg/mL, with recovery rates of ≥ 80% of protein. Data was analysed by FACS Diva 
Software. Each sample was analysed in triplicate. 
4.3.13 PBMC viability assays  
The effect of enoxaparin fraction on cell viability after 72 hours of incubation was 
assessed using two methods, trypan blue dye exclusion assay and lactate 
dehydrogenase (LDH) release into culture supernatant. Both assays employed 
routinely used methods. Cytotoxicity of treatment was determined using the LDH in-
vitro toxicology assay kit (Sigma-Aldrich, NSW, Australia), according to the 
manufacturer’s instructions. Briefly, PBMC culture supernatants were centrifuged at 
250g for 4 minutes. An aliquot containing 50 μL of cleared supernatant was mixed 
with 100 μL of a solution containing LDH assay substrate, LDH dye and LDH 
cofactor and incubated at room temperature for 20 minutes before the reaction was 
terminated by the addition of 15 μL of 1 N hydrochloric acid. Absorbance at 490 nm 
was measured spectrophotometrically using a plate reader (Spectra Max M2 
microplate reader, Sunnyvale, CA). Each sample was measured in triplicate. 
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4.3.14 Nuclear magnetic resonance (NMR) analysis 
4.3.14.1 Saccharide information of enoxaparin fraction  
Samples for NMR analysis were prepared in 50 mM potassium phosphate buffer 
(KPO4) and 99.9% D2O. All experiments were carried out on a Bruker Avance III HD 
600 MHz spectrometer using a TCI triple-resonance cryogenically cooled probe with 
z-gradients all controlled by the software Topspin™ 3.2 (Bruker Corporation, MA, 
USA). Spectra were recorded at 25°C. Characterisation of fraction was performed at 
100 µM using 1D and 2D 
1
H spectroscopy (TOCSY 120 ms, COSY, ROESY 500 ms) 
and 2D 
13
C-
1
H spectroscopy (HSQC, HSQCTOCSY 120ms) with standard Bruker 
pulseprograms. 
4.3.14.2 Putative binding of enoxaparin fraction to PHA 
Saturation Transfer Difference-nuclear magnetic resonance spectroscopy (STD-NMR) 
was used to assess the potential binding of enoxaparin fraction to PHA by using the 
stddiffgp19.3 pulseprogram from the Bruker library, incorporating suppression of the 
residual water resonance with a Watergate sequence. The method was validated using 
a sample of bovine serum albumin (10 µM), tryptophan and glucose (100 µM) 
following previously published guidelines [201]. STD build-up curves were observed 
with saturation times of 0.5, 1.0, 2.0 and 5.0 seconds, respectively, with a range of 
shaped pulse power levels from 30-60 dB. An optimum saturation of 2 seconds was 
chosen from the steeper portion of the build-up curve, and 32 dB of saturation pulse 
power with an on-resonance excitation pulse at -1 ppm and off resonance at 30 ppm. 
128 transients were recorded in 8192 data points with a relaxation delay of 1.5 
seconds.  The interleaved spectra were processed and difference spectrum calculated 
using Topspin™ 3.2 incorporating the stdsplit macro function. The potential binding 
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of enoxaparin fraction to PHA was examined using a 500 µL sample of fraction (100 
µM) and PHA (5 µM) prepared in D2O buffered with 50 mM KPO4 at pH 7.0. The 
above experimental design was repeated over a range of saturation times from 0.5-5 
seconds at 32 dB saturation pulsepower with up to 2000 transients recorded. 
4.3.15 Statistical analysis 
Results are presented as mean ± standard deviation (SD) or as percentage change in 
the release of cytokines following different types of treatments, compared either to 
PHA, Con A or PMA only controls. Each donor blood sample was treated as control 
(cells + cell stimulant) as well as treatment (cells + cell stimulant + enoxaparin 
fractions). The statistical analysis was performed on the raw data using a total mean 
response from all the mean values of controls as well as treatments. Given the fewer 
number of observations, statistical significance were evaluated using non-parametric 
Wilcoxon-signed ranked test and Kruskal-Wallis test, where applicable. Mann-
Whitney U tests were then utilised to compare inter-group differences in place of 
Dunnett’s post-hoc analysis. A p-value of <0.05 was considered statistically 
significant. 
4.4 RESULTS AND DISCUSSION 
4.4.1 Cytokine release  
The release of TNF-α from PBMCs of allergic asthmatics in the presence of different 
concentrations of PHA is shown in Figure 4.1. Concentration-dependent increase in 
the release of TNF-α was observed. The release of TNF-α was found to be 315.1, 
1099.0, 1465.8, 2337.8, 2852.7, 2925.4 and 2534.6 pg/mL at 1, 2.5, 5, 7.5, 10, 20 and 
40 μg/mL respectively. The concentration of PHA at 10 or 20 μg/mL was found to be 
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the most effective in releasing TNF-α from allergic asthmatic subjects. There was no 
statistical difference in the release of tested cytokine when 10 or 20 μg/ml of PHA 
was used. Therefore 10 μg/ml of PHA was used for subsequent experiments. The 
reduction of TNF-α levels at higher concentrations (40 μg/mL) is most likely due 
PHA-induced cell apoptosis which has been reported previously [159, 160]. We 
selected 72 hours as the incubation time period for all the experiments as previous 
studies has shown that 10 μg/mL of PHA is optimum to give an appropriate response 
for the cytokines of interest in 3-day cultures [202]. After 72 hour incubation with 
PHA, PBMCs from allergic asthmatic subjects released significantly higher levels of 
IL-4, IL-5, IL-13 and TNF-α than PBMCs of healthy controls (Figure 4.2A) with 
TNF-α showing the highest levels of 1652.6 pg/mL overall. The highest proportional 
change was observed for IL-5 in PBMCs from allergic asthmatic individuals, where 
its levels were increased by 98.7%.  
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Figure 4.1 Concentration-dependent effect of PHA on the release of TNF-α. PBMCs from 
allergic asthmatic subjects (n=2) were stimulated with various concentrations of PHA (1 to 40 
μg/mL) for 72 hours. Data is presented as mean ± SD. 
4.4.2 Separation of enoxaparin 
Beyond their well-established effect on blood-coagulation, LMWHs have been 
recognised for many other biological activities, including anti-inflammatory activity. 
Substantial evidence demonstrates that LMWHs could be effective for managing 
many inflammatory disorders including, asthma [41], ulcerative colitis [203] and 
lichen planus [204]. LMWHs have shown varying results, overall a clear benefit has 
been demonstrated, with enoxaparin being one of the most active LMWH [145, 146, 
205]. Intact enoxaparin has shown to inhibit the release of IL-4, IL-5, IL-13 and TNF-
α [190]. Nevertheless, the use of these complex macromolecules in inflammatory 
disorders is unlikely to progress because they harbour the inherent risk of bleeding 
complications due to their anticoagulant activities [161, 206]. To determine whether 
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the observed activity of intact LMWH is independent to its anticoagulant effect, 
enoxaparin was separated into different fractions with or without anticoagulant 
activity (Figure 4.2B-C). The approximate saccharide composition of each fraction 
ranging from two saccharide units (dp2; molecular weight ~600 Da) to 24 saccharides 
(dp24; molecular weight ~8000 Da) was previously determined using size-exclusion 
chromatography [105]. Each IC-derived enoxaparin fraction was collected, desalted 
and quantified. The concentration of NaCl in each desalted fraction of enoxaparin was 
found to be less <0.9% (w/v). This NaCl content was deemed acceptable since it is 
known that “normal” saline (0.9%, w/v, NaCl) is isotonic with body fluids and is used 
to dilute the fractions while performing the anti-factor Xa analysis and to wash the 
cultured cells during the determination of anti-inflammatory activity. Each fraction 
was tested for their effect on cytokine release from stimulated PBMCs of allergic 
asthmatic subjects. 
4.4.3 Effect of IC-derived enoxaparin fractions on cytokine release 
Since PHA induced the highest levels of TNF-α in the culture medium, this cytokine 
response was initially selected to test the effect of enoxaparin fractions in this cellular 
system. The isolated enoxaparin fractions modulated TNF-α release to different 
extents (Figure 4.2D). While the majority of fractions did not significantly change the 
levels of TNF-α, fractions 1 (disaccharide) and 4 (tetrasaccharide) significantly 
inhibited TNF-α release by 57.6 and 67.5% respectively. Interestingly, for the other 
two fractions (9 and 11) a trend towards increased TNF-α release was detected, which 
did not reach significance. To investigate the anti-inflammatory activity of enoxaparin 
in more detail we selected fractions 1 and 4 for further analysis.  
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Figure 4.2 Effect of enoxaparin 
fractions on ex-vivo cytokine release. 
(A) PHA-induced release of cytokines 
(logarithmic scale) from PBMCs of healthy 
(n=5) and allergic asthmatic (n=10) 
subjects. Each sample was analysed in 
triplicate and the data is presented as the 
average of five and ten individual samples 
for healthy and allergic asthmatic subjects, 
respectively. Data is presented as mean ± 
SD. (B) Ion-chromatographic (IC) 
separation of enoxaparin, fractionated 
using a CarboPac PA100 semi-preparative 
column; a 32-74% NaCl gradient over 70 
minutes; 2 mL/minute flow rate and a 
detection wavelength of 232 nm. The 
numbers indicate the area of all the 
fractions collected. Data represents a 
typical experiment out of five independent 
experiments. (C) Anticoagulant activity of 
IC-separated enoxaparin fractions. Data is 
presented as mean ± SD (n=3). 
Anticoagulant activity was observed from 
fraction 6 onwards. (D) Inhibition of TNF-α 
release by different fractions of 
enoxaparin. TNF-α was released by 
PBMCs of allergic asthmatic subjects 
(n=10) after ex-vivo stimulation with PHA. 
The relative percentile amount of each 
fraction (fraction 1 to 14) present in 500 
μg/mL of intact enoxaparin was: 9.18%, 
4.24%, 6.12%, 5.15%, 2.99%, 4.78%, 
20.32%, 11.4%, 10.53%, 7.35%, 5.98%, 
4.6%, 2.95% and 5.06% respectively. Data 
is presented as mean ± SD. ***p<0.001 
versus the PHA-stimulated control. 
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4.4.4 Effect of fractions 1 and 4 on cytokine release  
Using PBMCs from asthmatic subjects, the concentration dependent effects of 
fractions 1 and 4 were tested with regards to their inhibitory activity towards the 
release of IL-4, IL-5, IL-13 and TNF-α (Figure 4.3A-D). Both fractions significantly 
inhibited the release of all cytokines in a concentration-dependent manner. While 
fraction 1 showed maximal inhibition of cytokine release at 40 µg/mL, fraction 4 
maximally reduced cytokine release at 20 µg/mL. Higher concentrations of fraction 4 
did not result in a stronger inhibition. Instead a plateau of about 24-49% residual 
cytokine release compared to the PHA-stimulated control appeared to be the maximal 
possible level of inhibition by these fractions. Overall, inhibition by fraction 4 was 
greater than fraction 1, with maximum inhibition by 68.6%, 70.2%, 76.0% and 69.8% 
for IL-4, IL-5, IL-13 and TNF-α, respectively. The inhibitory effect of fraction 4 on 
TNF-α release in the presence of 20 µg/mL of PHA was also investigated and the 
percentage inhibition was found to be 67.14% which was not statistically significant 
to the observed inhibition seen with 10 µg/mL of PHA.  
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Figure 4.3 Concentration-dependent suppression of cytokine release by enoxaparin 
fractions. Inhibition of cytokine release by 0 to 40 µg/ml of enoxaparin fractions 1 and 4. 
Cytokines [IL-4 (A), IL-5 (B), IL-13 (C) and TNF- α (D)] were released by PBMCs of an 
allergic asthmatic subject (n=5) after ex-vivo stimulation with PHA. Data is presented as 
percentage of PHA-stimulated control. *p<0.05, **p<0.01 and ***p<0.001 versus PHA-
stimulated control. 
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The observed inhibition of cytokine release by the two enoxaparin fractions 1 and 4 
was comparable to the corticosteroid, fluticasone, one of the currently used agents in 
the management of asthma (Figure 4.4). There is evidence that the anti-inflammatory 
responses of heparins are known to be dependent on their chain lengths as well as 
sulfation pattern. For instance, it has been shown that the anti-proliferative activity 
exhibited by heparin requires oligosaccharide chains greater than six saccharides [90]. 
Moreover, O-sulfated heparin retains anti-proliferative activity and oversulfation at O-
positions enhances this activity [89, 91]. Similarly, the observed differences in the 
inhibition of tested cytokines by different fractions could possibly be due to various 
degree of polymerisation, where a minimum of two and a maximum of four 
saccharide units are required to bind cellular receptors and exhibit inhibitory effects. 
The difference in the observed inhibitory effects of fraction 1 and fraction 4 could be 
high degree of sulfonation especially at O-positions in fraction 4 resulting in enhanced 
inhibition of cytokine release.  
Chapter Four 
 
105 
 
 
Figure 4.4 Comparison between enoxaparin fractions and fluticasone. Inhibition of 
cytokine release in the presence of fraction 1 (40 μg/mL), fraction 4 (20 μg/mL) or fluticasone 
(0.5 ng/mL). Cytokines (IL-4, IL-5, IL-13 and TNF- α) were released by PBMCs of allergic 
asthmatic subjects (n=10) after stimulation with PHA (10 μg/mL). Data is presented as 
percentage of PHA only control. *p<0.05, **p<0.01 and ***p<0.001 versus PHA only control. 
4.4.5 Effect of fraction 4 on cellular viability and proliferation 
To rule out that the observed inhibition of PBMC activation by fraction 4 arose as a 
consequence of cytotoxic effects or changes in cellular proliferation, we assessed cell 
viability in the presence or absence of PHA and/or fraction 4 by detecting LDH 
release into the cell culture supernatant (Figure 4.5A). Fraction 4 did not induce any 
increase of extracellular LDH while PHA, as expected, showed significant toxicity. 
This toxicity was not affected by co-incubation of PHA with fraction 4 (Figure 4.5A). 
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Consistent with the LDH-release results, no signs of cytotoxicity were detected in the 
presence of fraction 4 alone when using trypan blue exclusion as the toxicity readout 
(Figure 4.5B). In this case, only mild signs of toxicity by PHA could be detected, 
which when combined with fraction 4 was no longer significantly different to 
unstimulated PBMCs. Based on cell counts, PHA was found to induce significant 
proliferation of PBMCs. Fraction 4, on the other hand, showed no effect on cell 
proliferation when compared to either PHA or untreated control (Figure 4.5C).  
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Figure 4.5 Effect of fraction 4 on cellular viability. (A) Viability of PBMCs is presented as 
mean % LDH release ± SD from allergic asthmatic subjects (n=3). Cells were incubated for 72 
hours in the presence of PHA, fraction 4 or PHA + fraction 4. *p<0.05 and **p<0.01 versus 
unstimulated control. (B) Viability of PBMCs from allergic asthmatic subjects (n=3) was 
determined by trypan blue dye exclusion test and is presented as % of viable cells remaining 
after 72 hours of incubation with PHA, PHA + fraction 4 or fraction 4 alone. Data is presented 
as mean ± SD. (C) Proliferation of PBMCs from allergic asthmatic subjects (n=3) was 
determined after 72 hours in the presence of PHA, fraction 4 alone or PHA + fraction 4. Cells 
were counted after incubation for 72 hours and expressed as million cells/mL. Data is 
presented as mean ± SD.  
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4.4.6 Time and target specificity of fraction 4 
To gain a better understanding of the inhibitory mechanism of the fraction 4 of 
enoxaparin we investigated the time dependency of this process. When the PBMCs 
were treated with fraction 4 at different times after PHA stimulation, the inhibitory 
effect was lost after 10 minutes (Figure 4.6A). Maximal inhibition of TNF-α release 
was only observed if fraction 4 was added concurrently with PHA or at most 1 minute 
after PHA stimulation (Figure 4.6A). On the other hand, when PBMCs were pre-
treated with fraction 4 up to 180 min before PHA stimulation, all time points showed 
effective inhibition of TNF-α release (Figure 4.6B).  
To understand if this inhibitory effect of fraction 4 was restricted to a specific 
form of stimulation or molecular target, three different modes of activation were 
tested (Figure 4.6C). Consistent with prior results, fraction 4 significantly inhibited 
the release of TNF-α after stimulation of PBMCs with PHA. Similarly, a significant 
inhibition of TNF-α release was also observed after stimulation of PBMCs with Con 
A in the presence of fraction 4 (Figure 4.6C). Interestingly, the inhibitory effect of 
fraction 4 on TNF-α release was found to be completely absent when PMA was used 
to stimulate the PBMCs (Figure 4.6C).  
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Figure 4.6 Time- and target-dependent inhibitory effect of fraction 4. Effect of fraction 4 
on TNF-α release by activated PBMCs of allergic asthmatic subjects (n=3). (A) Addition of 
fraction 4 at different time points after the addition of PHA and (B) addition of PHA at different 
time points after the addition of fraction 4. Data is presented as mean ± SD. *p<0.05 and 
***p<0.001 versus PHA only control. (C) Effect of fraction 4 on TNF-α release from activated 
PBMCs of allergic asthmatic subjects (n=3) after stimulation with either PHA (10 μg/mL), Con 
A (10 μg/mL) or PMA (5 ng/mL). Data is presented as mean ± SD. *p<0.05, **p<0.01 and 
***p<0.001 versus PHA or Con A or PMA only control respectively. 
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4.4.7 NMR analysis 
4.4.7.1 Saccharide information of fraction 4 
NMR analysis was performed to identify the number of saccharide units present in 
fraction 4 of enoxaparin. A 2D 
13
C-
1
H multiplicity edited HSQC of fraction 4 
specified the presence of four sugar units with single set of signals detected for each 
of the four sugar units (Figure 4.7). Therefore, fraction 4 of enoxaparin was confirmed 
to have a tetrasaccharide sequence.  
 
 
Figure 4.7 Saccharide Information of fraction 4. The 2D 
13
C-
1
H multiplicity edited HSQC 
spectrum for fraction 4. The blue contours represent signals from carbons with 1 or 3 attached 
protons and the cyan contours represent carbons with two attached protons, i.e. the CH2 
moieties of the two glucosamine units. This represents the presence of four sugar units with 
single sets of signals detected for each of the four sugar units and therefore, fraction 4 of 
enoxaparin was confirmed to have a tetrasaccharide sequence. 
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4.4.7.2 Lack of PHA binding to fraction 4  
PHA is known to bind complex polysaccharides as well as the T-cell receptor [207]. 
Therefore, using STD-NMR we examined if fraction 4 of enoxaparin could bind to 
PHA directly to rule out an experimental artefact. Since direct binding of the two 
molecules could impair the ability of PHA to bind and activate the T-cell receptor we 
needed to confirm that the observed inhibition of T-cell activation by fraction 4 was 
not due to this potential in-vitro artefact of our experimental cell system. In the 
absence of any available small-molecule as a putative PHA binder, the STD-NMR 
experiments were validated using bovine serum albumin, tryptophan and glucose as 
described previously. As anticipated, a clear saturation as seen in spectrum B, reveals 
binding of tryptophan to bovine serum albumin, while in the same spectrum, no 
saturation of the glucose component confirmed its lack of binding (Figure 4.8).   
 
Figure 4.8 Control data for Saturation Transfer Difference (STD) spectroscopy. Two 
1
H-
1D spectra are presented for a solution of bovine serum albumin, L-Tryptophan (Trp) and 
Glucose (Glc). Spectrum (A) is the reference spectrum with attenuation of residual solvent 
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using pre-saturation at the solvent frequency. Spectrum (B) is the STD spectrum calculated 
from the difference of two spectra with excitation off-resonance (30 ppm) and on resonance (-
1 ppm). The positive binding of Trp to BSA is indicated by the presence of signals that have 
obtained their excitation via the protein lattice. Glc does not bind and so does not register in 
the difference spectrum. 
Under identical experimental conditions, PHA did not bind fraction 4 since no 
saturation of this fraction was detected after excitation (Figure 4.9). Spectrum A 
shows fraction 4 resonances from the 
1
H-noespr1d experiment and spectrum B shows 
the only visible signals from excitation of PHA (Figure 4.9).  
 
Figure 4.9 NMR analysis elucidating lack of binding of fraction 4 to PHA. Two 
1
H-1D 
spectra are shown for the putative binding of fraction 4 to PHA. Spectrum (A) is the reference 
spectrum of fraction 4 and PHA obtained with suppression of residual solvent signal by pre-
saturation at the solvent frequency. Spectrum (B) is the STD difference spectrum calculated 
from spectra with an on-resonance pulse at -1 ppm and off-resonance pulse at 30 ppm. Only 
the baseline of PHA signals can be observed in this trace. No binding of fraction 4 can be 
detected. 
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Among the potential mechanisms that could account for the anti-inflammatory 
effect of heparins, their interaction with a broad range of bioactive molecules involved 
in the process of inflammation, such as cytokines, growth factors, adhesion 
molecules, tissue-destructive enzymes and cytotoxic mediators has been proposed 
[13]. However, the mode(s) of action behind the observed anti-inflammatory effect of 
various types of heparins in disorders like asthma is poorly understood. It was 
previously suggested that the anti-inflammatory activity of heparins could be 
dependent on the inactivation of nuclear factor-kappa B, the inhibition of 1,4,5-
inositol triphosphate-induced signalling or interaction with the CD11b receptor [40, 
74, 146]. Here we describe for the first time, another mechanism by which enoxaparin 
fractions can inhibit a PBMC-mediated inflammatory response induced by receptor-
activating ligands, such as PHA or Con A [208, 209]. Since the lectins, PHA and Con 
A are known to bind the CD3- and CD28-T cell receptor complex, as well as 
polysaccharides, the anti-inflammatory effects we observed by enoxaparin fractions 
could be a result of either: i) saturating the polysaccharide binding site of PHA and 
thereby blocking its binding to the T-cell receptor; ii) binding and blocking the PHA-
binding site on the T-cell receptor; or iii) binding to an allosteric binding site on the 
T-cell receptor which prevents T-cell receptor activation. Since the NMR analysis 
demonstrated that the enoxaparin fraction 4 does not bind to PHA, a specific or 
allosteric binding to cellular receptor(s) complex is likely. This hypothesis is 
supported by our observation that the enoxaparin fraction 4 was unable to prevent the 
inflammatory response when PBMCs were stimulated with PMA, which activates 
protein kinase C (PKC) downstream of the T-cell receptor [210]. Finally, the general 
binding between cell surface T-cell receptors and PHA or Con A occurs rapidly after 
co-incubation [211]. For maximum activation and subsequent proliferation it has been 
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shown that the antigen receptor has to be engaged for at least 2 hours [211, 212] but a 
variety of immediate early genes such as interferon-gamma are induced after 30 
minutes [213]. Based on the time-dependent inhibition of T-cell activation observed, 
our results strongly suggest that the potential mechanism by which enoxaparin 
fractions suppress the inflammatory response is by directly interacting with cell 
surface receptors and is covering different signalling pathways since both interleukins 
and TNF-α are supressed. It remains to be seen if this suppression is limited to 
activation through plant lectins or is extended to antigen-specific activation of the T 
cell receptor. The identification of specific unmodified enoxaparin fractions paves the 
way to map the specific binding site(s) involved in future studies. 
4.4.8 Effect of desulfated fraction 4 on cytokine release  
Since enoxaparin oligosaccharides are enriched with sulfate groups that are thought to 
be important for its anti-inflammatory activity, we examined the influence of sulfate 
groups by testing fraction 4 after desulfation of specific moieties with regards to their 
influence on the suppression of TNF-α release (Figure 4.10). It was observed that the 
inhibitory effect of fraction 4 was significantly reduced after complete and 6-O-
desulfation of the fraction while N- and 2-O/3-O-desulfated fraction had no significant 
influence on the release of TNF-α. The inhibitory effect on the release of TNF-α after 
6-O-desulfation was found to be reduced by more than 95%.  
Chapter Four 
 
115 
 
 
 
Figure 4.10 Effect of desulfation on anti-inflammatory activity of fraction 4. PBMCs of 
allergic asthmatic subjects (n=3) were stimulated with PHA in the presence of either 
completely desulfated, N-desulfated, 2-O/3-O-desulfated or 6-O-desulfated fraction 4 of 
enoxaparin. Data is presented as mean ± SD. *p<0.05, **p<0.01 and ***p<0.001. 
To avoid such risk associated with the intact LMWHs, a range of attempts have 
been made to separate non-anticoagulant and anticoagulant fractions of 
oligosaccharides. One available approach is to chemically or enzymatically 
depolymerise the parent LMWH. However, depolymerisation can result in a structural 
modification of oligosaccharides, with a loss of biological activities exhibited by the 
parent molecules [115, 174]. For example, some oligosaccharides of LMWHs are 
heat-sensitive and can undergo chemical modification, especially removal of 
important sulfate groups, during the elevated temperatures of the depolymerisation 
process [116]. Furthermore, the presence and location of specific sulfate groups is 
critical to elicit anti-inflammatory effects (Figure 4.11) [49, 214-219]. For instance, 
sulfate groups at the 6-O position are essential for inhibiting leukocyte adhesion while 
sulfate groups at the 2-O/3-O and N positions are required for the inhibition of 
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chemotaxis or proliferation [49, 214, 216]. Therefore, the loss of any of these sulfate 
groups as a result of depolymerisation will impair a specific aspect of the anti-
inflammatory response exhibited by the parent LMWH. Consequently, the protocol 
for separation, isolation and purification of oligosaccharide fractions from intact 
LMWH, as described here, represents a major step towards the identification of a sub-
fraction that retains full anti-inflammatory activity of the parent molecule [190]. Our 
results demonstrate for the first time the requirement of 6-O sulfate groups for the 
suppression of PBMC activation while, removal of 2-O/3-O- and N-sulfate groups had 
little effect. Although selective desulfation procedures were performed using well 
established and validated analytical methods, a major limitation of the current study is 
that we did not investigate and confirmed the integrity of the desulfated fraction of 
enoxaparin. 
 
Figure 4.11 Schematic representation of the different sulfate groups required to elicit 
various anti-inflammatory responses. 
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4.6 CONCLUSION 
In summary, the two identified fractions responsible for the anti-inflammatory effect 
of enoxaparin are composed of two and four saccharides. Therefore, the structure of 
these fractions eliminate the potential risk of bleeding as a minimum chain length of 
five saccharide residues (pentasaccharide) is required for the anticoagulant effect. 
Given the wide range of inflammatory mediators involved in the pathogenesis of 
asthma, supressing the release of multiple cytokines, as seen with the identified 
fractions, could provide significant clinical benefits. However, using more specific 
cellular models such as purified T-cells, anti-CD3/CD28 or intracellular staining of T 
cells, further work is required to determine whether enoxaparin fractions: i) act 
directly on T cell receptors and thereby, inhibit the release of T cell mediated 
cytokines and ii) retains the anti-inflammatory effect when an allergen other than 
PHA or Con A is used as a stimuli for the activation of T cells. The preliminary 
results obtained in the current ex-vivo study need to be confirmed by using pre-clinical 
in-vivo studies to determine dose-response relationships and to evaluate different 
formulation strategies. Due to their hydrophilicity and high molecular weight, 
intestinal absorption is likely to be very low. However, with respect to their use in 
asthma, a formulation for inhalation would not only deliver the fraction directly and 
selectively to its site of action, but it would also avoid systemic exposure to the drug, 
which overall makes this route of administration highly preferable. 
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In-Vitro Suppression of IL-6 and IL-8 Release from Human Pulmonary 
Epithelial Cells by Non-Anticoagulant Fraction of Enoxaparin  
5.1 ABSTRACT  
Background: Enoxaparin, a mixture of anticoagulant and non-anticoagulant fractions, 
is widely used as an anticoagulant agent. However, it is also reported to possess anti-
inflammatory properties. Our study indicated that enoxaparin inhibits the release of 
IL-6 and IL-8 from A549 pulmonary epithelial cells. Their release causes extensive 
lung tissue damage. The use of enoxaparin as an anti-inflammatory agent is hampered 
due to the risk of bleeding associated with its anticoagulant fractions. Therefore, we 
aimed to identify the fraction responsible for the observed anti-inflammatory effect of 
enoxaparin and to determine the relationship between its structure and biological 
activities.  
Methods: A549 pulmonary epithelial cells were pre-treated in the presence of 
enoxaparin and its fractions. The levels of IL-6 and IL-8 released from the trypsin-
stimulated cells were measured by ELISA. The anticoagulant activity of the fraction 
responsible for the effect of enoxaparin was determined using an anti-factor-Xa assay. 
The fraction was structurally characterised using nuclear magnetic resonance. The 
fraction was 2-O, 6-O or N-desulfated to determine the position of sulfate groups 
required for the inhibition of interleukins. High-performance size-exclusion 
chromatography was performed to rule out that the observed effect was due to the 
interaction between the fraction and trypsin or interleukins.  
Results: Enoxaparin (60μg/mL) inhibited the release of IL-6 and IL-8 by >30%. The 
fraction responsible for this effect of enoxaparin was found to be a disaccharide 
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composed of α-L-iduronic-acid and α-D-glucosamine-6-sulfate. It (15μg/mL) 
inhibited the release of interleukins by >70%. The 6-O sulphate groups were 
responsible for its anti-inflammatory effect. The fraction did not bind to trypsin or 
interleukins, suggesting the effect was not due to an artefact of the experimental 
model. 
Conclusion: The identified disaccharide has no anticoagulant activity and therefore 
eliminates the risk of bleeding associated with enoxaparin. Future in-vivo studies 
should be designed to validate findings of the current study. 
5.2 INTRODUCTION 
Asthma, a respiratory inflammatory disorder, affects millions of people around the 
world and its prevalence has increased markedly in recent years [144]. The 
pathogenesis of asthma is complex, involving different cell types, such as T-cells, 
neutrophils, mast cells, eosinophils, macrophages and epithelial cells of the lung 
[220]. Epithelial cells and macrophages act as the first-line of defence before the 
migration and recruitment of other types of inflammatory cells into the lungs upon 
exposure to various foreign particles, including allergens [221, 222]. Among various 
pro-inflammatory mediators, interleukin (IL)-6 and IL-8 are released by the 
pulmonary epithelial cells in response to their damage or stress caused by a variety of 
foreign particles [223]. IL-6 is a pro-inflammatory cytokine and its involvement in 
various immuno-regulatory effects, such as increased IL-4 production during Th2 
differentiation, increased Th17 differentiation, decreased Th1 differentiation and 
increased IL-4 dependent synthesis of immunoglobulins, causes further damage to the 
lungs [224, 225]. IL-8, a potent chemotactic agent, facilitates the migration of 
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neutrophils and T-cells, and priming of eosinophils [226]. These immune cells can 
then cause extensive tissue damage and prolong the inflammatory phase.  
Corticosteroids are currently used as first line agents for the treatment of 
asthma and are effective in supressing the release of various inflammatory mediators 
involved in the pathogenesis of disease. However, they are associated with severe side 
effects, especially with their long-term use in children, and there has been a consistent 
rise in the prevalence of difficult to treat corticosteroid-resistant asthma [143, 227]. 
More recently, monoclonal antibodies have been developed to treat various 
immunological disorders, including asthma. For example, omalizumab, a humanised 
monoclonal-immunoglobulin specific antibody, is the only biological approved for the 
treatment of severe, uncontrolled and steroid-resistant asthma. However, apart from 
its high cost and inconvenient route of administration, it is associated with serious 
side effects, such as anaphylactic reactions as well as occurrence of cardiovascular 
and cerebrovascular adverse effects [196, 228]. Therefore, there is a need for the 
development of novel therapeutic modalities for management of asthma.  
Enoxaparin, a well-known anticoagulant drug, has recently attracted much 
research interest for its anti-inflammatory properties. This low-molecular-weight 
heparin (LMWH) belongs to the family of glycosaminoglycans and is composed of 
various fractions, also known as oligosaccharides, of unfractionated heparin (UFH) 
[131]. Although enoxaparin is commonly used for the prophylaxis of deep vein 
thrombosis [229], clinical studies have implicated its usefulness for the management 
of various inflammatory conditions, including asthma [36, 41, 166]. Like UFH and 
other LMWHs, enoxaparin is also composed of a mixture of anticoagulant and non-
anticoagulant oligosaccharides [153]. Unfortunately, given the increased risk of 
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bleeding associated with anticoagulant oligosaccharides of enoxaparin, its use is not 
indicated for the management of inflammatory disorders [230]. However, clinical 
studies have indirectly indicated that the observed anti-inflammatory effects of 
heparins (UFH and LMWHs) are because of the presence of non-anticoagulant 
oligosaccharides and, hence, independent of their anticoagulant effect [12, 147]. One 
potential way to avoid the bleeding complications associated with heparins when used 
for the management of inflammatory conditions is to identify the non-anticoagulant 
oligosaccharides responsible for their anti-inflammatory effects. The current approach 
to obtain the oligosaccharides is to perform depolymerisation of heparins by chemical 
or enzymatic methods. However, a chemical or enzymatic depolymerisation results in 
the structural modification of oligosaccharides and it has been demonstrated that 
certain biological functions of the parent heparin could indeed be removed by the 
depolymerisation process [115, 173, 174]. Some oligosaccharides in heparins are heat 
sensitive and can undergo chemical modification, especially desulfation, with the 
elevated temperatures of the depolymerisation process [116]. An oligosaccharide’s 
sulfation pattern is a key determinant for its anti-inflammatory properties. 
Depolymerisation can also be performed through a freeze-drying process; however, 
freeze-drying results in physical changes of some oligosaccharides within the heparin 
molecule [117].  
An alternative approach is to separate, isolate and identify the non-
anticoagulant oligosaccharides of heparins without their prior chemical or enzymatic 
digestion. However, a major limitation in the separation of heparins is the lack of a 
high resolution technique as they are highly negatively charged and structurally 
complicated compounds [113, 118]. Nevertheless, we have recently developed a novel 
ion-exchange chromatographic (IC) technique that can effectively separate the 
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anticoagulant and non-anticoagulant oligosaccharides of enoxaparin without their 
structural modification [105]. Since our study indicated that enoxaparin can inhibit the 
release of two key pro-inflammatory mediators involved in the pathogenesis of 
asthma (IL-6 and IL-8), we first identified the IC-derived fraction responsible for the 
observed inhibitory effect of enoxaparin and then characterised its structure, as well as 
determined the specific position of sulfate groups required for the inhibition of IL-6 
and IL-8 release.   
5.3 MATERIALS AND METHODS 
5.3.1 Materials 
A549 human pulmonary epithelial cell line was purchased from the American Type 
Culture Collection (Manassas, VA, USA). Enoxaparin was obtained from Aventis 
Pharma Ltd. (NSW, Australia). UFH was purchased from Hospira Pty. Ltd. (Victoria, 
Australia). Sodium chloride, tetrahydrofuran, sodium hydroxide, N-methyl-N-
(trimethylsilyl) trifluroacetamide, methanol, acetic acid, Ham’s F12K medium, 
antibiotics (penicillin G and streptomycin), trypsin-ethylenediaminetetraacetic acid 
(EDTA), trypsin, thrombin, enzyme-linked immunosorbent assay (ELISA) kits for IL-
6 and IL-8, trypan blue exclusion assay kit, lactate dehydrogenase (LDH) activity 
assay kit, and potassium phosphate monobasic and dibasic were purchased from 
Sigma-Aldrich (Castle Hill, NSW, Australia). Fetal bovine serum, IL-6 and IL-8 
recombinant human proteins were obtained from Invitrogen (Grand Island, NY, 
USA). Deuterium oxide (D2O) was purchased from Cambridge Isotope Laboratories 
(Andover, MA, USA). 
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5.3.2 Human pulmonary epithelial cell (A549) culture 
For initial growth, the A549 cells were cultured in 75 cm
2 
tissue culture flasks 
(Corning, NL, Mexico) and grown to confluence in complete medium [Ham’s F-12 
Kaighn’s Modification medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and 100 μg/mL antibiotics (penicillin G and streptomycin)] and incubated 
at 37°C in a humidified 5% CO2 atmosphere as described previously [231].  
5.3.3 Preparation of stock solutions 
Stock solutions of enoxaparin at 1 mg/mL were prepared in serum free medium 
(Ham’s F12K) and filter sterilized through 0.2 µm pore size syringe filters (Pall Life 
Sciences, Victoria, Australia). Other stock solutions were prepared accordingly: 1.0 
μg/mL trypsin (A549 human pulmonary epithelial cell stimulant) in Ham’s F12K, 
stored at -20 °C. 
5.3.4 Preparation of epithelial cell culture supernatants 
At confluence, the cells were detached from the flasks using trypsin-EDTA solution 
and re-seeded in 24-well cell culture plates at a density of 1 × 10
5 
cells/well. The cells 
were incubated for 24 hours and grown to confluency in serum free medium. After 
reaching confluency, the cells were exposed to 0.003 μg/mL of trypsin in the presence 
of either Ham’s F12K medium (negative control) or different concentrations (5, 10, 
20, 40, 60, 80 and 100 μg/mL) of enoxaparin. After 24 hours of incubation (37°C, 
humidified 5% CO2 atmosphere), cultures were centrifuged, and supernatants were 
removed and analysed for the levels of IL-6 and IL-8 using ELISA. 
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5.3.5 Analysis of IL-6 and IL-8 in epithelial cell supernatants 
ELISA kits specific for the measurement of human IL-6 and IL-8 (pre-coated with 
capture antibody) were prepared as per manufacturer’s recommendations. Briefly, a 
known volume of standards and culture supernatants (100 μL and 50 μL for IL-6 and 
IL-8, respectively) was added to the pre-coated wells. Further, 50 µL/well of 
biotinylated detection antibody was added to each plate and incubated for 2 hours at 
room temperature and washed 5 times. Next, 100 µL/well of standard horseradish 
peroxidase conjugated streptavidin (a commonly used enzyme to modify substrate 
resulting in colour development) was added to each well and incubated for 30 minutes 
at room temperature in the dark. Plates were again washed 5 times and 100 µL/well of 
stabilised chromogen was added to each well. Plates were then allowed to stand in the 
dark for 30 minutes and the reaction was quenched using 100 µL/well of stop solution 
(1N hydrochloric acid). Measurement of the optical density was performed using a 
plate reader (Spectra Max M2 microplate reader, Sunnyvale, CA) at 450 nm. Each 
epithelial cell treatment was performed in triplicate and supernatants of each treatment 
were analysed in duplicate.  
5.3.6 Viability and cytotoxicity studies of enoxaparin on epithelial cells  
The effect of enoxaparin at maximal inhibitory concentration on either cellular 
viability of A549 cells or its cytotoxic effect on cells after 24 hours of incubation was 
assessed using two routinely used methods. The viability of cells was determined by 
the trypan blue exclusion.  The cytotoxicity of enoxaparin treatment was determined 
using the LDH in-vitro toxicology assay, as described before [149]. Briefly, the 
culture supernatants were centrifuged at 250g for 4 minutes. An aliquot of either 
blank (complete medium) or control (epithelial cells only) cells treated with trypsin or 
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co-incubated with enoxaparin, was mixed with an aliquot of solution containing LDH 
assay mixture (LDH substrate, LDH dye and LDH cofactor). The mixture was 
incubated at room temperature for 20-30 minutes and the reaction was quenched by 
the addition of 1 N hydrochloric acid (15 μL). The absorbance was measured 
spectrophotometrically using a plate reader (Spectra Max M2 microplate reader, 
Sunnyvale, CA) at a wavelength of 490 nm. Each sample was prepared and analysed 
in triplicate.  
5.3.7 Separation of enoxaparin 
The chromatographic separation of enoxaparin was carried out using a previously 
described ion-exchange chromatography (IC) technique [105] with minor 
modifications. Separations were performed on a biocompatible  chromatography 
system (Thermo Fisher Scientific, NSW, Australia) using a semi-preparative Dionex 
CarboPac PA100 (250 mm, 9 mm ID, 8.5 µm) strong anion-exchange column 
(Thermo Fisher Scientific, NSW, Australia). The chromatography system consisted of 
a HPG-3400RS binary separation pump, WPD-3000RS auto-sampler, TCC-3000RS 
column thermal compartment and UV-3000RS detector. The column thermal 
compartment was set at a temperature of 40°C and UV detection was performed at 
232 nm. An injection volume of 250 µL was chosen for this work, which allowed 10 
mg of enoxaparin to be loaded onto the column for each injection, and a total flow 
rate of 2.0 mL/minute was maintained throughout. Instrument control and data 
acquisition was performed using Chromeleon® software. The mobile phases were 
composed of Milli-Q water (A) and 2 M NaCl (B). The 2 M NaCl stock solution was 
prepared by mixing NaCl and Milli-Q water and the solution was filtered and 
degassed off-line. The optimised NaCl eluent gradient (mobile phase B) was from 32 
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to 74% over 0 to 70 minutes. The 14 fractions of enoxaparin were collected in 
centrifuge tubes over the elution period between 29 to 65 minutes. The collected 
fractions containing NaCl (0.64-1.48 M) were then subjected to desalting procedures.   
5.3.8 Desalting of enoxaparin fractions 
The IC-derived fractions of enoxaparin were desalted as described previously [105] 
with minor modifications. Each fraction was concentrated on a miVac DNA 
centrifugal concentrator (Genevac Ltd, Suffolk, UK) at 40°C. The concentrated 
solutions containing NaCl and enoxaparin fractions were desalted using PD MidiTrap 
G-10 columns (GE Healthcare Life Sciences, Uppsala, Sweden) having desalting 
capacity of more than 95%. The recovery of each fraction was determined by 
reanalysing the desalted fractions using IC under the same chromatographic 
conditions as described above. The concentration of each fraction was calculated 
using the differences in the peak areas of the desalted fraction and enoxaparin fraction 
eluted at the same time.  
The stock solution (1 mg/mL) of each fraction was prepared in serum-free 
Ham’s F12K medium. The fractions were tested for their effects on the release of IL-6 
and IL-8 from stimulated human pulmonary epithelial cells, as described above. 
Anticoagulant activity of the fraction responsible for the inhibitory effect of 
enoxaparin was determined using an anti-factor Xa assay. Its structural 
characterisation was then carried out using a nuclear magnetic resonance (NMR) 
technique.  
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5.3.9 NMR analysis of enoxaparin fraction 
The identified fraction was dissolved in potassium phosphate buffer at pH 7.0 
prepared in 99.9% D2O.  All data were acquired with a Bruker AVANCE III HD 4-
channel spectrometer with a 5mm triple resonance cryogenically cooled probe.  
Sample temperature was regulated at 298K and spectrometer field frequency was 
600.07 MHz and 150.88 MHz for 
1
H and 
13
C nuclei, respectively. Data acquisition 
and processing were executed within Topspin™ 3.2 software (Bruker Corporation, 
MA, USA). All chemical shifts are referenced indirectly to DSS (NMR standard) at 
0.0 ppm in 
1
H and 
13
C. The experiments conducted and their relevant acquisition and 
processing details are as follows: 
1
H-1D (“noesgppr1d”) with presaturation of residual 
solvent resonance, acquired with 64K datapoints in 8 transients, spectral width of 10 
ppm and a relaxation delay of 4 seconds. Raw data was processed with an exponential 
apodisation with a line-broadening factor of 0.3 Hz prior to Fourier transformation; 
13
C-1D (“zgpg30”) with proton decoupling acquired with 64K datapoints in 20,000 
transients, spectral width of 200 ppm and relaxation delay of 2 seconds. Raw data was 
processed with an exponential apodisation with a line-broadening factor of 1.0 Hz 
prior to Fourier transformation; 
1
H-
13
C-HSQC (“hsqcedetgpsisp2.2”) with multiplicity 
editing acquired with 2048 × 64 datapoints, 2 transients per 2D increment, spectral 
widths of 10 ppm and 165 ppm for 
1
H and 
13
C dimensions, respectively, and a 
relaxation delay of 1.5 seconds.  Data were processed with zero filling in both 
dimensions and a squared sine apodisation (SSB=2) to a resultant matrix of 4096 × 
1024 datapoints; 
1
H-
13
C-HMBC (“hmbcgpl2ndqf”) acquired with 2048 × 128 
datapoints, 16 transients per 2D increment, spectral widths of 10 ppm and 200 ppm 
for 
1
H and 
13
C dimensions, respectively, and a relaxation delay of 1.5 seconds.  Data 
were processed with zero filling in both dimensions and a squared sine apodisation 
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(SSB=2) to a resultant matrix of 4096 × 1024 datapoints; 
1
H-
13
C-HSQCTOCSY 
(“hsqcetgpml”) acquired with 2048 × 256 datapoints, 32 transients per 2D increment, 
spectral widths of 10 ppm and 165 ppm for 
1
H and 
13
C dimensions, respectively, 
TOCSY mixing time of 120 milliseconds and a relaxation delay of 1.5 seconds.  Data 
were processed with zero filling in both dimensions and a squared sine apodisation 
(SSB=2) to a resultant matrix of 4096 × 1024 datapoints. 
5.3.10 Desulfation of enoxaparin fraction 
5.3.10.1 Selective 2-O desulfation 
Selective 2-O-desulfation of identified fraction was performed using a previously 
described method [151].  Briefly, a solution containing 8 mg/mL of fraction was 
dissolved in 200 μL of 0.1 M sodium hydroxide. The mixture was then frozen and 
lyophilised. The residues were dissolved in 0.5 mL of Milli-Q water and acetic acid 
was added to adjust the pH of the mixture to 8.0. The mixture was evaporated to 
dryness and precipitated using 80% v/v of anhydrous methanol, followed by 
centrifugation at 3000 rpm for 10 minutes. The supernatant was carefully discarded 
and samples were kept at 4°C overnight. Any traces of methanol were removed using 
a miVac DNA centrifugal concentrator and the remaining precipitants were dissolved 
in 4 mL Milli-Q water to obtain 2-O-desulfated fraction of enoxaparin. 
5.3.10.2 N-desulfation  
A solution containing 8 mg/mL of enoxaparin fraction was mixed with 650 µL of 
tetrahydrofuran and 50 µL of Milli-Q water and incubated for 30 minutes at 50°C for 
partial N-desulfation, as described previously [151] with minor modifications. The 
solution was neutralised using 0.1 M sodium hydroxide. The resulting mixture was 
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evaporated to dryness and precipitated by the addition of anhydrous methanol as 
described above and dissolved in 4 mL Milli-Q water. 
5.3.10.3 Selective 6-O-desulfation  
Selective 6-O-desulfation of enoxaparin fraction was performed as previously 
described [151]. Briefly, 8 mg/mL of the fraction was mixed with 1 mL of solvent 
(tetrahydrofuran) and 1 mL of silylating agent (N-methyl-N-(trimethylsilyl) 
trifluroacetamide). The solution was incubated for 9 hours at 50°C. The resulting 
mixture was evaporated to dryness and precipitated by the addition of anhydrous 
methanol as described above and the precipitants were dissolved in 4 mL Milli-Q 
water.  
After desulfation, free sulfate groups were removed using a 600Da cut-off 
filter (Millipore, NSW, Australia) at 15000 rpm for 10 minutes. The concentrated 
supernatant was dissolved in 1 mL of Milli-Q water for further use. Each selectively 
desulfated enoxaparin sample was tested for its effect on the release of IL-6 and IL-8 
from stimulated human pulmonary epithelial cells. Each sample was prepared and 
analysed in triplicate.  
5.3.11 Binding of proteins to the identified fraction  
5.3.11.1 High-performance size-exclusion chromatography (HP-SEC) 
instrumentation 
The putative binding of the identified fraction to either trypsin or ILs was determined 
by HP-SEC. The HP-SEC system (Thermo Fisher Scientific, NSW, Australia) 
consisted of a HPG-3400RS binary separation pump and a WPS-3000TRS auto-
sampler. The system was connected to Corona Ultra RS charged aerosol detector (C-
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CAD; Thermo Fisher Scientific, NSW, Australia). C-CAD was used as per the 
manufacturer’s recommended settings of 35±0.2 psi for the nitrogen gas flow at 30°C 
nebuliser temperature. An injection volume of 10 µL and a total flow rate of 1.0 
mL/minute were maintained. Instrument control and data acquisition were performed 
using Chromeleon® software. 
5.3.11.2 HP-SEC analysis 
HP-SEC analysis was performed using two HP-SEC columns coupled in series; a 
Superdex™ peptide 10/300 GL (300 × 10 mm) and a Superdex™ 75 10/300 GL (300 
× 10 mm) column (GE Healthcare Life Sciences, Uppsala, Sweden) were used for this 
purpose. Isocratic elution of the tested analytes was performed with a mobile phase 
containing 100 mM ammonium acetate (pH 6.0) as eluent. The method was validated 
by investigating the intra- (n=6) and inter-day (five consecutive days; n=30) precision 
using peak areas of 10 µM of UFH, thrombin, trypsin, IL-6 or IL-8 or 100 µM of 
identified fraction. Mean intra- and inter-day accuracy was also determined and 
calculated as (observed concentration-expected concentration)/expected concentration 
× 100). Mean inter-day peak retention time for each of the analytes was also 
determined. The peak area and retention time of the analytes were determined using 
Cobra™ integration wizard software.  
5.3.11.3 Sample preparation for HP-SEC analysis  
A stock solution containing 20µM of UFH, thrombin, trypsin, IL-6 or IL-8 or 1000 
µM of identified fraction was prepared in potassium phosphate buffer. The stock 
solutions of thrombin, trypsin, IL-6 or IL-8 was diluted in ammonium acetate to 
obtain the concentration of 10 µM. The stock solution of UFH or identified fraction 
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was diluted in Milli-Q water to obtain the concentration of 10 or 500 µM. Each 
sample was prepared and analysed in triplicate. 
5.3.12 Statistical analysis 
Data are presented as mean ± standard deviation (SD) or as percentage change in the 
release of IL-6 and IL-8 following different types of treatments compared to trypsin-
stimulated controls. Statistical analysis was performed using GraphPad Prism (version 
6, GraphPad Software Inc, CA, USA), and significance was evaluated using 
independent sample or paired Student’s t-test, and one way analysis of variance 
(ANOVA), where applicable, followed by Dunnett’s multiple comparison test. A p-
value of <0.05 was considered statistically significant. 
5.4 RESULTS AND DISCUSSION 
5.4.1 Release of IL-6 and IL-8 
The calibration curves used for the measurement of IL-6 and IL-8 were generated 
using seven recommended concentrations of respective IL standards. The linearity, 
estimated by correlation coefficient (r
2
), was greater than 0.988. The levels (pg/mL) of 
IL-6 and IL-8 measured 24 hours after trypsin-induced stimulation of A549 epithelial 
cells are shown in Figure 5.1. The baseline levels of IL-6 and IL-8 were 42 and 26 
pg/mL, respectively. In the presence of trypsin, the levels of IL-6 and IL-8 were 
increased to 800 pg/mL and 2900 pg/mL (p<0.0001). In the current study, trypsin was 
used to activate the lung epithelial cells because it can induce the stimulation of 
proteinase-activated receptors (PAR) expressed by human alveolar as well as 
bronchial epithelial cell lines [232]. Recent in-vivo studies have shown that 
endogenous trypsin (mainly located in the lung) induced activation of PAR in human 
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lung epithelial cells releases IL-6 and IL-8, resulting in the progressive loss of lung 
functions [233]. 
 
Figure 5.1 In-vitro interleukin release. Trypsin-induced release of IL-6 and IL-8 from the 
epithelial cell culture supernatants.  Data is presented as mean ± SD. 
5.4.2 Effect of enoxaparin on IL-6 and IL-8 release   
As IL-6 and IL-8 are likely to be a potential target for new treatment modalities for 
this important disease, their release from the lung epithelial cells was determined in 
the presence or absence of enoxaparin. It inhibited the release of IL-6 and IL-8 in a 
concentration dependent manner (Figure 5.2A and 5.2B). Compared to control 
samples, the levels of tested ILs were not statistically different in the presence of 5 
and 10 µg/mL of enoxaparin (p>0.1466). The maximum inhibition was observed at 60 
μg/mL where the release of IL-6 and IL-8 was inhibited by 31% and 37%, 
respectively (p<0.0001). A further increase in the concentration of intact enoxaparin 
did not result in greater inhibition of IL release. LMWHs have been reported to inhibit 
the release of various inflammatory cytokines, including IL-4, IL-5, IL-13 and tumour 
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necrosis factor-alpha [145, 190, 234]. However, the current study for the first time 
demonstrated that enoxaparin can significantly inhibit the release of IL-6 and IL-8 
from the stimulated lung epithelial cells.  
 
Figure 5.2 Concentration-dependent effect of enoxaparin on interleukin release. Effect 
of different concentration of enoxaparin on the release of IL-6 (A) and IL-8 (B) following 
trypsin-induced in-vitro stimulation epithelial cells. Data is presented as percentage (mean ± 
SD) of the maximal observed IL-6 and IL-8 concentrations. *p<0.05, and ***p<0.001 versus 
trypsin-stimulated control. 
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5.4.3 Effect of enoxaparin on cell viability and proliferation  
To rule out that the observed inhibitory effect was because of enoxaparin-induced 
cytotoxicity or inhibition of cell proliferation, the cell viability and proliferation 
assays were performed in the presence or absence of intact enoxaparin. The 
concentration of 60 μg/mL of intact enoxaparin was selected to determine its effect on 
the viability and proliferation of A549 human pulmonary epithelial cells. After 24 
hours of incubation, 60 μg/mL of enoxaparin did not reduce the viability of epithelial 
cells compared to the control. Similarly, no effect on the number of cells 
(proliferation) was observed after the addition of 60 μg/mL of enoxaparin compared 
to the control (Figure 5.3A and 5.3B). Additionally, enoxaparin did not induce 
cellular toxicity since it was not found to increase the release of LDH in epithelial cell 
culture supernatants (Figure 5.3C). These results indicated that the suppression of IL-
6 or IL-8 release by enoxaparin was not related to its cytotoxic effect or changes in 
cellular proliferation. 
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Figure 5.3 Effect of enoxaparin on 
cellular viability and proliferation. (A) 
Viability of epithelial cells was determined 
by trypan blue dye exclusion test and is 
presented as % of viable cells remaining 
after 24 hours of incubation with trypsin, 
enoxaparin or trypsin + enoxaparin. Data 
is presented as mean ± SD. (B) 
Proliferation of epithelial cells was 
determined after 24 hours in the presence 
of trypsin, enoxaparin or trypsin + 
enoxaparin. Cells were counted after 
incubation for 24 hours and expressed as 
10
5
 cells/mL. Data is presented as mean ± 
SD. *p<0.05 versus unstimulated control. 
(C) Viability of epithelial cells is presented 
as mean % LDH release ± SD. Cells were 
incubated for 24 hours in the presence of 
trypsin, enoxaparin or trypsin + 
enoxaparin.  
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5.4.4 Effect of enoxaparin fractions on IL-6 and IL-8 release  
Enoxaparin is a mixture of structurally complicated and unidentified fractions. It has 
been suggested that different fractions of enoxaparin have different biological 
activities. For example, the pentasaccharide sequence (5 saccharides) of enoxaparin is 
required for its anticoagulant effect [235].  On the other hand, hexasaccharides (6 
saccharides) of enoxaparin are effective in inhibiting the macrophage-induced release 
of nitric oxide [105].  Therefore, to find out the fraction(s) responsible for the 
observed inhibitory effect of the parent compound, enoxaparin was separated into 
different fractions using an IC technique (Figure 5.4A). The effects of 14 IC-derived 
fractions on the release of IL-6 and IL-8 are shown in Figure 5.4B and 5.4C. The 14 
fractions were selected based on their previously reported molecular weights [105]. 
For example, the molecular weight of fraction 1, fractions 2, 3 and 4, and fraction 5, 6 
and 7 were found to be approximately 600, 1200 and 1800 Da, respectively. The 
tested concentration of each fraction reflected their concentration present in 60 μg/mL 
of enoxaparin (at which enoxaparin exhibited the maximal level of IL-6 and IL-8 
inhibition). 
Various fractions inhibited the release of IL-6 and IL-8 to different extents. 
While the majority of fractions did not significantly change the levels of IL-6 and IL-
8 (p>0.0614), fraction 1 inhibited the release of IL-6 and IL-8 release by 30% and 
35%, respectively (p<0.0001), and this effect was comparable to the suppression 
displayed by enoxaparin. Fraction 2 and 4 were found to inhibit the release of IL-6 
and IL-8 by 10 and 12%, respectively (p=0.0274 and 0.0230). Since fraction 1 of 
enoxaparin showed the maximum inhibition of tested ILs, it was selected for further 
analytical and bio-analytical investigations.  
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Figure 5.4 Effect of enoxaparin fractions on interleukin release. Ion-exchange 
chromatographic (IC) separation of enoxaparin. The separations were performed using a 
CarboPac PA100 semi-preparative column; optimised NaCl gradient was from 32-74% over 
70 minutes with a flow rate of 2 mL/minute and UV detection wavelength of 232 nm. The 
numbers indicate the area of all the fractions collected. Data represents a typical experiment 
out of ten independent experiments (A). Inhibition of IL-6 (B) and IL-8 (C) release by IC-
derived 14 fractions of enoxaparin (60 μg/mL) after trypsin-induced in-vitro stimulation of 
epithelial cells. The relative percentile amount of each fraction (fraction 1 to 14) present in 60 
μg/mL of intact enoxaparin was: 9.18%, 4.24%, 6.12%, 5.15%, 2.99%, 4.78%, 20.32%, 
11.4%, 10.53%, 7.35%, 5.98%, 4.6%, 2.95% and 5.06% respectively. Data is presented as 
percentage (mean ± SD) of the maximal observed IL-6 and IL-8 concentrations. *p<0.05, and 
***p<0.001 versus trypsin-stimulated control. 
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5.4.5 Concentration-dependent effect of fraction 1 on IL-6 and IL-8 release  
Like enoxaparin, fraction 1 also inhibited the release of IL-6 and IL-8 in a 
concentration-dependent manner (Figure 5.5A). The maximum inhibition of IL-6 and 
IL-8 was observed at 15 μg/mL and higher concentrations did not result in greater 
inhibition. At 15 μg/mL, it inhibited the release of IL-6 and IL-8 by 70 and 76%, 
respectively (p<0.0001).  
 
Figure 5.5 Concentration-dependent effect of IC-derived fraction 1 on interleukin 
release. Inhibition of IL-6 and IL-8 release by fraction 1 of enoxaparin (0 to 25 µg/mL) after in-
vitro stimulation of epithelial cells via trypsin. Data is presented as percentage of trypsin-
stimulated control (mean ± SD). **p<0.01 and ***p<0.001 versus trypsin-stimulated control. 
 
Fraction 1 of enoxaparin, as can be seen in Figure 5.4A, is composed of three 
different sub-fractions eluting at 30.0, 31.2 and 32.3 minutes, respectively. Although 
the molecular weights of the three sub-fractions (fraction 1A, 1B and 1C) were found 
to be similar, the IC technique was efficient enough to separate them from each other. 
The separation of IC is based on the interaction of the negatively charged groups (e.g. 
Chapter Five 
 
139 
 
sulfate groups) of enoxaparin fractions with the positively charged stationary phase of 
the separation column. The fractions with more negative charge elute later during the 
IC salt gradient separation. Therefore, sub-fraction 1A appears to have less negatively 
charged groups than fraction 1B or fraction 1C. As the potential anti-inflammatory 
effects of LMWHs depend on their degree, as well as pattern, of sulfation, we further 
investigated the effect of each sub-fraction on the release of IL-6 and IL-8. The effect 
of three different sub-fractions on the release of IL-6 and IL-8 is shown in Figure 5.6. 
Sub-fraction 1A inhibited the release of IL-6 and IL-8 by approximately 65% and 
74%, respectively (p<0.0001). On the other hand, sub-fraction 1B and 1C did not 
significantly inhibit the release of tested ILs (p>0.1683).  As sub-fraction 1A was 
found to be responsible for the majority of the inhibitory effect of fraction 1, its 
structure was characterised by NMR.  
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Figure 5.6 Effect of sub-fractions of IC-derived fraction 1 on interleukin release. 
Inhibition of IL-6 (A) and IL-8 (B) release by enoxaparin fraction 1 and its three different sub-
fractions (1A, 1B and 1C) after trypsin-induced in-vitro stimulation of epithelial cells. Data is 
presented as percentage (mean ± SD) of the maximal observed IL-6 and IL-8 concentrations. 
***p<0.001 versus trypsin-stimulated control. 
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5.4.6 Structural characterisation of sub-fraction 1A 
Full assignment of the dominant proton and carbon signals in the enoxaparin sub-
fraction 1A was made from analysis of the NMR data. Proton connectivity networks 
in the individual sugar rings were established from correlations in 
1
H-
1
H TOCSY 
spectra. Carbon assignments were derived through one-bond correlation of these 
protons to carbons in the 
13
C-
1
H HSQC spectrum (Figure 5.7). The 
13
C-
1
H HSQC-
TOCSY experiment (Figure 5.8) was used to discriminate between groups of 
interconnected protons in separate sugars for which overlap in the 
1
H-
1
H-TOCSY did 
not allow unambiguous assignment. The link between the two sugars was confirmed 
by a correlation across the glycosidic linkage between H4’ and C1 observed in 
heteronuclear multiple-bond correlation (HMBC) spectrum.  The NMR assignments 
and measured J-couplings of sub-fraction 1A are summarised in Table 5.1, with atom 
numbering consistent with previously reported data [175].  
 
Table 5.1 NMR assignments of enoxaparin disaccharide  
   
Atoms in the glucosamine unit are denoted by the prime superscript 
Cq (COO-) 169.1 ppm, C6 (Ido) 144.79 ppm 
 
 
 
 
 
  1 2 3 4 1' 2' 3' 4' 5' 6' 
1
H ppm 5.435 4.496 4.263 5.89 5.379 3.192 3.673 3.754 4.084 4.141 
4.285 
3
JHH Hz 3.36 3 3 4.44 3.48 10.16 
3.57 
10.43 9.39 9.98 
3.57 
11.26 
3.8 
13
C ppm 96.61 75.05 63.41 106.3 90.94 57.71 68.94 78.39 67.99 66.7 
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It was found to be a disaccharide of enoxaparin containing a unit of α-L 
iduronic acid and one of α-D glucosamine-6-sulfate. The glucosamine unit of the 
disaccharide was present in both α and β forms, and could be correlated with chemical 
shift and coupling observations for a similar disaccharide fragment of heparin [175] 
and spectra for glucosamine-6-sulfate in the Human Metabolome Database (HMDB) 
repository [236]. The iduronic acid unit did not display evidence of multiple 
conformations at the temperature used in this study. The glucosamine was 
predominantly in the α-form based on relative integral volumes between the two 
forms measured in the 
1
H-1D spectrum. 
 
Figure 5.7 
13
C-
1
H HSQC multiplicity edited spectrum for enoxaparin sub-fraction 1A.  
Axis units are chemical shifts in parts per million (ppm).  The dark blue contours denote 
correlations between carbon atoms with one or three attached protons and cyan contours 
carbons with a single attached proton.  The atom nomenclature from Table 1. is applied to the 
proton and carbon axis projections. 
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Figure 5.8 
13
C-
1
H HSQC-TOCSY 120ms spectrum for enoxaparin sub-fraction 1A.  Axis 
units are chemical shifts in parts per million (ppm).  The atom nomenclature from Table 1. is 
applied to the proton and carbon axis projections. 
 
5.4.7 Anti-factor Xa analysis of disaccharide of enoxaparin  
The anti-factor Xa activity of fourteen IC-derived fractions of enoxaparin is shown in 
Figure 5.9. As expected, the disaccharide of enoxaparin did not show any anti-factor 
Xa activity. Inhibition of factor Xa by anti-thrombin requires a formation of a 
complex composed of factor Xa, anti-thrombin and enoxaparin [237]. To mediate an 
interaction between factor Xa and anti-thrombin, a minimum chain length of 5 
saccharide (pentasaccharide) sequence of enoxaparin is required. It means the 
pentasaccharide of enoxaparin is the smallest fraction required to mediate inactivation 
of factor Xa by anti-thrombin. The identified disaccharide of enoxaparin was too 
small to act as a template through which anti-thrombin mediated inactivation of factor 
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Xa can occur. This finding is significant because the risk of bleeding is increased 
when enoxaparin is used for medical conditions other than where an anticoagulation 
effect is required. The identified disaccharide lacked the anticoagulant activity and 
therefore can eliminate the potential risk of bleeding associated with enoxaparin.  
 
Figure 5.9 Anti-factor Xa activity of fourteen enoxaparin fractions derived using IC 
technique. The anti-factor Xa assay is described in the experimental section. Data is 
presented as mean ± SD (n=3).  
 
5.4.8 Effect of desulfated disaccharide of enoxaparin on IL-6 release  
The presence of sulfate groups at specific positions, such as 2-O, N- or 6-O, are 
known to be essential to elicit an anti-inflammatory response to heparins [231]. 
Therefore, the selectively desulfated disaccharide was tested for its ability to inhibit 
the release of IL-6 (Figure 5.10). As expected, the disaccharide inhibited the release 
of IL-6 by approximately 70% (p<0.0001). While 2-O and N-desulfated disaccharide 
did not significantly change the observed inhibition of disaccharide (p>0.6018), the 
disaccharide-induced inhibition of IL-6 was reduced by 98% in the presence of 6-O-
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desulphated disaccharide (p<0.0001). The importance of O-sulfate groups in 
controlling the anti-inflammatory activity of heparins has been reported before. For 
instance, the presence of sulfate groups at O-position was found to be critical for: i) 
binding to inflammatory cytokines and chemokines, such as IL-4 and CXCL-12 [215, 
218], ii) formation of covalent complexes with proteolytic enzymes, such as thrombin 
[238] and iii) binding to various receptors, such as fibroblast growth factor receptors 
[239]. The present study, for the first time, reports the requirement of 6-O sulfate 
groups for the inhibition of IL-6 and IL-8 release from human pulmonary epithelial 
cells.  
 
Figure 5.10 Effect of various desulfated fraction 1A on IL-6 release. Epithelial cells were 
stimulated with trypsin in the presence of either 2-O-desulfated, N-desulfated or 6-O-
desulfated fraction 1A of enoxaparin. Data is presented as mean ± SD. ***p<0.001 versus 
trypsin-stimulated control. 
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5.4.9 Binding of proteins to disaccharide of enoxaparin 
Decreased levels of IL-6 and IL-8 observed through ELISA could potentially be 
because of: i) direct binding of disaccharides to trypsin and, hence, inhibiting the 
trypsin-induced activation of PAR (lung epithelial cell receptors); ii) binding of 
disaccharides to IL-6 and IL-8 and, hence, their reduced detection through ELISA or 
iii) binding of disaccharides to PAR and, hence, inhibiting PAR-induced release of 
IL-6 and IL-8 through specific intracellular signalling pathways. Specific binding 
between glycominoglycans (e.g. enoxaparin) and proteolytic enzymes (e.g. thrombin) 
has been reported before [240]. Direct binding of glycosaminoglycan disaccharide and 
proteolytic trypsin could impair the ability of trypsin to bind and activate the PAR. 
Therefore, we needed to confirm that the observed inhibition of release of ILs was not 
due to this potential in-vitro artefact of our experimental cell system. Hence, HP-SEC 
was used to investigate the putative binding between disaccharide and trypsin. In the 
current HP-SEC method, two separation columns were connected in series. The first 
column (Superdex™ peptide 10/300 GL) allowed the separation of proteins and 
carbohydrates having low MWs (0.1 to 8 kDa) and the second column (Superdex™ 
75 10/300 GL) provided the effective separation of analytes with high MWs (3 to 70 
kDa). Moreover, the detection of the tested analytes was carried out using a charged 
aerosol detector (CAD) instead of ultra-violet (UV) detector. The advantage of CAD, 
as compared to UV detection, is that the peak areas of analytes are not dependent on a 
UV chromophore, for which extinction coefficients can vary by orders of magnitude 
depending on the chemistry of analyte, but are dependent on the mass of analytes. The 
performance of the HP-SEC method was determined using intra- and inter-day 
precision and accuracy, and the inter-day retention time of each analyte. The intra- 
and inter-day precision relative standard deviation (RSD) for each analyte peak was 
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less than 4.1% (n=6) and 5.3% (n=5), respectively. The intra- and inter-day accuracy 
RSD for each analyte peak was less than 4.3% and 5.9%, respectively. Inter-day 
retention time RSD for each of the analyte peaks were less than 0.7% (n=6).  
The ability of HP-SEC to determine the binding between glycominoglycans 
and proteins was first investigated by analysing UFH (10 µM) and thrombin (10 µM). 
The HP-SEC chromatograms of UFH, thrombin and a mixture of UFH/thrombin (1:1 
molar ratio) are shown in Figure 5.11A. UFH and thrombin peaks were eluted at 65 
and 37 minutes. In HP-SEC analysis, the separation of analytes is based on their 
molecular size and, therefore, thrombin with a MW of 37 kDa eluted earlier than UFH 
(MW 15 kD). However, when a mixture containing UFH and thrombin was analysed 
(Figure 5.11A), a new peak was eluted at 16 minutes, suggesting the observed 
component had a higher MW compared to thrombin or UFH. When 
glycosaminoglycans bind to proteins, it results in the formation of a high MW 
complex. Therefore, the observed reduction in the peak areas of thrombin and UFH, 
and simultaneous elution of a new peak indicated the binding between UFH and 
thrombin. UFH is a mixture of complicated oligosaccharides ranging from 
disaccharides to oligosaccharides larger than 50-100 saccharides. Only 
oligosaccharides with a minimum of 18 saccharides can bind to thrombin and, 
therefore, as can be seen in Figure 5.11A, approximately 25% of UFH 
oligosaccharides did not bind to thrombin. The disaccharide of enoxaparin and trypsin 
was then analysed by HP-SEC. As shown in Figure 5.11B, trypsin and disaccharide 
were eluted at 53 and 136 minutes respectively. There was no difference in the 
chromatographic profile of disaccharide or trypsin when a mixture of 
trypsin/disaccharide (1:50 molar ratio) was injected into the HP-SEC system (Figure 
5.11B). For example, the peak area of trypsin remained unchanged when a solution 
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containing either trypsin or mixture of trypsin and disaccharide was injected. Also, no 
extra peak was observed when a mixture was analysed suggesting the decreased levels 
of ILs were not because of the interaction between disaccharide and trypsin. Apart 
from proteolytic enzymes, glycosaminoglycans are shown to interact with cytokines, 
chemokines and growth factors. For example, heparins can bind to IL-10, MCP-1 and 
epidermal growth factors and then modulate their biological activity [241-243]. 
However the HP-SEC results indicated that the disaccharide of enoxaparin did not 
bind to either IL-6 or IL-8.  
Trypsin is known to activate PAR by cleaving the receptor’s extracellular N-
terminal domain. This cleavage results in the formation of a new N-terminus which 
then interacts with trypsin causing activation of G-protein-coupled signal transduction 
pathway [244]. Interestingly, the N-terminal domain of various proteins is reported to 
be a binding site for heparins as well [245, 246]. For example, heparins bind to the N-
terminal domain of serine protease inhibitor resulting in the anticoagulant effect of 
enoxaparin [247]. Since, disaccharide of enoxaparin did not interact with either 
trypsin or the tested ILs, the observed decrease in IL levels could potentially be due to 
the interaction between N-terminal domain of PAR and disaccharide. Future 
experiments should be aimed to provide direct evidences of interactions between 
disaccharide of enoxaparin and N-terminus of PAR as well as the mechanistic insights 
via which the potential interaction occurs. In the current study only a single type of 
epithelial cell line was tested to investigate the effect of enoxaparin on the release of 
IL-6 and IL-8. However, upon stimulation, other types of epithelial cell lines with 
potentially different types of cell surface receptors also release pro-inflammatory 
mediators. Therefore, it would be interesting to investigate the effects of enoxaparin 
on such types of epithelial cells. 
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Figure 5.11 Binding of proteins with disaccharide of enoxaparin. Interaction of UFH with 
thrombin. HP-SEC chromatograms of UFH (10 μM), thrombin (10 μM) and a mixture of 
UFH/thrombin (1:1 molar ratio) (A). Interaction of IC-derived disaccharide with trypsin. HP-
SEC chromatograms of enoxaparin disaccharide (500 μM), trypsin (10 μM) and a mixture of 
trypsin/disaccharide (1:50 molar ratio) (B). Details of the HP-SEC experimental conditions are 
given in Methods. 
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5.5 CONCLUSION 
In summary, the identified fraction responsible for the anti-inflammatory effect of 
enoxaparin is composed of two saccharides. Therefore, it avoids the risk of bleeding 
as a minimum of pentasaccharide sequence is required for the anticoagulant effect. As 
IL-6 and IL-8 are important pro-inflammatory mediators involved in the early 
pathogenesis of asthma, inhibition of their release, as seen with the identified 
disaccharide, could provide a much needed novel therapeutic option for the 
management of clinical manifestations associated with this medical condition. 
However, future clinical studies should be conducted to confirm the preliminary 
findings of the current in-vitro study. 
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Redefining Approaches to Asthma: Bridging the Gap between Heparin and  
Anti-inflammation 
It will shortly be the 100
th
 anniversary of the discovery of heparin; enormous progress 
has since been made in understanding the mechanistic insight of this complex 
biological as an anticoagulant and recently as an anti-inflammatory agent. 
Identification of the molecular basis via which heparin exert its characteristic 
anticoagulant effect represented a landmark in the research of this macromolecule. It 
was recognized that only a small structure within heparin also referred to as a 
pentasaccharide sequence was solely responsible for its active principle by eliciting a 
high inhibitory action against the final two proteases of the coagulation cascade. 
Depolymerisation of unfractionated heparin generates heparin-derivatives also 
known as low-molecular-weight heparins (LMWHs). Heparins (unfractionated 
heparin and LMWHs) encompass a high degree of structural heterogeneity and 
complexity which make them one of the most information-dense molecules exhibiting 
multi-functional properties and hence, associated with a wide array of biological 
processes. Relatively recently, heparins have been shown to interact with manifold 
proteins and biological molecules, and thereby play a pivotal role in modulating 
inflammatory responses. As an anti-inflammatory agent, LMWHs like enoxaparin has 
been reported to possess clinical benefits in humans, including the once suffering 
from respiratory disorders like asthma, which is over and above its expected effects 
on blood coagulation. It seems arbitrary and still mysterious that a complex 
polysaccharide could be a useful anti-asthmatic agent.  
Although, heparins remain one of the most widely used anticoagulant agent, 
their effect on blood coagulation is seen as an adverse effect when exploiting their 
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anti-asthmatic potential. Rapid developments of emerging new analytical tools and 
methodologies permitted the identification of heparin chains which were accountable 
for the features linked with its potent anti-asthmatic effects and were observed to be 
due to the presence of non-anticoagulant molecules in the parent compound which are 
entirely separable from its role as an anticoagulant. These advances in analytical 
capabilities represent a cornerstone allowing biological and pharmacological testing 
of the non-anticoagulant fragments in several inflammatory disorders including 
asthma. Numerous analytical techniques with their specific uses have been developed 
to separate anticoagulant and anti-inflammatory properties of heparins. For instance, 
molecular weight or sequence analysis of heparin fractions via gel-permeation 
chromatography or a much more challenging task of separating the whole 
polysaccharide using techniques like ion-exchange chromatography (IC). Several 
chemically or enzymatically modified analogues have also been tested for anti-
inflammatory purposes. However, the anti-inflammatory potential of these analogues 
largely dependents on the efficacy of depolymerisation process since 
depolymerisation is known to produce structural modification in heparin fractions 
which may result in impaired the anti-inflammatory response. Questions still remain 
regarding their true pharmacologic potential, clinical limitations, safety and efficacy 
compared to the parent macromolecule.  
Understanding the complex biology these molecules mediate, necessitates 
better understanding of their structural information. The anti-inflammatory properties 
of heparins are known to be sequence-dependent and varying sizes of non-
anticoagulant sequences are reported to bind or inhibit individual proteins involved in 
the process of inflammation. Alongside the sequence dependency, conformationally 
defined patterns of sulphates were also shown to be critical and form the basis for 
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regulating the interaction with proteins and thereby induce biological activities. 
However, it has been recognised after selective desulfation of non-anticoagulant 
heparin fragments that some of the sulfate groups are compatible but are not essential 
for high affinity binding or inhibition of proteins. With a few exceptions, for the 
majority of anti-inflammatory effects, the knowledge of the active domains of non-
anticoagulant heparin molecules is still incomplete. However, increasing interest in 
exploiting the pharmacology of non-anticoagulant heparin have led to the 
identification of multiple mechanisms that may play a key role in regulating distinct 
aspects of anti-inflammatory response observed during asthma. The role of mast-cell-
derived heparin in regulating physiological and pathophysiological responses is yet to 
be fully elucidated, however it has been suggested that the release of heparin after the 
degranulation of mast cells may possess a protective or regulatory role to limit the 
extent of subsequent inflammation. In experimental models, heparin was found to 
inhibit degranulation of mast cells and subsequent release of inflammatory mediators 
via inhibition of inositol triphosphate signalling. Heparin was also shown to bind 
directly to adhesion molecules like selectins which are involved in the process of 
inflammation. It is via NH2-terminal lectin domain that carbohydrates calcium-
dependently bind to these molecules on the surface of interacting cells and hence, 
limiting inflammatory cell recruitment during inflammation. Our in-vitro and in-vivo 
studies provide an insight on the non-anticoagulant effects that have been ascribed for 
enoxaparin. The non-anticoagulant molecules of enoxaparin were obtained after 
separation of entire polysaccharide using ion-exchange chromatographic technique. 
Two non-anticoagulant fractions of enoxaparin were identified that significantly 
inhibited peripheral blood mononuclear cell activation. A di- and a tetra-saccharide 
fraction of enoxaparin was shown to inhibit the release of inflammatory mediators 
Chapter Six 
 
154 
 
like interleukin (IL)-4, IL-5, IL-13 and tumor necrosis factor-α. The data also suggest 
that the observed response is likely to be due to an interaction of 6-O-sulfated 
tetrasaccharide with cellular receptor(s). Similarly, in other experimental model, IC-
derived disaccharide of enoxaparin was found to significantly inhibit the release of 
other potential inflammatory markers like IL-6 and IL-8 from human pulmonary 
epithelial cells. The observed suppression of IL-6 and IL-8 by disaccharide was likely 
due to the inhibition of the activation of protease activated receptors on lung epithelial 
cell surface. The data from this study also demonstrated the importance of 6-O-sulfate 
groups to retain the observed anti-inflammatory activity of the non-anticoagulant 
enoxaparin fraction.  
In animal models, heparin has been reported to confer benefits in allergen 
induced airway hyper-response or platelet-activating factor induced bronchial 
hyperresponsiveness. In one such reports prevention of nitric oxide signalling by 
heparin was reported to have benefit in methacholine-induced airway 
hyperresponsiveness. In addition to having effects in experimental settings, heparin 
has also shown potential in the management of human asthma in several controlled 
clinical studies.  
It is evident from basic science investigations to clinical observations that 
heparin possess considerable promise for the management of asthma. It is reasonable 
to anticipate major advances in this field and will be fascinating to watch the future 
developments over the next few years as new anti-asthmatic agents that match the 
criteria required for a drug.  
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FUTURE DIRECTIONS 
Over the past few decades a lot of effort has been put into finding novel therapeutic 
targets for effective management of asthma. Many novel treatments are specific, 
targeting a single mediator or receptor. Absolute specificity to one protein, as seen 
with monoclonal antibodies is not the most effective way to treat complex disorders 
like asthma; one pathway may be blocked, however complexity of the disease is such 
that symptoms are not alleviated. Drugs with more widespread effects as seen with 
non-anticoagulant molecules of heparin might prove to be more effective alternative 
and at a more favourable cost.  
So far, continuous research have managed to concatenate many strings 
together and resolve many factors in this field including the identification of non-
anticoagulant molecules within heparin which are responsible for its anti-
inflammatory effects and the impetus for the development of advanced analytical 
techniques to dissociate non-anticoagulant molecules from the parent mixture. 
However, much still remains to be learned, the complexity of these macromolecules 
greatly complicate the detailed structure-activity relationships and the areas which 
require further investigation include: i) interpretation of fine/specific non-
anticoagulant sequences and their precise structural information (including the role of 
specific sulphate groups) to enable better understanding of structure-activity 
relationships from the point of view of answering biological questions and to provide 
new targets for therapeutic interventions in different inflammatory disease states and 
ii) the mechanisms that regulate the observed anti-inflammatory effects of various 
non-anticoagulant sequences of heparins. Emergence of understanding such exact 
structural requirements and mechanisms may help to develop myriad of structurally 
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different non-anticoagulant preparations which seems to be the best way forward to 
correlate these preparations to various proteins and respective biological activities 
with a goal to maximise the therapeutic benefit for the disease being targeted. It is 
also increasingly important to conduct complete characterisation of all structural 
elements within heparin that account for its anti-inflammatory response since heparin 
preparations are currently standardised for its use as an anticoagulant and there are 
possibilities that certain features that account for their anti-inflammatory effects may 
be lost or selected out while processing raw heparin. Future research should also focus 
on a particular delivery route that would confine these non-anticoagulant molecules to 
the target organ; in case of respiratory disorders like asthma, inhaled route would be a 
safe and preferable route of administration. The current sophisticated analytical 
techniques and methodologies provide a basic platform to explain the mystery behind 
heparin and anti-inflammation however, it is by no means a trivial undertaking. With 
this knowledge, we may in the near future be able to influence further clinical trials 
and look forward to expand its use as an anti-asthmatic agent.   
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